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ABSTRACT 
 
 
Idiopathic intracranial hypertension (IIH) is common in obese women and can lead to 
significant visual impairment. The cause of IIH is unknown and management controversial, 
due to the lack of prospective trials. This thesis provides a comprehensive review of the 
aetiology and management of IIH. The hypothesis that IIH is associated with a pro-
inflammatory cytokine profile, suggested by its established association with female gender 
and obesity, was tested. Laboratory studies demonstrated the novel finding of elevated 
leptin in the cerebrospinal fluid from women with IIH, suggesting a role in the pathogenesis 
of IIH. The first randomised controlled trial in IIH is then reported. Treatment with 
acetazolamide was examined prospectively in 50 patients, providing seminal information to 
guide the design of future large-scale trials and data on the natural history of the condition.  
The observation that management of IIH is guided by a variety of clinical parameters was 
translated into a simple composite scoring system which was prospectively tested. Visual 
fields and optic disc appearance are shown to have the greatest influence on clinical 
outcome. Finally, a systematic study of the evaluation of papilloedema in IIH highlights the 
major limitations of the widely adopted Frisen staging scheme in the condition.   
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CHAPTER 1  INTRODUCTION 
1.1 Clinical Characteristics 
1.1.1 Historical Background 
Idiopathic intracranial hypertension (IIH) is the most recent of a number of names for the 
clinical syndrome of elevated intracranial pressure, without enlargement of the cerebral 
ventricles and in the absence of space occupying lesions. The German physician Heinrich 
Quincke (1983) published what is widely regarded as the first description of the condition, 
calling it ‘meningitis serosa’. This appeared to be preceded by case reports describing the 
same condition as early as 1866. (Johnston et al., 2007) A second German neurologist, Max 
Nonne, (1904) identified cases of apparent cerebral tumour whose subsequent clinical 
course appeared to preclude a diagnosis of tumour, coining the term ‘pseudotumour 
cerebri’. From 1931 onwards, An English neurologist, Sir Charles Symonds, wrote a series of 
papers describing children who had elevated intracranial pressure in association with middle 
ear disease, which he called ‘otitic hydrocephalus’, suggesting that the raised pressure was a 
result of excess cerebrospinal fluid (CSF). (Symonds, 1956) 
By the turn of the 20th century, the terms serous meningitis and pseudotumour cerebri had 
been adopted, but diagnosis relied on clinical features or post mortem findings.  Cerebral 
pneumography permitted further study of the condition in live patients and this was later to 
be enhanced by ventriculography and encephalography. Around this time Davidoff and Dyke 
(1956) published a report of 15 cases with normal cerebral pneumography, all of whom 
improved with cranial decompression. In 1937, the American neurosurgeon Walter Dandy 
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(1937) described 22 cases of ‘intracranial pressure without brain tumour’ and is credited 
with the first diagnostic criteria for the condition. 
Foley (1955) published a detailed study dividing cases of the condition into those associated 
with ear disease and those with no known cause of raised intracranial pressure. He regarded 
hydrocephalus as an inappropriate term, since the cerebral ventricles were not enlarged and 
introduced the name ‘benign intracranial hypertension’ for non-otitic cases. He described 
amongst this cohort of predominantly female, young, overweight patients “a variety of 
proposed aetiological agents so numerous and diverse that one must suspect that none is a 
direct cause.” The term benign intracranial hypertension was used for many years until 
several reports of severe visual loss in the condition rendered the term ‘benign’ 
inappropriate. 
1.1.2 Definition  
With the advent of complex neuro-radiology, it has been possible to identify intracranial 
lesions and vascular pathologies in patients who might previously have been labelled as 
having IIH by one of its many names. Older reports were likely to have included patients in 
whom cerebral venous sinus thrombosis (CVST) had not been excluded since imaging 
techniques were in their infancy. The clinical presentation of CVST is identical to that of IIH, 
but the outcome and management is dramatically different and CVST carries a significantly 
worse prognosis. It is essential that CVST is excluded before a diagnosis of IIH is made. 
The diagnostic criteria have undergone several modifications over the years. Strict criteria 
now exist to ensure that a diagnosis of IIH is only applied to patients in whom all other 
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causes of intracranial hypertension have been excluded. (Friedman and Jacobson, 2002) 
These are shown in table 1.1 and are often referred to as ‘modified Dandy criteria’.  
Table 1.1 Diagnostic Criteria of Idiopathic Intracranial Hypertension  
(Friedman and Jacobson, 2002) 
 
 If symptoms and / or signs are present, they may only reflect those of generalised 
intracranial hypertension or papilloedema 
 Intracranial pressure, as measured in the lateral decubitus position, is elevated  
 The composition of the cerebrospinal fluid  is normal 
 There is no evidence of hydrocephalus, mass, structural or vascular lesion  
 No other cause of intracranial hypertension has been identified. 
 
Despite widely accepted criteria, controversy still surrounds the definition of IIH as a discrete 
clinical entity. Pseudotumour cerebri syndrome is still used by many to describe patients 
with the condition, as an ‘umbrella’ term that can include those cases where a causative 
factor is strongly suspected. (Johnston et al., 2007) Confusion arises as a result of the alleged 
association of the condition with various medical conditions and treatments, most of which 
have only been described in case reports or small series. Some researchers argue for the 
criteria to be relaxed, so the syndrome can include focal CNS abnormalities, radiological 
abnormalities relating to cerebral venous outflow obstruction and CSF abnormalities. 
(Johnston et al., 2002) In such cases, the term ‘pseudotumour cerebri syndrome’ may have a 
place. However, where there is convincing evidence that a drug or disease is causally or 
temporally related, the term secondary intracranial hypertension is more appropriate. 
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1.1.3 Epidemiology 
1.1.3.1 Incidence  
Early attempts to measure the incidence of IIH, or the syndrome by one of its alternative 
names, are likely to have overestimated the number of cases, due to the inclusion of 
intracranial hypertension secondary to venous sinus thromboses or other conditions difficult 
to elicit by older investigative techniques. In addition, most of the largest studies of 
incidence to date were completed prior to the widespread acceptance of the modern 
diagnostic criteria (Friedman and Jacobson, 2002), so the actual incidence of ‘truly 
idiopathic’ IIH is by no means certain. 
Around the world, a small number of population studies have attempted to measure the 
overall incidence (table 3.2). In the USA, Durcan et al (1988) reported the one-year incidence 
in the general population of Iowa to be 0.9 per 100,000 and of Louisiana, 1.07 per 100,000. A 
prospective longitudinal study in the well-defined population of Benghazi, Libya generated 
an annual incidence rate of 2.2 per 100,000.(Radhakrishnan et al., 1993) In Hokkaido, Japan, 
only two cases were found from the study of a population of around 5.8 million, giving a 
crude rate of 0.03 per 100,000.(Yabe et al., 2000). A review of all cases diagnosed in Belfast, 
Northern Ireland between 1991 and 1995 led to an overall incidence of 0.6 per 
100,000.(Craig et al., 2001) Researchers in Israel reported an incidence of 0.57 to 0.94 per 
100,000 general population, through the identification of 91 new cases during a one-year 
study period amongst a population counted by census of 5,970,000.(Kesler and Gadoth, 
2001).  
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Table 1.2:  Published studies of IIH Incidence 
 
Year Location Author Population size IIH Incidence per 100,000 
1988 Iowa, USA Durcan et al (1988) 2,913,808 0.9 
1988 Louisiana, USA Durcan et al (1988) 4,480,681 1.07 
1993 Benghazi, Libya Radhakrishnan et al (1993) 519,000 2.2 
2000 Hokkaido, Japan Yabe et al (2000) 5,780,000 0.03 
2001 Belfast, N Ireland Craig et al (2001) 1,640,000 0.6 
2001 Israel Kesler & Gadoth (2001) 5,970,000 0.75 
 
Incidence studies in IIH used a variety of ascertainment methods to study populations with 
different ethnic and genetic mixes. Taking all of these figures together and accepting the 
limitations of the data, an incidence of 1 in 100,000 people would seem a reasonable 
approximation. Thus in the general population, IIH is a relatively uncommon condition, 
similar in incidence to pituatory tumours, Guillain Barré Syndrome (acute inflammatory 
polyneuropathy) or cluster headache. However, confining studies to women aged 20-44 
years, who are 20% or more above their ideal body weight, increases the incidence to 15-19 
cases per 100,000,(Durcan et al., 1988) approaching that of more common conditions such 
as motor neurone disease and multiple sclerosis. The condition is certainly encountered by 
most UK neurology and ophthalmology centres on a regular basis. With the escalating 
prevalence of overweight and obesity around the world, it seems likely that the incidence of 
IIH will also increase. 
1.1.3.2 Gender and age distribution 
There is no doubt that IIH is more common in women. Reported female to male ratios from 
larger studies include 4.3:1,(Durcan et al., 1988), 5.7:1 (Craig et al., 2001), 8:1,(Kesler et al., 
2000) 9.3:1, (Galvin and Van Stavern, 2004), 11.5:1(Mezaal and Saadah, 2005) and 15:1. 
 6 
 
(Radhakrishnan et al., 1993) Some differences in clinical features between male and female 
patients have been described, as discussed later in the chapter. 
IIH is predominantly a disease of younger adults. In one major study, 59% of patients were in 
the third decade of life at diagnosis,(Durcan et al., 1988) and mean ages at onset of 
symptoms have been reported by others as 28,(Radhakrishnan et al., 1993), 29 (Craig et al., 
2001), 31 (Wall and George, 1991), 35 (Galvin and Van Stavern, 2004) and 36 years. (Mezaal 
and Saadah, 2005) 
The condition does occur in childhood, although no large epidemiological studies in this 
group of patients have been carried out. It is rare in prepubertal children and has different 
characteristics to the adult form, including no apparent predilection for obese females. 
(Cinciripini et al., 1999; Rose and Matson, 1967) Amongst older teenage children, however, 
the rates of obesity seem to mirror those of the adult IIH population (Rowe and Noonan, 
2002). A meta-analysis in 2007 confirmed these findings. (Genizi et al., 2007) Amongst the 
244 children included in the analysis, the percentage of females was 45% in children aged 0-
11 and 70% in those aged 12-18. Corresponding rates of obesity were 26% amongst the 
younger children and 64% for the older group. Younger children with IIH appear to represent 
a unique group, leading to the possibility of different mechanisms underlying the childhood 
form of the disease. 
1.1.3.3 Racial and Genetic factors 
Ethnic background has not been shown to affect the incidence of IIH, although few studies 
have addressed this question or involved sufficient numbers of patients. In Wall and 
George’s study (1991) of 50 patients, 31 were black and in the Detroit study of 77 patients, 
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race was documented in 74, with 50 African-Americans and 24 Caucasians recorded. (Galvin 
and Van Stavern, 2004) A series of 450 patients studied over 17 years by Bruce et al (2008) 
comprised 246 (55%) white, 197 (44%) black, 5 (1%) Hispanic and 2 (<1%) Asian patients. 
However, in these American studies, numbers may simply reflect the ethnic composition of 
the source population. Small case reviews have confirmed that IIH occurs in Chinese and 
Korean populations, (Hung et al., 2003; Tae Wan Kim, 2008) although conclusions about IIH 
incidence specific to these ethnic groups are also precluded by small study size.  
There is little to suggest a genetic predisposition or inheritance pattern in IIH. It has been 
reported in female homozygous twins, but the patients were both shown to have slightly 
large lateral ventricles, suggesting the possibility of hydrocephalus. (Fujiwara et al., 1997) 
Other isolated case reports of familial presentation have appeared in the literature, including 
a Croatian family in which six of 15 members studies were affected by IIH, although three did 
not have lumbar puncture to confirm elevated CSF pressure. (Karaman et al., 2003) 
In a review of 237 US patients with IIH, 11 families were identified in which two or more 
members had a confirmed diagnosis of IIH. In 11 families the relationship was parent to 
child, in four, sibling. (Corbett, 2008) Obesity was present in 85% of all 27 subjects, which 
may explain the apparent family connection. The authors of this small study suggest that 
screening of first degree relatives of patients with IIH may be of value, although screening 
for other obesity-related conditions could equally have been the recommendation. 
1.1.3.4 Body Mass 
Early publications recognised the association of obesity with the clinical syndrome later 
named as IIH. Foley’s paper (1995) on ‘toxic hydrocephalus’ commented that 14 out of 60 
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patients were ‘conspicuously obese’. Greer (1965), wrote of obesity in all of 20 female 
patients with ‘benign intracranial hypertension’ studied in a US case series, five of whom 
reported a gain in weight of 10 to 30lb in the six months preceding the study, and 
recommended weight reduction as the most effective long term treatment. 
The evidence linking IIH and obesity is now conclusive. Published rates amongst IIH patients 
of obesity, defined as body mass index (BMI) above 30kgm-2 include 71% (Radhakrishnan et 
al., 1993) 88% (Galvin and Van Stavern, 2004) and 91%. (Kesler and Gadoth, 2001) The mean 
weight of patients in Durcan and Corbett’s (1988) population study was 38% above that 
considered ideal body weight. In the North American prospective study of 50 patients by 
Wall and George,(1991) 47 were obese according to standard definitions and there was an 
average weight gain over the 12 months preceding the onset of symptoms of 7.7 kilograms.  
Likewise, the Benghazi case-control study showed that not only were 40 IIH patients 
significantly more overweight compared to 80 controls, but that 24 of the patients had 
gained over 10 kilograms in weight in the 12 months prior to diagnosis compared to only six 
in the control group. (Radhakrishnan et al., 1993)  
Even moderate weight gain appears to be associated with IIH. Patients with BMI of 25-30 
had an increased risk of IIH in a recent US case-control study, although higher categories of 
BMI were associated with progressively greater risk of the condition. (Daniels et al., 2007) In 
the same study, 29% of patients reported no gain in weight and it is important to note that 
IIH does occur in people who have normal or even low body mass, albeit less frequently.  
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1.1.4 Associated Factors 
With the exception of female gender and obesity, there are no proven associations in IIH. A 
variety of conditions and medications have been linked with the disease over the years, but 
whether the clinical syndrome occurs as a result of, or is simply a chance association with 
the factor in question is impossible to prove. Furthermore, the description of associated 
conditions in the context of a disease termed ‘idiopathic’ seems fraught with contradiction.  
Nevertheless, certain factors have been reported in association with IIH with sufficient 
frequency to warrant further attention.  
1.1.4.1 Vitamin A 
The fat soluble vitamin retinol (Vitamin A) is known to affect the structure of the arachnoid 
villi, the thin walled structures that project into the blood-filled sinuses of the dura and 
permit flow of cerebrospinal fluid (CSF) from the arachnoid space into the bloodstream. 
Studies of retinol-deficient animals have demonstrated raised CSF pressure although the 
exact relationship between the structural changes in the arachnoid granulations observed 
and the mechanism of raised pressure is uncertain. (Hayes et al., 1971) Cases have been 
reported of intracranial hypertension occurring in infants deficient in vitamin A, which 
resolved with replacement therapy. (Keating and Feigin, 1970) 
Excessive dietary intake of vitamin A has also been associated with raised intracranial 
pressure. Historical narratives of Polar Eskimos and their dogs suffering from the clinical 
features of intracranial hypertension, including headache and prostration, after ingesting 
large quantities of liver from polar bears were later linked to the high levels of vitamin A in 
the organ.(Fishman, 2002) A case was reported in 2000 of IIH in a patient who consumed 
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excessive quantities of raw carrots, rich in retinol, and improved clinically when her carrot 
intake ceased.(Donahue, 2000) The effects of vitamin A intoxication, comprising systemic 
disturbance as well as intracranial hypertension, have been further revealed through the 
increasing therapeutic administration of retinol-containing compounds for dermatological 
and other conditions, but the mechanism of the raised pressure has yet to be determined. 
Elevated retinol levels in patients with IIH have been demonstrated in a small number of 
specifically designed studies, summarised in table 1.3.  
Table 1.3 Published Studies of Vitamin A in IIH 
1st Author Year Numbers Methods Findings 
Jacobson 1999 16 IIH Patients 
70 Controls 
Serum retinol and retinol esters 
quantified by chromatography 
Significantly higher 
serum retinol in IIH 
patients, no 
differences in retinyl 
ester levels 
Selhorst 2000 58 IIH Patients 
40 Controls 
Serum retinol by fluourometric method 
(+Serum retinol binding protein (RBP) in 
30 patients & 17 controls) 
RBP but not retinol 
significantly higher in 
IIH 
Warner 2002 20 IIH patients 
58 Controls 
CSF retinol levels measured by 
chromatography  
CSF retinol 
significantly higher in 
IIH patients vs 
controls 
Tabassi 2005 20 IIH Patients 
20 Controls 
 
Serum and CSF retinol analysed by 
chromatography  
 
CSF but not serum 
levels significantly 
higher in patients 
than controls 
 
The finding of raised concentrations of serum retinol caused speculation about a non-
specific alteration in retinol metabolism contributing to IIH in predisposed individuals. 
(Jacobson et al., 1999) Although Selhorst et al (2000) found elevated levels of retinal binding 
protein in patients with IIH compared to controls, the lack of significantly elevated retinol 
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levels in the same patients suggested the alteration may lie in the transport mechanism. 
Warner et al (2002) were the first researchers to show elevated retinol in the CSF of some 
patients with IIH, although corresponding serum levels were not measured to assess the 
ratio between blood and CSF levels. When this was addressed by Tabassi and colleagues, 
(2005) CSF retinol levels were significantly higher in the IIH patients than in 20 controls, but 
serum levels did not differ between the two groups. 
There is enough data from studies to date to suggest that further study of the role of retinol 
in intracranial pressure is indicated.  Clearly, not all patients with IIH show abnormalities of 
retinol metabolism, but there may be a subset of patients in whom it plays a 
pathophysiological role.  
1.1.4.2 Medication 
Case reports have implicated several drugs in intracranial hypertension (see table 1.4).  
Table 1.4: Medication reportedly associated with intracranial hypertension 
Endocrine: 
Corticosteroid withdrawal 
Levonorgestrel 
Danazol 
Tamoxifen 
Growth Hormone 
Anabolic steroids 
Antibiotics 
Tetracycline and derivatives 
Nalidixic acid 
Nitrofurantoin 
Non-steroidal anti-inflammatories 
Indometacin 
Rofecoxib 
Vitamin A 
Retinol 
Retinoids  
Others 
Lithium 
Cimetidine 
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There have been many reports of IIH occurring in patients taking tetracycline-class 
antibiotics, including minocycline (Chiu et al., 1998, Kesler et al., 2004a) and 
doxycycline.(Lochhead and Elston, 2003) In a case-control study, self-reported use of 
tetracycline-class antibiotics was recorded in six of 34 patients compared to one of 41 
controls.(Daniels et al., 2007) The authors used a regression model to demonstrate an 
association between IIH and use of the drugs within six months of symptom onset within the 
cohort. Other prospective, case controlled studies have failed to firmly establish a causative 
relationship. (Durcan et al., 1988; Giuseffi et al., 1991) 
Abrupt withdrawal of corticosteroid therapy has been reported to cause a syndrome 
indistinguishable from IIH, in which clinical improvement follows reintroduction of the drug. 
(Neville and Wilson, 1970) This has not been conclusively shown in more recent controlled 
studies of IIH defined according to strict diagnostic criteria. (Giuseffi et al., 1991) 
The oral contraceptive pill has been historically connected with IIH. Later, specifically 
designed studies found no significant differences in the numbers of women taking 
exogenous hormonal medication in patients with IIH compared with control subjects or the 
general population.(Durcan et al., 1988; Ireland et al., 1990; Giuseffi et al., 1991) It is 
conceivable that earlier publications included undiagnosed cases of cerebral venous sinus 
thrombosis, incorrectly labelled as IIH, amongst women taking hormonal medication, which 
may have led to false assumptions about an association. Glueck et al (2005) reported a series 
of 65 women with IIH who had, with one exception, normal cerebral venography, in which 
24 (37%) were taking or had recently taken oral contraceptive or exogenous oestrogens. 
Such studies continue to influence popular view regarding an association, such that it 
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appears to be common clinical practice for women with IIH to be advised to avoid or 
withdraw hormonal medication. 
1.1.4.3 Pregnancy 
Pregnancy was traditionally regarded as causing an increased risk of IIH. Greer (1965) 
described eight cases of women with symptoms of benign intracranial hypertension 
between the first and fourth months of gestation. It was observed that the duration of their 
illness was brief in comparison to cases in non pregnant women, suggesting some relation to 
the rapid changes in levels of oestrogen and corticosteroid levels. 
In 1984, a retrospective case control study and literature review concluded that the 
apparent association with pregnancy reflects the age and gender of the typical patient with 
IIH.(Digre et al., 1984) Further rigorous investigation has failed to show any statistically 
significant relationship, with similar pregnancy histories amongst IIH patients and matched 
controls.(Durcan et al., 1988; Ireland et al., 1990) As with the use of oral contraceptive 
medication, a high prevalence of pregnancy is to be expected in a condition favouring 
women of reproductive age. 
1.1.4.4 Menstrual Dysfunction 
A history of menstrual irregularities does appear to be more common in IIH than in 
unaffected females. In one questionnaire study of 40 IIH patients, a change in menstrual 
pattern just prior to diagnosis was more frequently reported than in the reference period in 
39 controls. (Ireland et al., 1990) Age of onset of menses at or before age 13 years was also 
significantly more likely amongst case subjects. 
 14 
 
Menarche, oligomenorrhoea or amenorrhoea have preceded the onset of IIH in case reports 
(Greer, 1964) and larger studies have listed menstrual dysfunction amongst reported 
symptoms, (Foley, 1955; Durcan et al., 1988; Glueck et al., 2005; Kleinschmidt et al., 2000) 
There has been no published evidence of specific hormone dysfunction to explain these 
findings and it is worth noting that obesity itself is known to be associated with menstrual 
irregularities. 
1.1.4.5 Polycystic Ovary Syndrome 
Polycystic ovary syndrome (PCOS) appears to occur with increased frequency in IIH. In the 
study by Glueck et al, (2005) 37 (57%) of the 65 women with IIH were found to meet the 
diagnostic criteria for the syndrome. Two years previously, the same researchers had 
reported the syndrome in 15 (39%) of a separate cohort of 38 patients with IIH. (Glueck et 
al., 2003) Whilst this would appear to represent a much higher prevalence of PCOS than that 
of the general population, the high levels of obesity in both IIH cohorts and the lack of 
reliable data on the incidence of PCOS amongst a similarly obese population make 
conclusions difficult to reach.  
1.1.4.6 Sleep Disorders 
Sleep apnoea syndrome (OSA) is also prevalent amongst an obese population, but several 
recent papers have linked it with IIH. Purvin et al (2000) investigated four patients who had 
papilloedema and OSA. Although CSF pressure was normal on a daytime lumbar puncture in 
all, the one patient who had overnight intracranial pressure monitoring showed significant 
elevations in pressure accompanying periods of apnoea and arterial oxygen desaturation. A 
year later, Marcus et al (2001) reviewed 53 patients with IIH, 37 of who reported symptoms 
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of sleep disorder. Polysomnograms were carried out in 14, confirming OSA in six cases. Lee 
et al (2002) carried out a prospective, multi-centre review over five years of male patients 
with IIH and identified six cases of OSA amongst 18 men meeting the full diagnostic criteria 
for IIH. In the largest published series of IIH, Bruce et al (2009) confirmed OSA in 25 (4%) of 
655 women and (16) 24% of 66 men. It is possible that this retrospective series may have 
underestimated the prevalence of the condition, since many men in the study did not 
undergo sleep studies. It remains unclear whether there is a disease association between 
OSA and IIH, or if OSA plays a causative role in the condition, such that intracranial 
hypertension secondary to OSA is a separate clinical entity to ‘true’ IIH.  
1.1.4.7  Anaemia 
The most recent diagnostic criteria for IIH specify severe iron deficiency anaemia as a 
condition that can masquerade as IIH. (Friedman and Jacobson, 2002)  Biousse et al (2003) 
reviewed the English and French literature and found 30 cases in which signs of isolated 
raised intracranial pressure (ICP) were associated with anaemia. Unfortunately, in many 
cases, CSF opening pressure was not recorded nor cerebral venous sinus thrombosis 
excluded. Most recently, Bruce et al (2009) reported anaemia of less than 12gdl-1 in 56 (9%) 
of women and 3 (5%) of 66 men with IIH. There have been further examples in medical 
literature to suggest more than an incidental association between IIH and iron deficiency 
anaemia, but controlled studies have yet to prove any causal relationship. (Tugal et al., 1994) 
A retrospective consecutive case series at the Birmingham and Midland Eye Centre, UK, 
between 2005 and 2007 of 107 new cases of IIH according to strict diagnostic criteria found 
six instances of microcytic anaemia, with haemoglobin levels below 10.2gdl-1. (Mollan et al., 
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2009) The prompt resolution of symptoms and improvement in visual function upon 
correction of the haematological abnormality in all cases was highly suggestive of an 
association between anaemia and raised intracranial pressure. Testing patients who present 
with signs of IIH to exclude anaemia is recommended.  
1.1.4.8  Other Co-morbid Conditions 
Systemic arterial hypertension has been reported as occurring in 14 to 32% of patients with 
IIH.(Wall and George, 1991; Galvin and Van Stavern, 2004; Ireland et al., 1990; Kesler and 
Gadoth, 2001) In one study, blood pressure was significantly higher amongst people with IIH 
than matched controls.(Ireland et al., 1990). Hypertension was reported in 21% of women 
and 24% of men in the review by Bruce et al. (2009) Whether there is a true disease 
association or simply a reflection of the high incidence of elevated blood pressure amongst a 
population with increased body weight is unclear.  
Other co-morbid conditions associated with IIH include diabetes mellitus, thyroid disease, 
hypoparathyroidism, stroke, chronic migraine, ulcerative colitis and systemic lupus 
erythematosus.(Durcan et al., 1988; Wall and George, 1991; Galvin and Van Stavern, 2004) 
There are published examples  of apparent IIH occurring in patients with a variety of other 
conditions, including hepatitis A and E,(Thapa et al., 2009a; Thapa et al., 2009b), 
transplanted kidneys (Durcan et al., 1988) leukaemia, (Vartzelis et al., 2009) and the 
lysosomal storage disease cystinosis, (Dogulu et al., 2004) although a complex drug history 
often complicates the picture. Similar to the numerous proposed associations of medication 
with IIH, the prefix idiopathic is questionable when the condition can reasonably be assumed 
to be the sequel of a recognised underlying disease.  
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1.1.5 Clinical Features 
1.1.5.1 Headache  
Headache has consistently been shown to be the most common symptom of IIH, occurring in 
68 to 98% of patients (Wall and George, 1991; Radhakrishnan et al., 1993; Kesler and 
Gadoth, 2001) and featuring as the presenting complaint in many. (Durcan et al., 1988) It 
appears to be less common amongst children with the condition, who may frequently 
present with other signs such as irritability or visual failure. (Lim et al., 2004)  
In a prospective study comparing 50 people with IIH and 100 control subjects, headache was 
shown to occur frequently in both groups, but it was the daily occurrence of headache that 
differentiated IIH patients from controls. (Giuseffi et al., 1991) The headaches show variation 
in their clinical features and may be indistinguishable from other headache types such as 
migraine and tension-type headache. (Mathew et al., 1996) Friedman and Rausch (2002) 
studied a cohort of 82 patients with IIH and found 68% meeting the diagnostic criteria for 
primary headache as defined by the International Classification of Headache Disorders, 
ICHD-1. The headaches were divided as tension-type in 30%, migraine without aura 20%, 
chronic tension-type headache 10% and analgesia overuse in 8%. Isolated cases of cluster 
headache in association with IIH have also been reported. (Volcy and Tepper, 2006; Testa et 
al., 2008) One small, retrospective study found that patients were divided according to 
whether they had throbbing, migraine-like headaches (6 out of 16 IIH patients) or 
oppressive, heaviness headaches (9 out of 16). (Volcy-Gomez and Uribe, 2004) In the study 
by Wall and George, (1991) 39/50 patients said the headache was pulsatile, 41 said it was 
different from previous headaches and 44 felt it was the worst headache they had ever 
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experienced. A questionnaire study by the same author found in 63 patients that the 
headache occurred daily in 74% and often had features of presence on wakening and pain in 
a nerve root or retro-ocular distribution. (Wall, 1990) A further study showed ocular pain to 
be a much more predominant feature in patients with IIH than controls. (Daniels et al., 2007) 
Other researchers found that the headache of IIH can be unilateral, or generalised and may 
be worsened by coughing, straining or the Valsalva manoeuvre.(Corbett et al., 1982) Quite 
often, headache may be the only presenting symptom.(Galvin and Van Stavern, 2004) 
    
1.1.5.2 Visual Disturbance   
Disturbance of vision is the second most prevalent symptom of IIH. Visual symptoms usually 
accompany headache, but may occur in isolation, as found in 19.5% in one study of 77 
patients.(Galvin and Van Stavern, 2004) A variety of symptoms are reported, including 
blurring, double vision or short-lived visual abnormalities. Transient visual ‘obscurations’, 
variously described as shadows, dark patches or black spots in the field of vision, affecting 
one or both eyes and resolving after a few seconds or minutes, are reported in 57 to 72% of 
patients. (Wall and George, 1991; Radhakrishnan et al., 1993; Kesler and Gadoth, 2001) They 
may occur with changes in posture. Both the exact pathophysiology and the prognostic 
significance of transient visual obscurations remain unknown. (Schirmer and Hedges, 2007) 
Visual symptoms in the review by Bruce et al (2009) were divided into vision changes, 
transient visual obscurations and diplopia, with frequencies amongst 655 women of 20%, 
11% and 5% respectively. Other eyesight abnormalities occur less frequently, and include 
diplopia and ‘sparkles’ (photopsia) or the sensation of flashes of light. Even less commonly 
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patients present with visual loss, although central vision is usually spared until late in the 
course of the illness. (Rowe and Sarkies, 1998)   
1.1.5.3 Additional Symptoms 
Intracranial noises occur frequently, usually described as ‘whooshing’ or ‘roaring’ in the ear. 
The sounds are often pulsatile. In prospective analyses, such noises occur in as many as 60% 
of patients. (Wall and George, 1991) Lower frequencies, such as 6% or less in some large 
series probably represent marked underestimation of symptoms by a retrospective 
approach. (Bruce et al., 2009; Giuseffi et al., 1991; Kesler and Gadoth, 2001) It has been 
proposed that tinnitus in IIH is produced as an effect of the raised CSF pressure on the 
vestibulocochlear nerve. (Kapoor, 2008b)  
Nausea and vomiting may appear, reported in one prospective study in 40%. (Mezaal and 
Saadah, 2005) Signs of meningeal irritation sometimes occur, including neck stiffness and 
photophobia in addition to nausea.(Friedman and Jacobson, 2002) Rarer symptoms in adults 
also include shoulder, back, arm and radicular pain. Sense of smell may be affected, with 
hyposmia reported in some series. (Kapoor, 2008a) 
In addition, psychological symptoms have been reported in IIH. Some patients complain of 
poor memory and mild generalised intellectual impairment has been found on 
neuropsychological testing in one study of 20 patients. (Sorensen et al., 1986b) Behavioural 
changes and disorders of attention and concentration have been reported in children with 
IIH. (Parness-Yossifon et al., 2008) There have been case reports of affective and dissociative 
disorders in patients with IIH although psychiatric illness may of course co-exist with IIH. 
(Duggal, 2005, Kuzman et al., 2008)  One study compared social function and symptoms of 
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anxiety and depression amongst 28 patients with IIH to 30 weight-matched and 30 normal 
weight control subjects.(Kleinschmidt et al., 2000) IIH patients were significantly more 
depressed than normal weight but not weight-matched controls and had worse scores than 
all controls on many items of the Spielberger State-Trait Anxiety Inventory and Short Form 
36 Health Survey (SF36). These findings mirror those of Daniels et al, (2007) who showed 
that vision-specific and overall health-related quality of life measures were affected to a 
greater extent in IIH than other neuro-ophthalmological disorders. They too concluded that 
obesity and weight gain seem to have the greatest effect on the mental health aspects of IIH. 
It is important to note also that patients with IIH may be entirely asymptomatic and present 
only after routine optician’s tests reveal swollen optic discs.     
1.1.5.4 Papilloedema 
Papilloedema is almost a universal finding in IIH and its absence should cause the diagnosis 
to be questioned. Since the invention of the ophthalmoscope in the late 19th century, much 
has been written about the evaluation of papilloedema as well as the anatomical changes 
involved in optic disc swelling and their consequences. Grading of the severity of 
papilloedema is discussed in chapter 4. 
1.1.5.4.1. Assessment of Papilloedema 
Slight oedema of the disc may be difficult to detect using the direct ophthalmoscope, even 
when pupils are chemically dilated to allow visualisation of a greater portion of the retina, so 
examination with a slit lamp is required. This is a combination of a high intensity light source 
with a microscope and series of lenses to allow detailed examination of the structures of the 
eye via a magnified, 3-dimensional view. Stereoscopic retinal photography also produces a 
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stable, enlarged image of the optic disc which is easier to assess than the ophthalmoscopic 
view and forms a lasting record of the disc appearance for later comparison.  In equivocal 
cases, fluoroscein angiography may be needed to display the leakage of dye from retinal 
vessels which is typical of papilloedema. However, this test involves the intravenous 
administration of fluorescein with a theoretical risk of complications and is avoided when 
possible.  
Congenital, anomalous variations in the architecture of the optic nerve head may mimic 
papilloedema and cause further diagnostic confusion.(Friedman and Jacobson, 2002; 
Friedman, 2001) The diameter of the scleral opening impacts on the appearance of the disc 
margin, with smaller openings tending to blur the appearance. (Frisen, 1982) Eyes with 
congenitally blurred disc margins are reported to have certain morphological features that 
distinguish them from those with true papilloedema, such as sharp, glittering light reflexes 
and normal nerve fibre bundles when examined with red-free light. (Hoyt and Knight, 1973) 
Nevertheless, such patients often undergo extensive investigation before conclusions over 
the benign nature of the discs are reached. Discs can be misshapen, tilted or show excessive 
pallor. Some people have ‘crowded’ optic discs in which there is little or no physiological 
cupping (the empty space in the optic nerve surrounded by the optic nerve fibres, described 
by the cup to disc ratio). The optic nerve head is small in diameter with nerve fibre bundles 
tightly crowded at the border. One large Chinese study found an approximate incidence for 
the general population of 38 in 1,000, defining crowded discs as small with slightly 
prominent border and no signs of pathology. (You et al., 2008)  
Drusen are white condensations of hyaline-like extracellular materiel situated in the optic 
discs. Although initially thought to be innocuous, drusen may be associated with visual 
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obscurations, visual field defects and even visual loss via ischaemic or occlusive events. They 
are thought to affect less than 1% of the population (Lorenzen, 1966) and may be inherited, 
seen in young patients or acquired with age. Giant forms may occur and haemorrhage may 
accompany drusen in the deep papillary region beneath the retina or in the substance of the 
optic disc.(Sanders et al., 1970) Superficial deposits of hyaline are easy to detect on the disc 
surface, but when buried deeper in the substance of the nerve, they may cause dome-
shaped elevations closely resembling papilloedema. (Acaroglu et al., 2002) Even greater 
difficulty arises if papilloedema occurs in addition to the presence of pre-exisiting optic 
nerve head drusen. 
Certain features are said to help with the discrimination of optic nerve head drusen from 
papilloedema, such as visible blood vessels at disc margins, a sharp peripapillary nerve fibre 
layer, elevation confined to the disc and a small, cupless disc. (Acaroglu et al., 2002) In some 
cases however, additional imaging techniques are required to assist in the diagnosis. 
Ultrasonography of optic nerves has been widely available for some time and various types 
of apparatus are in use. The reflectivity of the nerve is low compared to that of the sheath 
and this led to the successful introduction of the A-scan technique during the 1970s. 
(Ossoinig, 1979) The later transorbital B-scan approach allowed a distance behind the globe 
to be chosen to consistently measure the nerve diameter. (Hansen and Helmke, 1996) 
Three-dimensional coronal C-scan ultrasound imaging with computerised reconstruction is 
also now available as an accurate and inexpensive tool for optic nerve measurement. (Garcia 
et al., 2004). Ultrasound can be a rapid, non-invasive way of detecting drusen, which appear 
as reflective, foreign-body type lesions due to their calcium content. Traditional CT scans will 
also detect their presence, but involve ionising radiation. Optical coherence tomography 
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(OCT) is an imaging modality analogous to ultrasound, but using time of flight of light instead 
of acoustic waves. (Hu et al., 2008) The axial resolution in retinal tissue is much greater than 
that of ultrasound or CT scans. Confocal scanning laser ophthalmoscopy is an alternative 
technique for obtaining topographic retinal images. (Mulholland et al., 1998) The Heidelberg 
Retinal Tomograph uses a scanning diode laser to rapidly acquire an image of the nerve head 
as a series of aligned, transverse sections and has a high sensitivity for detecting small 
changes in optic disc volume. Although not yet widely used in clinical practice, such imaging 
appears to have a role in the evaluation of papilloedema and IIH. 
 
Figure 1.1 Optical Coherence tomography used to create a cross sectional image of the optic nerve. 
A colour scale is used to represent the intensity of the reflected coherent light waves. The arrow 
marks the distended peripapillary retinal nerve fibre layer. Image courtesy of Dr A.J Sinclair. 
 
1.1.5.4.2 Pathogenesis of Papilloedema 
The term papilloedema describes swelling due to raised intracranial pressure of the optic 
nerve head, or optic disc, the location in the eye where the optic nerve and retina connect. 
The main arterial supply to the anterior optic nerve is via the posterior ciliary arteries, with 
some supply of the more superficial part by the branches of the central retinal artery, with 
drainage almost exclusively via the central retinal vein and its tributaries, then into the 
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cavernous sinus. (Mackenzie and Cioffi, 2008) Papilloedema in brain tumours was initially 
thought to be a consequence of pressure on the cavernous sinus causing congestion of the 
ophthalmic vein and subsequent oedema of the optic nerve head. (Von Graefe, 1860) Later, 
electron microscopy studies showed that axonal swelling and not vascular disturbance was 
more likely to be the major factor. (Tso and Fine, 1976) Studies of experimental 
papilloedema in primates demonstrated prominent swelling and anatomical disruption of 
axons, confined to the surface nerve fibre layer of the optic nerve and anterior part of the 
prelaminar optic nerve head, but no vascular leakage. (Tso and Hayreh, 1977a; Tso and 
Hayreh, 1977b) Axonal degeneration but not swelling was seen in the myelinated 
retrolaminar optic nerve, where abundant extravasation was observed. The authors 
acknowledged that such features could be caused by a variety of pathological events, 
including mechanical crushing of the nerve, malignant hypertension and cyanide poisoning, 
thus were not specific for raised intracranial pressure. Additional studies showed 
disturbance of axoplasmic transport to be one of the major events in papilloedema due to a 
variety of conditions sharing a final common pathway. 
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Figure 1.2: Cross section of globe and optic nerve showing brain membranes 
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Astrocytes are the predominant cell type in the optic nerve head, tightly packed into spaces 
between collagenous beams and extending processes into bundles of axons. The optic nerve 
is regarded as a prolongation of brain substance, rather than an ordinary cerebrospinal 
nerve, due to its unique anatomy. As it passes from the brain to extend to the orbit it 
receives sheaths from the three cerebral membranes, pia, arachnoid and dura mater, in a 
‘cul-de-sac’ arrangement (Figure 1.2). It is surrounded by CSF throughout its length and its 
subarachnoid space is in direct communication with that of the brain, thought for many 
years to be free and bidirectional in nature. More recently, studies have challenged this 
assumption and led to the concept of compartmentation of the subarachnoid space in the 
optic nerve. (Killer et al., 2003) Differences in the concentration of beta-trace protein have 
been detected between spinal CSF obtained at lumbar puncture and CSF from the optic 
subarachnoid space. (Killer et al., 2006) In addition impaired communication of CSF between 
intracranial and optic nerve subarachnoid spaces has been demonstrated by a study of three 
patients with IIH who received intrathecal contrast medium then underwent CT-
cisternography. (Killer et al., 2007) The concept of separation of the optic nerve 
subarachnoid space from the other compartments of CSF may help to explain the 
asymmetry of papilloedema seen in some patients with IIH.  
1.1.5.4.3 Asymmetric Papilloedema 
Discs with markedly different appearances are not rare and truly unilateral papilloedema 
does occur in IIH. An example is shown in Figure 1.3 
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Figure 1.3: Asymmetric papilloedema in a 42 year old woman with IIH. The right fundus shows no 
papilloedema, the left fundus shows marked swelling of the optic disc. 
 
 
Foley (1955) noted ‘conspicuously unequal’ papilloedema in three instances in his report of 
60 patients. Unilateral papilloedema was seen in four of 57 patients in one more recent 
series(Corbett et al., 1982) and highly asymmetric papilloedema in six of 26 patients with IIH 
in another. (Lepore, 1992)  
Any of three factors, high CSF pressure, low intraocular pressure and low perfusion pressure, 
can lead to axoplasmic flow stasis and papilloedema. (Wall and White, 1998) Hence existing 
vascular disease or ocular conditions such as glaucoma provide a theoretical explanation for 
the asymmetrical disc swelling. However, these factors can be excluded in most cases, 
leaving CSF pressure to explain the phenomenon. (Kirkham et al., 1973) Animal studies as 
well as the response in humans to surgical procedures demonstrate that papilloedema 
resolves or lessens when raised pressure in the optic nerve sheath is reversed. Thus it seems 
likely that asymmetric papilloedema reflects asymmetry in the optic nerve sheath. 
Differences in the structure of the optic nerve sheath subarachnoid spaces adjacent to the 
optic canals, where the diameter of the nerve is narrowest, could affect their response to 
elevations of intracranial pressure, causing differences in local pressure at the optic nerve 
heads. (Wall and White, 1998)   
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1.1.5.4.4 IIH Without Papilloedema 
In 1972, a case report was published of an obese woman with severe headache, bilateral 
sixth nerve palsies and elevated CSF opening pressure, but whose fundoscopic assessment 
showed optic discs with defined borders and the presence of venous pulsations. (Lipton and 
Michelson, 1972) This may have been the first reported case of ‘pseudotumour cerebri with 
no papilloedema’. Since then, a body of evidence has grown for a distinct variant of IIH in 
which papilloedema does not occur.  
Marcelis and Silberstein (1991) described ten patients fulfilling the diagnostic criteria for IIH 
and reporting headaches with migrainous features, who did not develop papilloedema at 
any time during a follow-up period of up to ten years. The authors speculated that possible 
mechanisms for the phenomenon included bilateral defects of the optic nerve sheath, either 
congenital or acquired, or elevations of the intracranial pressure that were intermittent and 
insufficient to produce disc swelling. 
Mathew et al (1996) performed lumbar punctures in 85 patients with refractory migraine 
and found 12 patients had CSF opening pressures above 270mm water. None had 
papilloedema, visual obscurations or diplopia. This led to a call for all patients with 
treatment-resistant headache and migrainous features to have CSF pressure measurement, 
to exclude a diagnosis of ‘Idiopathic Intracranial Hypertension Without Papilloedema 
(IIHWOP).’ In 1998, Wang et al (1998) conducted a case-control retrospective study of 85 
patients with intractable chronic daily headaches, normal neurological examination and no 
papilloedema, all of whom had also undergone lumbar puncture. In 25 patients, the pressure 
was above 240mm on at least one occasion, leading to the diagnosis of IIHWOP. In 
comparison with the control group (60 patients with normal CSF pressure), the IIHWOP 
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cases had significantly higher incidences of pulsatile tinnitus, blurred vision and increased 
BMI.  
Further small series describing IIHWOP have been published subsequently, including 
paediatric case reports. (Wraige et al., 2002; Winner and Bello, 1996) More recently a 
Brazilian study reported six cases of IIHWOP amongst 61 patients with chronic migraine 
consecutively investigated with imaging and lumbar puncture. (Vieira et al., 2008) The CSF 
opening pressures amongst the six cases were not greatly elevated, ranging from 242 to 
300mm, with three values below 250mm. Confidence in the diagnosis of IIH was attributed 
by the authors to the clinical outcomes and headache response to lumbar puncture; 
improvement was seen in all six cases.  
The International Classification of Headache disorders 2nd edition (ICHD-II) now 
acknowledges that whilst the majority of patients with IIH do have papilloedema, a variant 
without papilloedema can be observed. An estimated prevalence for IIHWOP of 5.7% was 
reported from a cross-sectional analysis which identified 20 patients from a total of 353 
neuro-ophthalmology patients seen in a Utah University department between 1990 and 
2003. (Digre et al., 2009) Whilst all patients studied had elevated CSF opening pressure, the 
mean value for the IIHWOP cohort was slightly lower (309mm v 373mm, p=0.031). Visual 
fields at presentation were normal in 73% of IIHWOP patients compared with 13% of 
controls (p=0.002). Bilateral daily headaches affected both groups similarly, but aura was a 
more common symptom amongst the IIHWOP group (p=0.035).  
Whilst IIHWOP is now widely recognised, its diagnosis requires a high index of suspicion in 
addition to thorough neuro-ophthalmological assessment and careful CSF pressure 
measurement. The significance of a single CSF pressure measurement at lumbar puncture 
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has, as with all cases of IIH, been called into question in IIHWOP, due to potential variability 
of CSF pressure over time and the risk of both false positive and false negative values. 
Torbey et al (2004) call for the use of continuous CSF pressure recording in establishing the 
diagnosis of IIHWOP. In a retrospective review of ten patients with chronic daily headache, 
suspected to have IIHWOP on the basis of clinical presentation and opening CSF pressure 
above 200mm at lumbar puncture, the results of CSF pressure measurement via a lumbar 
catheter for 2.1 ±0.2 days were said to play a vital role, both in confirming the diagnosis of 
IIHWOP and supporting the decision to proceed to therapeutic surgical intervention. Four of 
the ten patients had lumbar puncture CSF pressures below 250mm, yet all patients had 
some abnormalities of the CSF waveform considered to be pathological, such that eight 
patients were referred for surgical CSF diversion procedures. The abnormalities were only 
detected during periods of sleep or rest, due to the frequent movement artefacts in the 
recordings at other times. The co-existence of normal baseline CSF pressure, (awake, resting 
pressures of below 204mm for all patients), with patterns of unstable elevated pressures is 
highlighted by this small study and no adverse events were reported. However, continuous 
CSF pressure monitoring is invasive and carries a significant risk of complications such as 
infection, thus rigorous prospective evaluation would be needed before it could be adopted 
as routine screening for IIHWOP. 
1.1.5.5 Visual Impairment 
Visual impairment is the main morbidity of IIH. Patients often fail to present with 
symptomatic visual loss so detailed assessment of visual function is required. Tests of colour 
vision are often recorded in routine clinical practice, but are seldom reported in published 
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studies. The prevalence of genetic colour vision deficiency in the general population may 
limit their use.  
1.1.5.5.1 Visual Acuity 
The refracted visual acuity is often normal when tested in patients with IIH. Reduced central 
visual acuity does occur, but review of the recent literature suggests this to be the case in 
less than a quarter of patients at presentation.(Wall and George, 1991; Radhakrishnan et al., 
1993; Galvin and Van Stavern, 2004; Craig et al., 2001)  
 Loss of vision seems to occur via diffuse, ischaemic damage to the optic nerve fibres caused 
when the vascular supply of the nerve is compressed by swelling. (Wall and White, 1998) 
Preservation of central vision is thought to be due to the relative surplus of visual processing 
elements serving the central portion of the visual field, such that peripheral vision is more 
likely to be affected by diffuse damage to the optic nerve. Testing the best refracted visual 
acuity in both eyes, using standard letter charts, remains an important part of the 
assessment of patients with IIH, since if abnormalities are present, the degree of optic nerve 
damage can be considered substantial and indicative of the need for urgent treatment. 
Amongst patients with early loss of central vision, other causes such as optic neuritis and 
ischaemic optic neuropathy should be considered and excluded if necessary. 
1.1.5.5.2 Contrast Sensitivity 
Letter charts provide information about just one aspect of visual perception. Sensitivity to 
visual contrast using stimuli with a range of spatial frequencies can also be measured. The 
technique is based on patterns or gratings, ranging from coarse (low spatial frequencies) to 
fine patterns (high spatial frequencies.) Sinusoidal gratings are often used, in which the 
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luminance of alternating light and dark bars are varied in a sinusoidal fashion, with the 
spatial frequency corresponding to the number of pairs of light and dark bars per degree of 
visual angle. Specifically designed plates or computer generated images projected on a 
monitor are used to display the patterns. 
An alternative to gratings is the Pelli-Robson contrast sensitivity chart. (Pelli et al., 1988) It 
consists of rows of letters of the same size but decreasing contrast. (Figure 1.4) Wall-
mounted, it is normally viewed from a distance of one metre, from where the letters equate 
approximately to one cycle per degree, giving a measure of contrast sensitivity at one spatial 
frequency. Letters on the chart are organised into groups of three, i.e. triplets, there being 
two triplets per line. Within each triplet, letters have the same contrast. The contrast 
decreases from one triplet to the next, thus the difficulty increases line to line as well as in 
the middle of each line. Such charts have practical advantages although print quality must be 
calibrated and charts displayed according to precise guidelines to meet the standards 
required of a clinical instrument. 
Contrast is best defined as the difference in luminance between the letter and background, 
divided by the luminance of the background. This ratio of luminances is known as the Weber 
contrast and differs from the Michelson contrast used for grating stimuli. The lowest visible 
contrast is called the contrast threshold, the reciprocal of which is the contrast sensitivity, 
using expressed as the Log10 contrast sensitivity. Thus the higher the Log10 contrast 
sensitivity, the better the person’s vision and steps on the scale correspond to equal effects.  
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Figure 1.4: Pelli-Robson contrast sensitivity chart 
 
Studies have shown that abnormalities in contrast sensitivity occur more frequently amongst 
patients with IIH than healthy control subjects.(Wall, 1986; Bulens et al., 1988) In IIH case 
series and prospective studies, abnormal contrast sensitivity occurs in significantly more 
patients at presentation than loss of acuity, and in some cases visual field loss, which has led 
to claims that it is a more sensitive measure of visual dysfunction.(Wall, 1986; Wall and 
George, 1991; Verplanck et al., 1988)  
 
1.1.5.5.2 Visual Field Defects  
Testing of visual fields by confrontation in patients with IIH may elicit few abnormalities, but 
formal perimetry reveals that visual field defects are often present and enlargement of the 
blind spot is nearly always seen. In general, visual field abnormalities are one of the earliest 
indicators of ophthalmic disease. Perimetry, the systematic examination and quantification 
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of the three-dimensional island of vision, has developed as an essential tool in their 
evaluation.  
Kinetic perimetry involves a light stimulus of known intensity and size being moved to find 
the most peripheral location where it is seen by a person maintaining fixation on a central 
target. An examiner manually presents the light stimulus to the patient and records their 
response on a standardised chart. The result is a plot of several loci connected by a line 
called an isopter, defining a zone of equal visual sensitivity. Smaller and dimmer lights result 
in isopters closer to the centre where the visual threshold is lowest. Goldmann perimetry 
uses this method; examples are shown in Figures 1.5 and 1.6. 
Static or automated perimetry involves the presentation by a computer of a brief static light 
stimulus at various loci throughout the visual field and recordings of the intensity of light at 
which it is seen. The Octopus Perimeter and the Humphrey Visual Field Analyser are both 
examples, with the latter now most commonly in use.(Werner, 1991) There are various test 
patterns for central, peripheral or full fields and a variety of screening strategies are 
possible. Software, such as the Statpac programme, is available to perform the screening 
and threshold tests as well as to aid in the interpretation of results. Visual thresholds are 
recorded in terms of decibels of attenuation, with lower thresholds having higher numerical 
value. Statpac compares the results of individual tests with normal population visual field 
data stored in the computer. Two values are calculated; the mean deviation (MD) is the 
average amount by which the measured threshold differs from the age corrected norm and 
the pattern standard deviation (PSD) is a measure of localised non-uniformity of the hill of 
vision. An example of automated perimetry is shown in Figure 1.7. 
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Figure 1.5: Visual field (Goldmann perimetry) from the right eye of a 54 years female with IIH 
showing marked constriction 
 
 
Figure 1.6: Goldmann fields with minor enlargement of the blind spot as the only abnormality 
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The Statpac software also monitors and records the patient’s fixation on the central target 
during the test. Further measures of test reliability are provided by the recording of false 
negatives, when patients fail to respond to a light stimulus brighter than one previously 
responded to and false positives, in which patients respond to a stimulus that was not 
presented. Fatigue and inattention as well as volitional variability of response may lead to 
such errors. Even amongst technically acceptable visual fields, with low rates of false 
positives and negatives, variability may have a significant impact on their interpretation. In a 
large study of patients with ocular hypertension, retesting the visual fields failed to replicate 
abnormalities in the majority of cases. (Keltner et al., 2000) Abnormalities were not 
confirmed for 604 (85.9%) of the 703 originally abnormal and reliable visual fields when 
retests were carried out as part of the Ocular Hypertension Treatment Study.  It is thought 
that a learning effect may influence the results of repeat perimetry and it is essential to 
confirm any abnormalities detected on an initial assessment. (Yenice and Temel, 2005)  
Perimetry appears to be a sensitive test in IIH. At the initial visit in the study by Wall and 
George, (1991) Goldmann perimetry was abnormal in 87% of eyes and Humphrey 
automated perimetry in 92%. By comparison, abnormal Snellen acuity was present in only 
22% of the same group of patients.  Other large studies in IIH have documented similar 
rates, with automated perimetry tending towards greater sensitivity. (Rowe and Sarkies, 
1998)  
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1.7a
1.7b 
Figure 1.7: Visual fields (Humphrey 24-2 automated static perimetry) from the right eye of a 
woman with IIH. Generalised reduction in sensitivity with enlargement of the blind spot and an 
inferonasal defect are shown. 1.7a: Visual thresholds as shown by greyscale diagram and 
numerical results; 1.7b: Numeric and symbolic representations of the calculated total and pattern 
response deviations from normal. 
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The visual field defects in papilloedema mirror those of other anterior optic nerve 
pathologies, such as glaucoma and anterior ischaemic optic neuropathy. Enlargement of the 
physiological blind spot is seen in most cases of IIH, related to the effect of the swollen optic 
nerve head occupying a larger area of retina (Figure 1.6). Often fields in IIH with blind spot 
enlargement are categorised with normal fields, unless they encroach on fixation, due to the 
benign and common nature of the finding. The locations of other visual field defects in IIH 
reflect the retinal nerve fibre arrangement and its relation to swollen areas of the optic disc. 
Of these ‘disc-related’ defects, peripheral rim constriction appears to be the most common 
(figure 1.5). Inferonasal steps are the next most common (figure 1.7), then arcuate scotoma, 
arch-shaped defects in the field of vision as well as nasal defects.(Rowe and Sarkies, 1998; 
Hung et al., 2003; Galvin and Van Stavern, 2004) Other less common defects include central, 
paracentral and caecocentral scotomata, with temporal and altitudinal losses even less 
frequently recorded. (Wall et al., 1991) (Figure 1.8) 
Rather than providing extensive descriptions of the various field defects in series of patients 
with IIH, many researchers apply a grading system to group and summarise the findings. 
Wall and George (1991) published detailed grading systems for both manual and automated 
perimetry in their prospective study of 50 patients with IIH. Grades 0, 1, 2, 3, 4 and 5 were 
described in each, with 0 being normal visual field and 5, blinding visual field loss. This 
grading system has subsequently been adopted in several published studies in IIH. (Rowe 
and Sarkies, 1998; Celebisoy et al., 2007; Bruce et al., 2009) Interestingly, the grade of visual 
field defect did not correlate with the severity of papilloedema in the original 
description.(Wall and George, 1991) A later study by one of the authors did find  that 
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amount of optic disc oedema was related to the severity of visual loss, although there was 
considerable inter-individual variation. (Wall and White, 1998)  
 
Nasal step left eye (Goldmann) 
 
Temporal loss right eye 
(Humphrey) 
 
Inferior arcuate and central scotoma 
left eye (Humphrey) 
 
Moderate inferior arcuate scotoma 
right eye(Humphrey) 
Figure 1.8 Examples of less common visual field defects in IIH 
1.1.5.6 Additional Signs  
It is a requirement of the modern diagnostic criteria for IIH that neurological examination is 
normal except for the presence of signs reflecting generalised intracranial hypertension and 
papilloedema.(Friedman and Jacobson, 2002) Unilateral or bilateral sixth cranial nerve 
palsies can therefore be expected and have been specifically documented in some studies at 
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rates of 17 to 33%.(Corbett et al., 1982; Radhakrishnan et al., 1993; Mezaal and Saadah, 
2005) Abducens palsies are more likely to be unilateral and appear to be more common 
amongst children. (Johnston et al., 2007) Other cranial nerve defects have been reported 
very rarely, in single case reports, including facial and oculomotor palsies. (Bakshi et al., 
1992; Capobianco et al., 1997)   
Afferent papillary defects are also seen, although their frequency has not been formally 
reported in many studies. Wall and George (1991) found relative afferent papillary defects in 
nine patients. Rarer ophthalmological complications have been described, including 
choroidal neovascularisation (Castellarin et al., 1997) and metamorphosia, a visual distortion 
in which straight lines appear curved, normally seen in association with retinal folds. 
(Warner and Katz, 2005) A degree of optic atrophy, seen as small, pale optic discs, may be 
visible in some cases of IIH, where there has been prolonged papilloedema and optic nerve 
fibre loss. 
1.1.6 Investigation  
1.1.6.1 Imaging 
Since IIH is largely a diagnosis of exclusion, patients presenting with signs and symptoms of 
raised intracranial pressure must be sufficiently investigated to rule out cerebral pathology 
and ventricular enlargement. Historically, plain skull X-rays and occasionally air 
encephalograms or ventriculograms were carried out. Whilst there are no pathognomonic 
radiological signs in IIH, an empty sella turcica and variable diminution in ventricular size 
have been frequently reported, although the latter has been debated. (Boddie et al., 1974) 
Computed tomography (CT) then became the investigation of choice until it was superseded 
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in recent years by magnetic resonance imaging (MRI). Posterior scleral flattening, relative to 
the normal curvature of the globe, prelaminar enhancement of optic nerves within the 
globe, vertical tortuosity of the orbital optic nerves and distension of the perioptic 
subarachnoid space, as well as empty sella, have recently been shown to be sensitive and 
specific markers of raised intracranial pressure amongst IIH patients in a restrospective MRI 
series. (Brodsky and Vaphiades, 1998) 
To comply with the most recent diagnostic criteria, cerebral venous sinus thrombosis (CVST) 
must also be excluded. (Friedman and Jacobson, 2002) Thrombosis of the cerebral venous 
circulation can present with an identical clinical picture to IIH (Biousse et al., 1999) and may 
even fulfil the older ‘modified Dandy’ criteria for IIH. (Sylaja et al., 2003) It is possible to 
overlook sinus thrombosis on CT or MRI unless formal study of the cerebral vasculature is 
undertaken by computed tomographic venography (CTV) or magnetic resonance venography 
(MRV). (Lueck and McIlwaine, 2002) Thrombosis is usually recognisable on MRV if it affects 
the superior sagittal sinus, but the lateral and transverse sinuses are more difficult to assess 
as they display greater anatomical variation. (Higgins et al., 2004) There is some evidence 
that MRV may miss lesions in the transverse sinuses altogether and that direct retrograde 
cerebral venography may be a more thorough means of excluding defects. (Owler et al., 
2003) Even more information may be gained through the use of manometry to reveal 
pressure gradients within the cerebral venous sinuses. Stenoses, or narrowings of the 
venous conduits have been demonstrated in some patients with IIH. (Farb et al., 2003) Thus, 
the ‘gold standard’ to exclude CVST is probably the combination of direct venography with 
manometric pressure measurement, but in current clinical practice, MRV or CTV are 
considered adequate.   
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1.1.6.2 Intracranial pressure measurement 
The intracranial pressure (ICP) is usually measured by lumbar puncture examination to 
determine the pressure of the CSF. Although this is an indirect measure of the ICP, in 
contrast to direct measurement within the brain tissue or ventricles, it is believed to be an 
accurate reflection of the true intracranial pressure in conditions in which there is free 
circulation of the CSF. (Lenfeldt et al., 2007) The lumbar puncture examination is performed 
with the patient lying in the lateral decubitus position. A pressure recording of over 20 
centimetres of water is generally considered to be abnormal. It is essential that the patient is 
as relaxed as possible and time should be allowed for the pressure to stabilise. The knees 
and hips should be in the extended position during pressure recording, since there is 
evidence that a flexed posture as well as the Valsalva manoeuvre can elevate the pressure.  
In one prospective study, 15 patients with various neurological disorders underwent lumbar 
puncture and measurement of CSF pressure. (Neville and Egan, 2005) Patients with an initial 
opening pressure of above 20cm were excluded. The mean resting pressure amongst the 15 
patients was 14.6cm (range 10-19), which rose to 32.3 (range 26-47) cm when patients were 
asked to perform a Valsalva manoeuvre, with hips in flexion and bearing down against a 
closed glottis. All of the patients were thus able to elevate their pressure to levels that would 
normally be considered pathological. It is common practice for some lumbar punctures to be 
performed with patients in the seated position, particularly when the procedure is 
technically difficult due to patient obesity or other factors. Care is therefore needed in the 
interpretation of single recordings of CSF pressure to avoid over-diagnosis of intracranial 
hypertension. 
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There is considerable debate as to whether obesity itself is a cause of mildly elevated CSF 
pressure. A study of 134 patients diagnosed as having pseudotumour cerebri found an 
average CSF pressure, recorded by direct manometry, of 34.4 centimetres of water, 
compared to mean values of 13.6 and 16.7 amongst 15 non-obese and 41 obese controls 
respectively. (Corbett and Mehta, 1983) There was no correlation between CSF pressure and 
obesity, nor was the difference in pressures between the obese and non-obese controls 
significant when analysed statistically. Bono et al (2002) studied a group of 100 patients who 
were having lumbar punctures for diagnostic purposes, none of whom had papilloedema or 
abnormalities on MRI and MRV scans. No patient had a CSF opening pressure above 200mm. 
The obese subjects tended to have slightly higher CSF opening pressures but the differences 
were not significant. The authors concluded that a pressure above 200mm in a patient of 
any body weight was an indication for further investigation to exclude cerebral venous sinus 
thrombosis. 
There is also a risk that lumbar puncture measurement of CSF pressure can fail to detect 
cases of intracranial hypertension. Continuous recording of CSF pressure has shown that the 
pressure changes over time, building up to a crescendo followed by sudden falls (Johnston, 
1974) or reaching high, rapidly changing levels over 24 hours, which lack any particular 
rhythm and occasionally drop to normal values.(Gucer and Viernstein, 1978) Overnight 
monitoring in IIH shows that the baseline pressure is usually increased and that plateau or A 
waves (sustained above 50 mmHg for 5 to 20 minutes) and B waves (rhythmic, 5 to 50 
mmHg, 0.5 to 2 cycles per minute) are often present. (Czosnyka and Pickard, 2004; Torbey et 
al., 2004) In theory, a single lumbar puncture may lead to normal pressure recordings in IIH. 
There is evidence that fluctuations in CSF pressure can occur in established IIH, such that 
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patients may have pressures within the normal range on repeat lumbar punctures despite 
the presence of symptoms and papilloedema. (Rabinowicz et al., 1968) However, 
practicalities and risks such as infection preclude the routine use of prolonged CSF pressure 
measurements and multiple lumbar punctures in routine clinical practice. 
 Attempts have been made to measure CSF pressure by other, less invasive methods. 
Intraocular pressure, measured by tonometry has been reported to correlate with 
intracranial pressure as measured by lumbar puncture. (Sajjadi et al., 2006) A later review 
found that the two measures did not correlate and suggested that variability in techniques 
of measurement as well as the various intra-ocular factors contributing to intra-ocular 
pressure could explain the differences. (Han et al., 2008) MRI and ultrasonography studies 
have suggested that the optic nerve sheath diameter can accurately predict raised 
intracranial pressure and that such measurement from imaging is feasible in the majority of 
patients. (Geeraerts et al., 2008a; Geeraerts et al., 2008b) However, any finding of optic 
nerve sheath diameters suggestive of intracranial hypertension would simply indicate a need 
for more precise measurement of pressure. Whilst it can be an uncomfortable procedure 
and alternatives would be welcomed, as yet there are no proven substitutes for lumbar 
puncture in IIH. 
Analysis of the CSF in the patient with suspected IIH is mandatory, and its composition must 
be normal to conform to the diagnosis. CSF pleocytosis, indicating possible inflammatory 
conditions or infections, must be excluded. The only exception is that CSF protein content 
may be lower than the generally accepted normal of less than 0.4gl-1 in some patients with 
IIH. (Chandra et al., 1986)   
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1.1.7 Management 
The goals of treatment in IIH are to reduce the elevated CSF pressure, preserve visual 
function and relieve symptoms. Combinations of medical, physical and surgical measures are 
commonly used.  
1.1.7.1 Therapeutic lumbar puncture 
Historically, repeated lumbar punctures formed the mainstay of treatment for many 
patients, using withdrawal of CSF to directly lower the intracranial pressure. Case series have 
reported the use of serial lumbar punctures, alone or in combination with other therapeutic 
interventions, with varying degrees of success. (Johnston et al., 2007) There have been no 
prospective trials however and it is not clear in many cases what the clinical consequences of 
not repeating the procedure would have been. It is widely believed that repeated lumbar 
puncture may result in a hole in the dura, maintaining lowered pressure via a small amount 
of chronic CSF leakage, but the prevalence of this phenomenon and its effect, if any, is 
entirely unknown. The removal of an average volume of 15-25 ml of CSF has been shown to 
be enough to reduce the pressure to below 10 cm of water, but in the same study, it took an 
average of only 82 minutes for the pressure to return to pre-drainage levels. (Johnston and 
Paterson, 1974)  
The unpopularity of the procedure amongst patients as well as its uncertain clinical benefit 
has led to multiple lumbar punctures being largely phased out of current practice. In 
addition, the complication of post lumbar puncture low-pressure headaches may occur, 
which can be difficult to treat and might confuse the assessment of headache symptoms in 
IIH. There are certain instances in which serial lumbar punctures may still have a role. If 
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acute or rapidly progressive visual loss occurs in IIH, it may be essential to promptly reduce 
the pressure in an attempt to preserve vision via immediate drainage of CSF. Given the brisk 
restoration of CSF volume, this is unlikely to be a lasting solution, insertion of a lumbar drain 
being a more definitive approach, but lumbar puncture has the advantage of usually being 
simple and quick to perform. Lumbar punctures are also safe in the management of 
pregnant patients when temporary control of CSF pressure is required urgently and surgery 
or drug treatment is contraindicated. (Lueck and McIlwaine, 2002)  
1.1.7.2 Medication  
1.1.7.2.1 Acetazolamide 
Acetazolamide is the drug most commonly used to treat IIH. It inhibits the enzyme carbonic 
anhydrase, resulting in bicarbonate wasting in the renal tubules and creating a 
hyperchloraemic metabolic acidosis in addition to a mild diuresis.  
 
Figure 1.9: Skeletal formula representing the molecular structure of acetazolamide, chemical 
nomenclature N-(5-sulfamoyl-1,3,4-thiadiazol-2-yl)acetamide or C4H6N4O3S2. 
 
Acetazolamide is used in the treatment of glaucoma due to its effect of lowering intraocular 
pressure by reducing the production of aqueous humour. It is also used to prevent and treat 
altitude sickness, via its effect upon ventilation and blood oxygenation. (Leaf and Goldfarb, 
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2007) The effect of the metabolic acidosis on respiratory function has also lead to its 
successful use in sleep apnoea syndrome. (White et al., 1982) The mechanism of action in IIH 
is not fully understood. Early studies in rabbits showed a reduction of CSF production 
following administration of acetazolamide (Tschirgi et al., 1954) and the first study to 
demonstrate a similar effect in humans was that of eleven patients by Rubin et al (1966) 
Subjects ranging in age from 9 to 61 years were studied under conditions of regulated 
intracranial pressure, during CSF perfusion chemotherapy for CNS tumours. CSF production 
was calculated from measurements of concentrations of inulin added to the perfusates. 
Intravenous acetazolamide was found to reduce the rate of CSF production to varying 
degrees amongst the subjects, but always with a maximum response achieved in the first 90 
minutes and a maximum duration of response not exceeding 30 minutes. In a more recent 
study, Schoeman et al (1994) studied eight children receiving acetazolamide for IIH using 
continuous lumbar CSF pressure monitoring. Mean baseline pressure was significantly lower 
after one week of treatment and normalised within six weeks of treatment onset in all cases. 
 A study in rabbits linked the effect of acetazolamide to the inhibition of carbonic anhydrase 
in the choroid plexus, where epithelial cells are structurally similar to those lining the renal 
tubules. McCarthy and Reed (1974) showed that the maximum absolute reduction in CSF 
flow with intravenous acetazolamide was 50% and that the acetazolamide had no effect 
upon CSF production until well over 99% of the carbonic anhydrase activity, measured by a 
changing-pH method, had been inhibited. However, different animal studies have shown 
that acetazolamide diminishes the rise in CSF bicarbonate when given by direct 
intraventricular administration but not intravenously, suggesting that its clinical effects are 
not due to carbonic anhydrase inhibition within the CNS.(Leaf and Goldfarb, 2007) 
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Acetazolamide is theoretically capable of crossing the blood-brain barrier, but it is likely that 
only negligible concentrations accumulate when given in normal human doses, particularly 
via the oral route as is common practice in IIH. Typical oral doses also fail to produce a rise in 
cerebral blood flow, suggested by some as an alternative mechanism of action. (Huang et al., 
1988; Grossmann and Koeberle, 2000)  
Acetazolamide belongs to the sulphonamide group of drugs and can be associated with 
rashes, electrolyte disturbances and nephrocalcinosis. Aplastic anaemia is a rare adverse 
effect for which some clinicians routinely screen. Patients frequently complain of 
paraesthesiae (altered sensation or ‘pins and needles’) as well as parageusia (altered taste), 
especially with carbonated drinks. The latter, as well as reported side effects of nausea and 
anorexia, has led to the suggestion that part of the apparent efficacy of acetazolamide can 
be attributed to reduced oral intake and subsequent weight loss. (Wall, 1995)  
Not only is the mechanism of action of acetazolamide unclear, but the magnitude of its 
clinical effect in IIH, in any, is unproven. No randomised controlled trials of acetazolamide 
have been undertaken and retrospective studies frequently report its use in combination 
with other modalities. In an Australian case series, acetazolamide was the primary treatment 
in 45 (31%) of 144 cases of adult and childhood IIH. (Johnston et al., 1981) Of these 45 cases, 
it was judged to be effective in 21 (47%), ineffective or partly effective in 22 (49%) and 
stopped due to complications in two cases (4%). Acetazolamide was the most common 
treatment in the prospective study by Wall and George, (1991) given to 29 of the 50 patients 
enrolled. By the end of the study, 11 of these patients were classified as better, 11 as 
unchanged and 7 as worse when their visual fields were compared. 
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Johnson et al (1998) studied 15 women with IIH who received a minimum of four weeks 
treatment with acetazolamide during a 24-week period. Nine of the 15 patients had 
complete resolution of their papilloedema during the study and a further two, partial 
improvement. Four patients showed no improvement in their optic disc appearance, despite 
acetazolamide treatment. All of the patients who improved had lost weight, with a 
significant correlation between degree of papilloedema resolution and percent weight 
reduction, but the four subjects with no improvement had lost no weight during the study. 
The authors concluded that the improvement was due to the weight reduction rather than 
acetazolamide in this cohort. 
Only one small prospective trial involving acetazolamide in IIH has been carried out to date. 
Celebesoy et al (2007) recruited 40 adults with IIH to an open-label study comparing 
acetazolamide with topiramate. Alternate allocation, not randomisation, was employed to 
assign patients to either drug and patients were assessed at three, six and 12 months. No 
difference was found between the visual field grades in either group at any time point, 
although a significant improvement was seen overall. The widespread use of acetazolamide 
has thus developed in the absence of a robust evidence base. It is likely that the low cost, 
ease of administration and relatively good tolerability as well as a lack of proven alternatives 
have contributed to its popularity. 
Acetazolamide is generally avoided in pregnant patients. The United States Food and Drug 
Administration (FDA) categorises it in ‘Pregnancy Category C, (‘animal reproduction studies 
have shown an adverse effect on the fetus and there are no adequate and well-controlled 
studies in humans, but potential benefits may warrant use of the drug in pregnant women 
despite potential risks.’) Slight differences exist in the Australian classification, where 
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Pregnancy Category B3, (‘Drugs which have been taken by only a limited number of pregnant 
women and women of childbearing age, without an increase in the frequency of 
malformation or other direct or indirect harmful effects on the human fetus having been 
observed’) is applied to acetazolamide. Teratogenic effects have been reported in animals, 
such as cortical and limb malformations. There are no adequate human studies of its use in 
pregnancy and a recent review of the literature failed to find any reliable reports of adverse 
pregnancy outcomes amongst women treated with the drug. (Lee et al., 2005)  
1.1.7.2.2 Diuretics 
If acetazolamide is poorly tolerated, diuretics such as furosemide are sometimes substituted. 
A few reports in the literature describe the ability of furosemide to reduce CSF production. 
In the rabbit studies by McCarthy and Reed (1974) both furosemide and acetazolamide were 
shown to depress production of CSF for several hours after intravenous administration. 
Interestingly, for an equal reduction of CSF production, inhibition of carbonic anhydrase 
activity by acetazolamide was significantly greater than that by furosemide. This suggests 
that a mechanism other than carbonic anhydrase inhibition is involved in the reduction of 
CSF formation by furosemide. More recent rabbit experiments showed that maximum CSF 
flow reduction of 20% was achieved by intravenous furosemide compared to a 40-60% 
reduction after infusion of acetazolamide. (Vogh and Langham, 1981) In the same study, 
bumetanide was shown to have no effect on CSF production. 
There is very little data in the literature regarding the clinical use of diuretics in IIH. Jefferson 
and Clark (1976) concluded that ‘dehydration therapy alone is sufficient treatment for IIH’ 
following their study of 25 adults treated with hydroflumethiazide, chlorthalidone, oral 
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glycerol or urea. Striking improvements in papilloedema, improvement in visual acuity and 
reduction in blind spot size on serial measurements were presented as evidence that 
dehydrating agents could entirely remove the need for surgery in treating IIH. Two 
prospective studies from a Danish centre reported the use of chlorthalidone or furosemide 
in addition to acetazolamide as standard medical therapy for IIH. (Krogsaa et al., 1985; 
Sorensen et al., 1988) No study has systematically examined the use of diuretics and it 
seems their main use is as an alternative when acetazolamide is contraindicated. 
1.1.7.2.3 Corticosteroids 
A beneficial response to corticosteroid treatment in IIH was first reported by Paterson et al. 
(1961) Rapid improvement in the symptoms and signs of raised intracranial pressure was 
observed in five of six patients, the response being described as ‘not uniform’ due to its 
absence in one patient. Corticosteroids were widely adopted over the following three 
decades as first line management, chosen in preference to other measures such as repeated 
lumbar punctures and diuretics or given in addition.  
Steroid administration has been shown to be effective in reducing brain swelling and is 
standard practice in the management of some causes of cerebral oedema. (Rasmussen and 
Gulati, 1962) Studies have also shown that steroids can reduce CSF production. (Lindvall-
Axelsson and Owman, 1990) The effect of steroids on CSF absorption is less clear. One study 
in dogs showed that four weeks of high dose steroid administration had no effect on infusion 
tests of resistance to outflow or CSF absorption measured by radionuclide studies. (Johnston 
et al., 1975) In a study of nine patients treated for ‘pseudotumour cerebri’ with oral 
prednisolone, two patients were tested for CSF outflow resistance before and after four 
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weeks of therapy. In this case, marked reduction in resistance as well as a decrease in resting 
CSF pressure was observed after treatment, associated with marked resolution of 
symptoms.  
High-dose intravenous methylprednisolone has been suggested as a treatment for florid 
papilloedema and acute severe visual loss in IIH following an observation by Liu et al (1994) 
that it led to rapid reversal of visual dysfunction and lasting clinical improvement in three of 
four patients tested. Patients received tapering oral doses of steroid after five daily 
infusions, but were also receiving oral acetazolamide. In a larger series, 31 of 37 patients in 
an initial cohort treated with steroids alone (prednisolone, betamethasone or 
dexamethasone) had resolution of all symptoms and signs. (Johnston et al., 1981) Seven of 
the patients had intracranial pressure monitoring which showed a significant reduction after 
three months, although pressures were still above normal. A later cohort from the same 
study showed the use of steroids alone to be less effective, leading to clinical improvement 
in just 11 of 31 patients, one of whom had later recurrence of their disease. Neither of the 
two studies adhered to rigorous diagnostic criteria for IIH and probably included cases of 
cerebral venous sinus thrombosis, such that the mechanism of action of corticosteroids as 
well as the aetiology of the intracranial hypertension was variable. Nine of the 50 patients 
with IIH in the prospective study by Wall and George (1991) received corticosteroid therapy, 
five of whom had clinical improvement at the end of the study. The remaining four had a 
worse outcome, based on visual field and papilloedema grade, such that they were referred 
for surgical treatment. Some of the patients received acetazolamide in addition to the 
corticosteroids and the study was not designed or powered to evaluate the effect of 
intervention.  
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Concerns over the side effects of steroid treatment have greatly reduced their use. A 
complication rate of 13% was reported in the series reported by Johnston et al, (1981) with 
steroid therapy resulting in diabetes mellitus, fluid retention, peptic ulceration, weight gain 
and psychotic symptoms. Weight gain is a particularly unwelcome long term effect in the 
typical IIH patient, so corticosteroids are now rarely included as first line management. 
 
1.1.7.2.4 Octreotide 
The somatostatin analogue octreotide has been shown to ameliorate headache and improve 
visual symptoms and papilloedema in three patients with IIH. (Antaraki et al., 1993) In two of 
these patients, a reduction in CSF pressure was found when measurements pre and post 
treatment were compared. More recently, a Greek centre recruited 26 patients with IIH to 
an open label prospective study of daily treatment with subcutaneous octreotide injections 
for a mean duration of 42 weeks. (Panagopoulos et al., 2007) Significant clinical 
improvement in headache and papilloedema was observed in 24 of the 26 patients (92%). 
Median times to improvement of headache and papilloedema were seven and 45 days 
respectively. Visual disturbances affected 20 of the study patients and resolved by the end of 
the three year follow up period in 18. The two patients who did not respond to octreotide 
therapy also failed to improve when treated with acetazolamide plus corticosteroids and 
went on to receive surgical intervention. CSF pressure measured at lumbar puncture before 
and one month after treatment showed a significant reduction from 34.4 to 14.7 cm (mean 
values), p<0.001.  
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No other trials have been performed to assess the role of octreotide in IIH. The study by 
Panagopoulous et al (2007) was uncontrolled and unblinded, so limited conclusions can be 
drawn. Octreotide exerts inhibitory effects on the growth hormone / insulin-like growth 
factor axis (Plewe et al., 1984) and has been used for the treatment of headache associated 
with acromegaly and pituatory tumours with some success. (Williams et al., 1987) There are 
also case reports of its use in migraine (Kapicioglu et al., 1997) and cluster headache. 
(Matharu et al., 2004) Whether the apparent benefit in some IIH patients is due to an 
analgesic mode of action in addition to an effect on the raised intracranial pressure is 
unknown. 
1.1.7.2.5 Topiramate 
The antiepileptic drug topiramate, a sulfamate-substituted monosaccharide, has a complex 
mode of action with multiple mechanisms including some weak carbonic anhydrase 
inhibition. Initially licensed for the control of seizures, it has become a recognised migraine 
treatment and has been used off-licence in a variety of other conditions. A case report in 
2002 described improvements in headache and visual symptoms amongst three obese 
female patients with IIH when topiramate was given, where acetazolamide had been used 
without success. (Pagan et al., 2002) A later case report showed that papilloedema and 
headache improved in a 20 year old female when topiramate was introduced to treat 
recurrent IIH after acetazolamide, CSF drainage and corticosteroids had failed. (Finsterer et 
al., 2006) A retrospective chart review by Shah et al (2007) identified 17 female IIH patients 
treated with topiramate between 1997 and 2005 and studied a variety of outcome measures 
over a mean period of 54 months. Topiramate was used with acetazolamide in three cases, 
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with furosemide in one and as single drug therapy in the remaining 13 (76%). Symptomatic 
improvement was reported in some patients and optic disc oedema either improved or 
stabilised in all patients. There was a significant improvement in mean disc oedema grade 
(p=0.033) but not in the Humphrey automated perimetry mean deviation (p=0.58). Seven 
patients lost weight, but quantities were not provided. Despite the limitations of the study, 
the authors recommended that topiramate be considered as an adjuvant or second-line 
agent for the treatment of IIH. 
One study has attempted to examine the use of topiramate for IIH in a clinical trial. In the 
Turkish study by Celebisoy et al (2007) 20 patients received topiramate as an alternative to 
acetazolamide by a random-allocation design. Although a treatment effect was not found, 
‘prominent relief’ of headache was reported after a mean treatment period of 3.75 months 
(mean 3.3 months in patients receiving acetazolamide).  Weight loss was observed amongst 
patients in the topiramate arm over the 12 month study period (mean 9.75kg), significantly 
more than that in the acetazolamide arm (p<0.001). Other side effects reported were distal 
paraesthesiae and concentration difficulties, although no patient discontinued the drug. 
Some centres now routinely consider topiramate as an IIH treatment option. Where 
headache is a prominent symptom, the known migraine prophylaxis effect may be 
beneficial, especially where there are migranous characteristics to the IIH headache or the 
two conditions co-exist. Topiramate has also shown benefits in a variety of other headache 
disorders. (Silberstein et al., 2006) Headache is the most common and disabling symptom of 
IIH and successful management often needs to include adequate analgesia. The side effect 
of weight loss may also be an advantage for obese patients.      
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1.1.7.2 Surgery 
Some patients require surgical intervention to control their symptoms or prevent 
deterioration of their visual function. Surgical treatment needs to be considered from the 
outset for patients presenting with visual loss and at any time when there is deterioration in 
visual function. (Lueck and McIlwaine, 2002) Some authors argue that the decision to 
operate rests entirely on the quantitative visual field status. (Corbett and Thompson, 1989) 
Surgery may also be appropriate where close monitoring and effective medical treatment of 
the patient is not feasible, or if there is intractable headache.  
1.1.7.2.1 Subtemporal decompression 
Introduced in the late 19th century, the technique of craniectomy and opening the dura over 
the inferolateral surface of the temporal lobe to decompress the brain was for many years 
standard surgical practice for resistant cases of intracranial hypertension. The procedure can 
be unilateral or bilateral. The main complications are epilepsy, meningitis and focal 
neurological deficit as well as the usual complications of major surgery, including death and 
venous thromboembolism. (Johnston et al., 2007) 
The outcome after subtemporal decompression for IIH has not been formally studied and 
early reports indicated wide variability in its effects on symptoms and CSF pressure. 
(Davidoff, 1956; Jacobson and Shapiro, 1964) In the Glasgow series by Johnston et al, (1981) 
subtemporal decompression was performed in 43 patients, in five cases as the initial 
treatment. In the majority, it was used after serial lumbar punctures had failed to control the 
intracranial hypertension. 30 (70%) of the 43 patients had resolution of all symptoms and 
signs within six months of the procedure. The remaining 13 patients required further 
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treatment after the surgery and five had worsening of their vision post-operatively. Epilepsy 
complicated 12 of the 43 cases and two patients had late recurrence of their IIH, two and 14 
years later. 
More recently, Kessler et al (1998) conducted a retrospective review of eight patients 
treated with ‘liberal’ decompression via 6-8cm temporal craniectomies. All cases were 
female and had progressive worsening of visual function despite diuretics and serial lumbar 
punctures. All patients had prompt resolution of their papilloedema within one month of 
surgery, but only three remained symptom free over the mean follow-up period of 21 years. 
In addition, five patients needed CSF diversion procedures less than two months after the 
original surgery, due to persistence of headaches and tense bulging at the craniectomy site. 
The authors claim that subtemporal decompression should be regarded as a ‘first-line 
therapeutic option in any patient who fails medical treatment’.  
The role of subtemporal decompression in IIH is now limited and has largely been replaced 
with less radical procedures. It may be an option for a small number of patients when such 
procedures fail. Where it is used, bilateral craniectomies with specific techniques of dural 
splitting to protect the cortical surface are recommended. (Johnston et al., 2007)  
1.1.7.2.2 CSF Diversion Procedures 
CSF diversion procedures involve diverting the CSF from the lumbar subarachnoid space to 
the peritoneal cavity (lumbo-peritoneal or LP shunt) or from a lateral ventricle to the 
peritoneal cavity (ventriculo-peritoneal or VP shunt), the right atrium (ventriculo-atrial, VAT 
shunt) or the pleural space. CSF flow occurs from high to low pressure, through a catheter 
with a valve device to prevent reversal of flow. CSF diversion procedures have a significant 
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failure rate which can require revisional surgery, as well as a high frequency of 
complications, including over drainage and low pressure headaches, infections, obstruction 
and general operative complications. (Rosenberg et al., 1993) Less commonly, subdural 
haemorrhages, radiculopathies, tonsilar herniation and syringomyelia have been reported. 
(Lueck and McIlwaine, 2002)  
Generally, ventricular shunts are more straightforward to insert, although LP shunts may be 
technically easier in the presence of smaller ventricles. LP shunts can be more difficult to 
anchor however, which may lead to catheter dislocation. For some patients, drainage of the 
ventricular system or lumbar subarachnoid space is impossible, due to such anatomical 
factors as small ventricles, spinal deformity and scarring of the lumbar thecal space or 
impractical, due to failure of previous LP or VP shunts. Lee et al (2004) published a case 
series of five patients with ‘pseudotumour cerebri’ who had catheters placed directly into 
the cisterna magna (cerebromedullary cistern). The distal shunts drained into the pleural 
space or via the internal jugular vein into the right atrium. Intracranial telemetric pressure 
recordings demonstrated that intracranial pressure was lowered, but two of the patients 
required shunt removal for complications. In the three patients who kept their shunts, there 
was some improvement in headache although all continued to require additional pain 
management. The high complication rate probably limits the use of this type of shunt to 
patients lacking a more suitable drainage site. 
Complications are common and limit the effectiveness of all shunts. A review of 37 LP and 
nine VP shunts in 73 patients from six US institutions found that only 14 patients (19%) 
remained symptom free after a single procedure. (Rosenberg et al., 1993) In total, 64% of all 
shunts in the study needed replacement within six months. After shunt failure (55%), low-
 58 
 
pressure headaches were shown to be the most common adverse events, affecting 21%. 
According to the author, whichever type of shunt is chosen, the patient can expect an 
average of 2.2 surgical procedures and a mean time to shunt failure of around 9 months.  
There is some evidence from small studies that revision rates may be lower amongst VP 
shunts. Bynke and colleagues (2004) compared two published series of patients treated with 
LP shunts to their own cohort of 17 patients who received VP shunts. Annual revision rates, 
but not the proportion of patients requiring revision, were lower in the VP group. In the 
same year, McGirt et al (2004) published the findings of a review spanning 30 years in a 
single US centre. 42 patients underwent 115 procedures between 1973 and 2003, 79 LP 
shunts and 36 VP or VAT shunts. The risk of shunt obstruction was three times higher 
amongst the LP shunts, where there was a 2.5-fold increase in risk of shunt revision. Other 
complications, including over-drainage, distal catheter migration and shunt infection were 
similar between the groups. Recurrence of headache despite a functioning shunt was also 
common, occurring in 67% of patients within 36 months. Patients without papilloedema and 
those with symptom duration of longer than 2 years were shown to have a significantly 
higher risk of headache recurrence. 
The complication rates for all CSF diversion procedures are substantial and may appear 
unacceptably high to the patient. Nevertheless, carried out by an experienced 
neurosurgeon, such operations can be sight-saving and have been shown to be effective to 
varying degrees on all the clinical manifestations of IIH. Techniques have been developed 
which may improve the effective placement of ventricular shunts, such as endoscopy or 
stereotactic imaging. These remain to be formally evaluated in IIH and further study of CSF 
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diversion procedures as a whole are needed, to improve what remains a cornerstone of IIH 
management. 
1.1.7.2.2 Optic Nerve Sheath Fenestration 
In this procedure, the optic nerve is decompressed, via a fenestration or ‘window’ in the 
surrounding sheath. An incision is made in the orbit via a medial or lateral approach, and the 
optic nerve immediately behind the globe approached. (Figure 1.10) An incision is made in 
the dura mater of the nerve sheath up to a maximum of 1cm in length, or occasionally 
multiple smaller openings are created. (Keltner, 1988) A transnasal endoscopic approach has 
also been described in a case report of one patient. (Gupta et al., 2003) Unilateral 
procedures are usually carried out, with the second eye being operated on at a later date if 
worsening vision occurs, although bilateral optic nerve sheath fenestrations (ONSF) are 
sometimes undertaken. 
    
Figure 1.10: Cross-section of optic nerve showing site of optic nerve sheath fenestration 
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The exact mechanism of action of ONSF is uncertain. One theory is that the effect is due to 
the formation of a chronic fistula, such that the egress of CSF is maintained and the CSF 
pressure on the nerve sustained. (Keltner, 1988) An alternative explanation is that there is 
localised scarring of the meninges, such that transmission of the high CSF pressure to the 
optic nerve head is prevented. The situation is further complicated by the observation that 
unilateral ONSF procedures can lead not only to resolution of optic nerve swelling on the 
side of the surgery, but also to improvement of contralateral disc swelling and even 
headaches, suggesting an effect beyond localised lowering of pressure.(Berman and 
Wirtschafter, 1992; Acheson, 2004)  
To an experienced ophthalmic surgeon, ONSF is a relatively minor procedure and, unlike 
shunts, involves no insertion of foreign bodies. (Lueck and McIlwaine, 2002) Complications 
are usually transient and benign. Diplopia, oculomotor disorders, anisocoria (inequality of 
pupil diameter) and dellen (localized reduction of corneal thickness) are the most prevalent 
adverse events and repeat procedures are occasionally required. (Keltner, 1988; Banta and 
Farris, 2000)  
Resolution of papilloedema following ONSF is often, but not always, associated with 
improvements in visual acuity and fields. In a study of 86 patients (158 eyes) treated with 
ONSF, visual acuity and visual fields improved or remained stable in 94% and 88% 
respectively. (Banta and Farris, 2000) A more recent, smaller study found significant 
improvement in visual field mean deviation scores following  ONSF (p=0.03) and self-limiting 
complications in just five of 32 patients. (Chandrasekaran et al., 2006) A UK 5-year audit by 
Knapp and Sampath (2005) reported that ten (77%) of 13 patients were able to discontinue 
medical therapy following ONSF. Visual fields were improved in 18 of 27 eyes, unchanged in 
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two and worse despite surgery in four. Acuity improved in only four patients and was 
unchanged in the remainder. 
Visual function may deteriorate many years after ONSF. Even after initially successful 
operations it may be necessary to proceed to CSF diversion, to halt progressive visual loss or 
treat intractable headaches. (Spoor et al., 1994; Banta and Farris, 2000) No prospective trial 
has ever compared ONSF and CSF diversion. In clinical practice, the choice between ONSF 
and CSF diversion is often made on the basis of local preference and available expertise as 
well as the balance between headache and visual symptoms as predominant features in the 
individual case. (Binder et al., 2004)  
1.1.7.2.4 Endovascular stenting 
The inclusion of endoluminal venous sinus stenting as a surgical option for IIH is 
controversial, but the procedure is worthy of mention due to its recent popularity in specific 
centres and patient groups. If the evidence for the existence of intracranial venous outlet 
obstruction in ‘true’ cases of IIH is accepted, it is understandable that attempts to evaluate 
the effects of surgically relieving the obstruction have been undertaken. 
Isolated case reports in the literature appeared to show that placement of an endoluminal 
stent could result in clinical improvement in IIH. These were followed in 2008 by a study 
undertaken to assess the clinical and radiological outcomes amongst ten adult patients with 
IIH treated consecutively with endovascular venous stenting. (Donnet et al., 2008) All 
patients had headache, papilloedema and other clinical features refractory to treatment 
with acetazolamide as well as stenoses demonstrated on three-dimensional MR venography. 
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Papilloedema and tinnitus resolved in all subjects, headache in six (60%). Three months post 
treatment, CSF pressure was below 19cm in all patients (mean pre-treatment 40.2cm.)  
The striking clinical improvements and the lack of adverse events reported make the 
technique seem attractive as an alternative management strategy. Further investigation to 
assess the importance of venous sinus pathology in the aetiology of IIH as well as evaluation 
of the safety and efficacy of the stenting procedure is required, before clear 
recommendations can be made. 
1.1.7.3  Weight Reduction  
It is widely believed that weight reduction improves the course of IIH amongst overweight 
individuals. The striking and robust association between IIH and obesity, as well as 
observations since the earliest descriptions of the condition that weight loss accompanied 
clinical improvements, has led to advice about weight reduction being standard clinical 
practice. Only a few studies have attempted to assess the effect formally. 
In 1974, nine patients were reported whose papilloedema resolved after a mean weight loss 
of 34 kilograms, through a low calorie adaptation of a rice diet. (Newborg, 1974) A more 
recent study of 58 patients showed significantly lower grades of papilloedema amongst 
those who lost at least 2.5 kilograms during any 3-month period, but no significant 
differences in their visual fields or acuities. (Kupersmith et al., 1998b) A positive relationship 
between weight reduction and improvement of optic nerve swelling was also demonstrated 
by Johnson et al (1998) in a retrospective review of 15 female IIH patients. The average 
weight loss in six patients who had marked resolution of their papilloedema was 6.2% and, 
whilst the study included patients who were also taking acetazolamide, a significant 
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correlation was found between percentage weight reduction and change in papilloedema 
grade. 
Surgically-induced weight loss has also led to case reports of improvements in IIH. Loss of 
36.9 kilograms due to a gastric exclusion procedure was associated with a reduction in the 
CSF pressure, disappearance of papilloedema and near-normalisation of visual fields in one 
obese patient. (Amaral et al., 1987) Sugerman et al (1999) studied 24 severely obese female 
IIH patients treated surgically with gastric bypass in 23 and gastric banding in one. Within 
four months of surgery, papilloedema and cranial nerve dysfunction had resolved in all 
women; headache and tinnitus improved in all but one patient. Over time, weight regain in 
two patients was associated with a recurrence of symptoms. Normalisation of elevated dural 
venous sinus pressures has also been shown to accompany the successful treatment of IIH 
with weight-reduction surgery. (Nadkarni et al., 2004)   
The first prospective study to formally evaluate the effect of weight loss in IIH was reported 
by Sinclair et al. (2009). Symptoms, headache severity and papilloedema were shown to 
improve significantly amongst 25 adult females with longstanding IIH who lost an average of 
15.2kg body weight on a low-calorie, supervised, total meal replacement diet over three 
months. In addition, the mean intracranial pressure, as measured by serial lumbar 
punctures, was shown to fall significantly following the intervention. Whilst visual acuity and 
Humphrey visual field mean deviation scores showed no change throughout the study, 
objective evidence of improvement following weight loss of optic nerve swelling, using 
ultrasonographic measurement, was provided.  
Despite growing evidence, further research is required to quantify the optimum amount, 
timing, and methods of weight loss in IIH management. There appears to be a subgroup of 
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IIH patients for whom weight loss may be the only action required to bring about resolution 
of their clinical symptoms. There is certainly sufficient data to support the routine inclusion 
of dietary and other weight-reduction advice into standard IIH management strategies.  
1.1.7.4 Monitoring  
There is no consensus about the most effective way to monitor patients with IIH, or which 
clinical assessments most reliably identify those patients at greatest risk of visual loss. If the 
arguments against repeated lumbar punctures as a treatment for IIH are upheld, regular 
measurement of the intracranial pressure to monitor the condition is similarly not an option. 
Furthermore, lumbar punctures can fail to accurately measure fluctuating CSF pressure and 
may provide ‘isolated fragments of information that cannot be depended on for therapeutic 
decision-making’. (Corbett and Thompson, 1989)   
Formal perimetry seems to be the most precise method of identifying visual loss and has 
been shown to exhibit statistically greater sensitivity in comparisons with Snellen acuity and 
contrast sensitivity. (Rowe and Sarkies, 1998) This is explored and discussed in chapter 3.
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1.1.7.5 Outcome 
1.1.7.5.1  Visual Loss 
For the majority of patients, IIH lives up to its old name as a benign condition, without 
impairment of vision in the long term. However, there are a small but significant number of 
patients for whom the condition follows a more aggressive course. Blindness does occur and 
several studies have demonstrated sustained loss of vision in IIH, as summarised in table 1.5. 
Table 1.5:  Published reports of visual loss as an outcome of IIH 
Year Study type Author 
No. of 
patients 
No. with 
visual loss (%) 
Comment 
1974 Retrospective Boddie et al  34 4 (8) 
Three patients had visual 
loss at presentation 
1980 Retrospective Rush 63 7 (11) 
Visual acuity worse than 
6/9 at last visit 
1982 Retrospective Corbett et al 57 14 (25) 
24 eyes in 14 patients blind 
or profoundly visually 
impaired 
1984 Retrospective Orcutt et al 68 21 (31) 
5 eyes in 4 patients severe 
visual loss 
1988 Prospective Sorensen et al 24 1    (4) 
Plus chronic papilloedema 
in 42% 
1991 Prospective Wall et al 50 5 (10) 
Two patients blind in both 
eyes, three blind in one eye 
1993 Prospective Radhakrishnan et al 81 16 (20) 
Moderate to severe loss. 
Mild loss in a further 21% 
1998 Prospective Rowe et al 35 6 (17) 
Three patients had visual 
loss + optic atrophy at 
presentation 
 
In an early, retrospective review of 34 patients, four (8%) had sustained visual impairment, 
although three of these had severe visual symptoms and signs at presentation. (Boddie et 
al., 1974) Rush (1980) described seven patients with final Snellen visual acuity worse than 
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6/9 from a cohort of 63 observed over a seventeen period, none of whom improved despite 
treatment. In the study by Corbett et al (1982) spanning five to 41 years of observation, half 
of the eyes studied in 57 patients had no loss of visual field or acuity at a follow up 
assessment, but 24 eyes in 14 patients were blind or profoundly visually impaired. In 11 of 
these patients, loss of sight occurred gradually or in a stepwise fashion over months or years, 
but in eight, the visual loss at presentation was as severe as it would ever be. The rate of loss 
of vision was variable and for many patients, symptoms were minimal and the loss 
undetected until severe. Orcott et al (1984) reported visual dysfunction (described as 
reduction in visual field and / or acuity) in 21 (31%) of 68 patients and some definite loss of 
vision in 49% of all eyes, of which 6% was severe. 
Amongst 24 patients studied prospectively in Denmark, only one had optic atrophy and 
severe visual impairment after a mean observation of 49 months, yet ten patients (42%) 
developed chronic changes of the optic disc. (Sorensen et al., 1988) In the study by Wall and 
George, (1991) two of 50 patients became blind in both eyes and three developed blindness 
in at least one eye. In the Libyan population survey, 20% of patients had moderate to severe 
loss of vision at follow up, with only 58.6% of patients having entirely normal visual field 
status. (Radhakrishnan et al., 1993) In a more recent, prospective study involving 35 
patients, a poor outcome in terms of visual fields was documented in 17%, but three of 
these patients presented with visual loss and had evidence of optic atrophy on examination. 
(Rowe and Sarkies, 1998)   
An attempt to describe the incidence and characteristics of acute and rapidly progressive 
visual loss in a series of 16 patients with ‘fulminant’ IIH was published in 2007. (Thambisetty 
et al., 2007) Amongst 572 patients from two centres over a ten year period, 16 (2.8%) were 
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identified who fulfilled the criteria of acute onset of signs and symptoms and visual loss 
occurring within 4 weeks of presentation or rapid worsening of visual loss over a few days. 
Visual loss was very rapidly progressive in all patients; the time between the patients’ first 
symptom and their worst visual loss ranged from 7 to 28 days (mean 16.1.) All of the 
patients received surgery following their initial medical management (ONSF in 5, LP shunt in 
9, VP shunt in 2 patients.) Despite this, visual field abnormalities persisted in all patients and 
eight (50%) remained legally blind. 
Accurate information regarding the natural history of IIH is difficult to obtain and early 
studies may be inaccurate if strict adherence to modern diagnostic criteria was not 
observed. However, a conservative estimate based on available data is that 10% of patients 
exhibit lasting and clinically relevant visual loss. Aggressive surgical intervention may be 
required in a small group of patients and the need for watchful monitoring is clearly 
apparent, especially since patients may be asymptomatic until visual disaster has already 
occurred. 
1.1.7.5.2 Risk Factors for poor outcome 
Attempts have been made to identify clinical and demographic features that may predict the 
course of IIH. Several studies have explored the characteristics of patients showing worse 
visual outcome. Corbett et al (1982) found that visual deterioration was not predicted by the 
presenting symptoms, with the exception of frank visual loss at onset. A statistically 
significant association was found, however, between visual loss and systemic hypertension, 
since 61% of patients with persistently elevated blood pressure had marked unilateral or 
bilateral visual impairment when re-examined. Poor outcome in the study by Orcutt et al 
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(1984) did not correlate with gender, symptoms, chronicity of papilloedema, high CSF 
pressure or excess body weight. Patients with a known cause of intracranial hypertension 
were also included in this study, but the presence or absence of a known cause was also not 
associated with a particular outcome. Similarly, Radhakrishnan et al (1993) found no 
correlations with visual outcome amongst age at diagnosis, body weight, duration of 
symptoms, oral contraceptive use, steroid treatment, nor CSF opening pressure. Amongst 
the 16 cases of ‘fulminant’ IIH described by Thambisetty et al, (2007) four had controlled 
systemic hypertension but the group appeared to have no remarkable clinical characteristics 
to explain their poor outcome. 
Gender has been shown by some studies to have an effect on IIH. Kesler et al (2001) 
observed that 78% of women but only 25% of men were overweight in a retrospective 
review of 141 patients and that diagnosis of IIH appeared to be made later amongst male 
patients. Digre and Corbett (1988) compared 29 men with ‘pseudotumour cerebri’ to age 
matched female patients and concluded surgical intervention may be required more 
frequently to prevent visual loss in men. Further evidence of a worse prognosis amongst 
men was provided by a retrospective review of 721 consecutive IIH patients. (Bruce et al., 
2009) Men (66) had significantly worse visual acuities and visual fields at initial and final 
evaluations than 655 women, with a relative risk of severe visual loss, defined by the US 
criteria for legal blindness, of 2.1 (p=0.002.) Male sex remained an independent factor for 
severe visual loss in at least one eye when adjusted for age and diagnosis of sleep apnoea. 
The effect of race on outcome was examined by the same author in a retrospective chart 
review. (Bruce et al., 2008) Black patients (197) were found to have higher CSF opening 
pressure, worse LogMAR acuities, worse visual field grades and higher degrees of 
 69 
 
papilloedema than 253 non black patients with IIH. The relative risk of severe visual loss for 
black patients compared with non-black patients was 3.5 (p < 0.001) in at least one eye and 
4.8 (p < 0.001) in both eyes. Logistic regression analysis identified race, anaemia, BMI and 
male gender as independent risk factors for severe visual loss. 
The apparently beneficial effect of weight reduction on the clinical course of IIH supports the 
finding by some studies that body weight affects outcome. Of the many variables examined 
by Wall and George, (1991) only weight gain over the year preceding IIH diagnosis was 
significantly associated with visual deterioration as measured by perimetry grade. None of 
the patients without weight loss in Johnson’s study had improvement in their papilloedema. 
(Johnson et al., 1998) Other studies have failed to show a clear association between body 
mass and outcome.(Corbett et al., 1982; Orcutt et al., 1984; Rowe and Sarkies, 1998)  
No study has specifically compared IIH outcome between children and adults or formally 
evaluated the effect of age on final visual function. Small reports have suggested that poor 
visual outcome in children may result, at least in part, from difficulties in communication of 
symptoms and clinical assessment. (Cinciripini et al., 1999; Rowe and Noonan, 2002; Scott et 
al., 1997) A retrospective case series of 96 patients found that pubertal patients had a less 
favourable outcome than prepubertal, teenage and adult patients. (Stiebel-Kalish et al., 
2006) Puberty was identified as the sole predictor of poor outcome, the definition of which 
included permanent visual field constriction and evidence of optic neuropathy. Logistic 
regression analysis of the data suggests that a less favourable outcome is in IIH associated 
with a ‘critical period’ around puberty. A secondary observation from the study was that 
severe, high grade papilloedema at presentation appeared to correlate with poor outcome. 
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Several studies have associated the severity of papilloedema with poor outcome. Patients 
with high grade or atrophic papilloedema as well as haemorrhages near the disc had worse 
visual outcome in the study by Orcutt et al. (1984) The presence of additional features at 
fundoscopy, such as haemorrhage and exudates, have been found to accompany significant 
central field losses.(Friedman and Jacobson, 2002) Wall and White (1998) studied a series of 
patients with asymmetric papilloedema to determine whether visual loss was related to the 
degree of disc swelling. Nine patients judged to have interocular papilloedema difference of 
two or more Frisen grades underwent detailed prospective assessment of their visual 
function. Vision was worse in the eyes with the more severe disc swelling on all measures, 
including three different visual field assessments, visual acuity, colour vision and contrast 
sensitivity.  Interestingly, the prospective study of 50 patients by the same author found that 
the severity of visual loss could not be predicted from the severity of the papilloedema. 
(Wall and George, 1991) Other studies have failed to demonstrate a clear relationship 
between papilloedema and visual outcome, including that of Corbett et al. (1982) Visual loss 
was not statistically related to the degree of papilloedema in the study by Rush, (1980) nor 
to the presence of visual obscurations and duration of symptoms. In some cases, the 
development of optic atrophy and its impact on the appearance of the disc may explain the 
apparently conflicting findings. In addition, the assessment of papilloedema has been largely 
subjective to date, as discussed in chapter 4.  
1.1.7.5.3 Recurrence 
IIH can reoccur months to years after the original episode has resolved. Five of the patients 
in the study by Corbett et al (1982) had recurrent disease, occurring four months to nine 
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years after the initial attack. No particular risks to vision were identified amongst the 
recurrent cases. The investigation by Kesler et al (2004b) of 54 patients with IIH over a mean 
period of six years, found that only 33 (61%) had a single episode. Seven patients had two 
episodes, ten had three, three patients had four episodes and one patient had a total of 
seven. None of the relapses occurred in patients taking acetazolamide and no recurrences 
were observed beyond 72 months, although this reflected the design of the study. 
Researchers in Iowa reviewed 410 adult patients to evaluate recurrence in IIH, defined as 
return of symptoms after resolution and return of previously resolved papilloedema after no 
medication had been given for at least six months. (Shah et al., 2008) Twenty patients were 
identified who met the inclusion criteria and had been observed over a minimum of ten 
years. A stable course without recurrence was reported in 11 patients. In six patients, there 
was a delayed worsening of clinical features following an initially stable course, after a mean 
period of 72 months. Three patients had ‘true’ recurrence of disease, after 12, 31 and 78 
months respectively. 
Crude IIH recurrence rates from the three studies are calculated as 8% (Corbett et al., 1982) 
38% (Kesler et al., 2004b) and 15%. (Shah et al., 2008) It is already clear from the literature 
that many patients will require monitoring over long periods and this is reflected in modern 
clinical practice. Well-designed, prospective, longitudinal studies are required to more 
accurately predict rates of recurrence as well as to identify predisposing factors for relapses 
in IIH or for disease that worsens after a period of apparent stability.  
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1.2 Pathogenesis 
1.2.1 Mechanisms of raised intracranial pressure  
The pathophysiology underlying the raised intracranial pressure in IIH is unclear. Hypotheses 
have developed around the main determinants of CSF pressure: the rate of CSF production, 
the compliance of the CSF space and the resistance to the egress of CSF. (Donaldson, 1981)  
 
   
 
Arachnoid granulation 
 
 
 
Lateral ventricle 
 
Subarachnoid space 
 
Superior saggital sinus 
 
 
Choroid plexus 
 
 
Third ventricle 
 
 
Fourth ventricle 
 
Figure 1.11: Diagrammatic representation of the circulation of CSF in the brain (midsagittal 
section). Arrows represent direction of CSF flow. 
 
1.2.1.1 Excessive CSF production 
CSF is produced by ependymal cells, predominantly in the choroid plexus, a rich network of 
blood vessels in the ventricles. In humans, the total volume is approximately 140ml. (Speake 
et al., 2001) The estimated rate of production in humans is 0.37 ml per minute or 
approximately 500 ml in 24 hours, the whole CSF volume being renewed every 6 to 8 hours. 
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(Wright, 1978, Wall et al., 2001) CSF circulates from the choroid plexus through the 
interventricular foramina (foramen of Monro) into the third ventricle, and then through the 
cerebral aqueduct (aqueduct of Sylvius) into the fourth ventricle, where it exits through two 
lateral apertures (foramina of Luschka) and one median aperture (foramen of Magendie). It 
then flows through the cerebellomedullary cistern down the spinal cord and over the 
cerebral hemispheres. This is shown in figure 1.11. 
Early attempts to determine the cause of the raised pressure in IIH suggested that CSF 
hypersecretion may occur. (Quincke, 1893) The technique of isotope cisternography, in 
which technetium labelled serum albumin is infused via lumbar catheter, permitted 
calculation of the estimated CSF production rate and demonstrated the converse, that levels 
in IIH were even lower than previously quoted normal rates. (Johnston and Paterson, 1974) 
More recent studies have confirmed the lack of significant differences in the production rate 
between IIH patients and controls. (Malm et al., 1992) The only condition in which excessive 
secretion of CSF is known to occur, the uncommon tumour choroid plexus papilloma of 
childhood, does not give rise to a similar clinical picture to IIH. (Walker, 2001) There is thus 
little to support the concept of CSF hypersecretion in IIH and it is now largely excluded as a 
possible cause of the condition. 
1.2.1.2 Brain Water Content 
Considerable research has failed to show convincing evidence of diffuse brain oedema in IIH. 
Early histological studies suggestive of intracellular and interstitial oedema in ten patients 
with IIH were reported by Sahs and Joynt. (1956) The samples were obtained at the time of 
subcortical decompression procedures and artefactual changes may have been present. The 
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slides have been re-examined and repeated without confirmation of the initial claims. (Wall 
et al., 1995)  
Imaging studies have also led little support to the theory of increased brain water. MRI 
studies have tentatively suggested diffuse, mild oedema when heavy T2-weighted and 
balanced pulse sequences were used. (Moser et al., 1988) Bastin et al (2003) used MRI to 
measure proton longitudinal relaxation time and mean water diffusivity at various brain 
regions of ten patients with IIH and ten controls. No significant differences were seen in 
either parameter, from any region. Bickaci et al (2006) used T1, T2 and fluid retention 
inversion recovery (FLAIR) MRI sequences as well as three-dimensional time-of-flight to 
study 16 patients with IIH and 16 controls matched for age, sex and weight. No 
abnormalities indicative of oedema were seen in any of the various gray matter regions 
examined. 
Accepting the conflicting results of studies, there is little to support a theory of brain 
oedema in IIH. Cerebral oedema of sufficient severity to increase the intracranial pressure 
seems incompatible with the degree of preservation of neurological function as well as the 
generally benign clinical course seen in IIH.  
1.2.1.3 Reduced CSF absorption 
A more popular hypothesis is that IIH is a syndrome of reduced CSF absorption. The 
circulating CSF is returned to the systemic circulation via the dural venous sinuses. Studies 
supporting the arachnoid villi and granulations as the primary absorption sites date back 
over many years. (Weed, 1914; Pollay and Welch, 1962) Animal studies show that 
extracranial lymphatics provide an alternative pathway, via transport through the cribriform 
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plate into the nasal mucosa. (Boulton et al., 1996; Sinclair et al., 2002) An early study used 
the intrathecal saline infusion test (ITSIT) to show an apparent resistance to drainage of CSF 
in four out of five patients diagnosed as having pseudotumour cerebri. (Martins, 1973) 
Johnston and Paterson (1974) published similar work using isotope cisternography to 
demonstrate a marked delay in CSF circulation, with hold up of technetium isotope in the 
subarachnoid space. Altered patterns of CSF clearance were reported using similar methods 
amongst six of seven obese IIH patients by Orefice et al. (1992) Sorensen et al (1986a) used 
lumbo-lumbar perfusion methods to measure conductance to CSF flow, the reciprocal of 
resistance; all 11 patients in their study had values below normal. Abnormally low 
conductance was also shown by Gjerris et al (1985) using this method in all of 14 patients 
with the diagnosis of benign intracranial hypertension.  
In 1992, Malm et al (1992) claimed to have identified two possible mechanisms of the raised 
CSF pressure in IIH. The following highly significant differences in 13 patients compared to 45 
controls were reported: elevated CSF lumbar pressure, reduced conductance of CSF outflow 
pathways and increased pressure difference across CSF outflow pathways. Amongst those 
patients whose outflow conductance was very low, a dysfunction of the arachnoid villi was 
proposed as the cause of the increased hydrostatic pressure necessary to sustain the bulk 
flow of CSF. In a second group of patients, however, the outflow conductance was normal or 
only slightly reduced, but high pressures were recorded in the sagittal venous sinuses. The 
role of cerebral venous sinus pressure in the pathophysiology of IIH is discussed below. 
Whatever the mechanism is of the raised CSF pressure, it must account for the lack of 
ventricular dilatation seen in IIH. If the more likely hypothesis is accepted, that CSF 
absorption is impaired, it would suggest that there is an increase in the total CSF volume. 
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This is supported to some extent by the positive clinical response seen in IIH to reduction of 
the CSF volume, by lumbar puncture or other methods. Measurement of CSF volume is not 
easily performed and attempts using MRI techniques have been inconclusive. (Condon et al., 
1986) The co-occurrence of small or normal-sized ventricles and increased CSF volume 
would also need explanation. Since in IIH it is assumed no structural blockage exists, 
ventricular dilatation would only occur once the CSF volume exceeded that which could be 
accommodated by the freely patent subarachnoid space. It has been suggested that, in IIH, a 
new equilibrium is reached, in which the system controlling CSF absorption is ‘reset’ with the 
elevated intracranial pressure and CSF volume. (Johnston and Paterson, 1974) Levine et al 
(2000) conducted a comprehensive literature review and presented a detailed mathematical 
study to explore this further. They were able to demonstrate that small, normal sized or 
slightly enlarged ventricles can result from increasing CSF pressure uniformly in the 
ventricles and the subarachnoid space and that the model was consistent with the 
hypothesis that IIH is caused by abnormal CSF absorption into the bloodstream.  
1.2.1.4 Increased cerebral venous pressure 
Whether the raised CSF pressure is the primary problem in IIH or the consequence of high 
pressure in the cerebral venous sinuses, due either to anatomical narrowing or generalised 
venous hypertension, is widely debated. In patients with proven venous sinus thrombosis 
(Figure 1.12), the high intracranial pressure that occurs is relieved by drainage or diversion of 
CSF, although it is uncertain precisely how this happens. (Biousse et al., 1999) Venography 
shows narrowing of the cerebral venous sinuses leading to functional outflow obstruction in 
many cases of IIH, in the absence of occlusion by thrombus. In one prospective, blinded MRV 
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study, substantial, bilateral sinovenous stenoses were seen in 27 of 29 IIH cases, leading the 
authors to conclude that the dural venous sinuses are anatomically different in this 
condition. (Farb et al., 2003) Raised pressure, in the absence of thrombosis, within the 
superior sagittal and transverse sinuses, has been demonstrated by others. (King et al., 1995) 
Whether such findings are due to high pressure in the CSF or the actual cause of the 
intracranial hypertension is not known, but there is evidence to support both explanations. 
 
Figure 1.12: CT Venogram showing filling defect in the sagittal sinus (arrow) 
 
The hypothesis of apparent venous stenosis as a secondary effect assumes that the venous 
compartment will ‘give way’ to that of the expanding CSF, and that either the vessel walls 
are externally compressed or that partial obstruction of the lumen occurs, due to enlarged 
arachnoid granulations. Both types of filling defect were observed in the MRV study by Farb 
et al. (2003) There have been reports of stenotic lesions in the lateral sinuses resolving after 
CSF diversion procedures (Higgins and Pickard, 2004) and a demonstration by King et al 
(2002) of a drop in the measured transverse sinus pressures of eight IIH patients, following 
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direct removal of CSF by cervical puncture. In the latter study, the largest falls in venous 
pressure were seen in patients with the highest intracranial pressures, although not all the 
patients had elevated venous sinus pressure. The results appeared to suggest that 
obstruction to venous outflow, at the level of the transverse sinus, in IIH is due to high 
intracranial pressure and is reversed by lowering this pressure. Even if the theory of direct 
compression of the veins by intracranial pressure is accepted, exactly what expands, or 
pressurizes, the CSF remains unclear.  
The findings of many other studies lend support to the opposing argument: that the venous 
stenoses are the primary lesion in IIH. Higgins et al (2003) performed dilatation and stenting 
of the lateral venous sinuses of 12 patients with refractory IIH who were found to have high 
venous sinus pressures at manometry. Five patients became asymptomatic from their IIH 
and a further two showed some clinical improvement, although the remainder were 
unchanged and there was no consistent relationship between the amount of pressure 
reduction and symptom relief. Karahalios et al (1996) also found high pressure with normal 
anatomy in the venous sinuses of five patients with IIH, as well as showing that the right 
atrial pressures were increased, leading them to suggest that right-sided heart failure 
underlies a ‘universal mechanism’ of elevated venous pressure in the condition. Sugerman et 
al (1997) claimed that raised intracranial pressure is a direct result of intra-abdominal 
pressure, via elevation of the diaphragm, raised pleural pressure, impeded cerebral venous 
return, and consequently sustained elevation of the venous pressure. However, clinical 
evidence of right heart failure is usually lacking amongst patients with IIH.  
Nevertheless, the possibility of some shared pathophysiological mechanism in IIH and 
venous sinus disease remains enticing. Unrecognised, non-occlusive thrombus lining the 
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dural vessels has been suggested as a possible mechanism for the impairment of 
cerebrospinal fluid absorption leading to IIH. (Sussman et al., 1997) In addition, some 
authors believe there may be an underlying thrombophilia in IIH patients who have cerebral 
venous outflow obstruction without demonstrable thrombosis. The familial thrombophilic 
states are known to predispose to the formation of venous thrombosis, but it is possible that 
IIH has an independent connection. Backhouse et al (1998) reported two cases of Factor V 
Leiden mutation in association with IIH and a single case of essential thrombocythaemia in 
combination with IIH, in a female patient who had venous sinus obstruction excluded by 
angiography, has been reported. (Esack et al., 1989) A further case of IIH in association with 
raised serum anticardiolipin antibodies and strong lupus anticoagulant activity, but no 
evidence of cerebral sinus thrombosis is reported. (Orefice et al., 1995) Dunkley and 
Johnston (2004) discovered thrombophilic defects in 17 out of 25 patients with a diagnosis 
of pseudotumour cerebri, only four of whom were found to have frank cerebral venous 
thrombosis. Sussman et al (1997) studied the strength of association between risk factors for 
thrombosis and IIH in more detail. Amongst their findings was an incidence of 
antiphospholipid antibody of 31% in 29 patients with IIH, compared to 6% in 16 healthy 
control subjects and 17% in 18 patients with other neurological disorders recruited as a 
second control group, although the statistical analysis of these results was not reported.  
The first prospective study failed to find epidemiological evidence to implicate an underlying 
prothrombotic state in IIH. (Backhouse, 2001) 25 of 30 IIH patients with normal MRV had 
normal thrombophilia screens and the remaining five had minor abnormalities that were not 
significant when compared to a control population of 90. More recently, a consecutive case 
study by Glueck et al (2005) compared serologic coagulation measures and polymerase chain 
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reaction (PCR) for five gene mutations in 65 women with IIH to 102 healthy female controls. 
Significantly more women in the IIH group possessed one of the gene mutations known to 
be associated with arteriel and venous thrombosis. Other significant findings were 
thrombophilic high concentrations of factor VIII present in 14 IIH cases, compared with none 
of the controls and an increased concentration of lipoprotein A, associated with 
hypofibrinolysis, in 19 patients but only 3 controls. The results may have been influenced by 
the high prevalence of polycystic ovary syndrome; 37 (57%) of the IIH cohort met the 2003 
diagnostic criteria for the condition.  
There is little evidence as yet to reliably link IIH with any specific haematological 
abnormality. More research is needed to determine whether stenoses in the cerebral 
venous sinuses have a causative role in cases of truly ‘idiopathic’ intracranial hypertension 
and to determine the prevalence of previously undetected thromboses in the condition. In 
addition, the possibility that a pro-thrombotic state may influence the absorption of CSF at 
the level of the arachnoid villi in some cases of IIH warrants further study. 
1.2.2 Endocrine abnormalities 
Whatever the pathological mechanism may be in IIH, it must explain the predilection of the 
disorder for obese women of child-bearing age. The consistent diagnosis of high numbers of 
such patients has focussed interest on a possible endocrine basis for the condition, with the 
sex hormones being obvious candidates. Furthermore, the metabolism of sex steroids is 
influenced by the adipose tissue and the metabolic effects of obesity vary according to 
gender and menopausal status. 
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Studies of endocrine function in patients with IIH have involved only small numbers of 
patients. In 15 patients with IIH, conventional tests of anterior and posterior pituitary 
function and peripheral target glands did not show significant abnormalities, except for a 
slight reduction in the growth hormone (GH) response to hypoglycaemia. (Sorensen et al., 
1986a) Subnormal GH responses were also shown by Reid and Thomson (1981) in three of 
five patients with chronic IIH, but the response was also seen in one of the obese control 
patients and can occur in healthy, overweight people.(Sorensen et al., 1986a) Post-mortem 
examinations of arachnoid villi and human choroid plexus have demonstrated somatostatin 
receptors which may affect local CSF dynamics. (Katz et al., 2002) The neuropeptide 
somatostatin, a hormone that inhibits the release of growth hormone, has been suggested 
to play an as yet undefined role in the elevation of the CSF pressure in IIH, supported by 
reports of the successful use of its long-acting analogue, octreotide, in the condition. 
(Antaraki et al., 1993)  
Water permeability in several biological membranes and brain water content is affected by 
another hormone, arginine vasopressin (AVP). In two studies by Sorensen et al, the 
concentration of AVP in the CSF was found to be significantly elevated in patients with IIH, 
despite similar plasma osmolality and AVP levels in patients and controls. (Sorensen et al., 
1986a; Sorensen et al., 1982) A similar result was reported in a further study of 15 patients 
and 16 controls, but when CSF pressure measurement was included, no direct relationship 
between that and the CSF AVP level was demonstrated. (Seckl and Lightman, 1988) The 
importance of this seemingly consistent finding to the pathogenic processes in IIH is not 
known; the increased AVP may be either a cause or a result of the raised intracranial 
pressure, if it is connected at all. 
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A number of small studies have implicated steroid hormones in the aetiology of IIH. 
Glucocorticoids and sex steroids affect the transport capacity in the choroid plexus and may 
have marked effects on intracranial pressure dynamics, as shown in rabbit studies by 
Lindvall-Axelsson et al. (1990) Daily treatment with betamethasone significantly reduced the 
formation of CSF when compared with untreated controls. The reduced CSF formation was 
mirrored by reduced uptake of choline and a lower ATP-ase activity in the choroid plexuses 
of the lateral and third cerebral ventricles. Progesterone treatment of oestrogen-primed 
rabbits, but not oestrogen alone, had a similar effect.  
Extraovarian production of oestrone has been proposed as a factor in the menstrual 
dysfunction reported by some obese women with IIH. (Donaldson and Binstock, 1981) 
Donaldson and Horak (1982) reported oestrone levels in the CSF of six obese young women 
with IIH in the range of 38 to 815 picograms per ml, compared to levels of less than 5 in five 
control patients. After treatment with dexamethasone and a low-calorie diet, three of the 
patients were shown to have suppression of these high CSF oestrone levels, accompanying 
clinical improvement, despite little change in their serum oestrone levels. Oestradiol and 
oestriol were not detected in the CSF, which may simply reflect the low sensitivities of the 
assays used. Raised CSF oestradiol, as well as oestrone, was found in a study of five IIH 
patients by Toscano et al. (1991) These abnormalities were accompanied by reductions in 
testosterone, androstenedione, and ratios of androstenedione to oestrone and testosterone 
to oestradiol in the CSF, when compared with 12 control patients. Plasma levels of all 
hormones were comparable between patients and controls. 
Despite the findings of initial studies and the evidence linking polycystic ovary syndrome 
with IIH, (Glueck et al., 2005) the notion that abnormalities of sex steroids or indeed any 
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hormones underlie the disease process in IIH remains unproven. Adipose tissue is now 
regarded as an actively secreting endocrine organ and is considered separately below. 
1.2.3 Obesity and pathogenesis 
The exact mechanisms behind the high incidence of obesity in IIH are elusive. The theory of 
Sugerman et al (1997) of raised intracranial pressure as a direct result of intra-abdominal 
pressure requires the presence of centrally distributed obesity. It fails to account for the high 
preponderance of females in IIH, because women are less likely to have a central, 
androgenic distribution of their body fat than men. The metabolic and endocrine features of 
the obese state appear to offer greater potential to explain the disease process in IIH. 
Ghrelin is a hormone with significant effects upon appetite and energy balance that has 
been studied in IIH. A peptide derived predominantly from the stomach, it acts as on the 
arcuate nucleus as a potent stimulus to the consumption of calories. (Seckl, 2004) 
Subramanian et al (2004) analysed fasting plasma levels in 65 patients with the condition, of 
which 68% were defined as being obese. The results were compared with those from a 
control population of 25, 76% of whom were obese and no significant differences were 
detected between the two groups.  
In vitro and in vivo studies of serum, CSF and adipose tissue have shown obesity to be 
associated with chronic, low grade inflammation and an abnormal, pro-inflammatory 
cytokine profile. (Straczkowski et al., 2002; Dandona et al., 1998; Panagiotakos et al., 2005; 
Straczkowski et al., 2006) This inflammatory response is thought to have causative links with 
diabetes, cerebrovascular disease, asthma, and cancer. (Wellen and Hotamisligil, 2005) 
Adipose tissue, now regarded as an endocrine organ, secretes a wide variety of proteins 
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including pro-inflammatory cytokines, chemokines and hormones. Activated adipose tissue 
recruits macrophages that are thought to contribute to the production of inflammatory 
mediators. (Weisberg et al., 2003) The principal cytokines include tumour necrosis factor 
alpha (TNFα),(Park et al., 2005) interleukin-1 beta (IL-1β), (Maedler et al., 2002) interleukin-6 
(IL-6), (Vozarova et al., 2001) interleukin-8, (IL-8) (Straczkowski et al., 2002) monocyte 
chemoattractant protein-1 (MCP-1), also known as CC-chemokine ligand-2, (CCL2), (Sartipy 
and Loskutoff, 2003) hepatocyte growth factor (HGF), (Bell et al., 2006) nerve growth factor 
(NGF) (Nisoli et al., 1996) and  plasminogen-activator inhibitor type 1 (PAI-1). (De Pergola 
and Pannacciulli, 2002) Amongst the most abundantly secreted cytokines are those secreted 
by the adipose tissue, the adipokines leptin and adiponectin. Adiponectin, also synthesised 
by adipose tissue, circulates at higher concentrations in human serum than leptin. (Tilg and 
Moschen, 2006) Unlike leptin, adiponectin levels are reduced in obesity (Cote et al., 2005) 
and its actions are predominantly anti-inflammatory. (Berg and Scherer, 2005) The major 
role of adiponectin appears to be in enhancing insulin sensitivity. (Berg et al., 2002) The roles 
of other, less abundant and more recently discovered adipokines such as resistin are still 
debated. 
1.2.3.1 Leptin 
Leptin is a single chain peptide hormone comprised of 167 amino acids, synthesised 
predominantly by adipocytes. (Meier and Gressner, 2004) It has a number of diverse 
physiological functions, including roles in haematopoiesis, bone formation and initiation of 
puberty. (Tilg and Moschen, 2006) It is a potent pro-inflammatory cytokine that is known to 
influence both innate and adaptive immunity. (Aleffi et al., 2005) The major role of leptin, 
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however, is in the modulation of appetite and energy balance. (Klok et al., 2007) A product 
of the Ob gene, its name is derived from the Greek word meaning thin. Studies in mice with 
mutations of the Ob gene showed that severe obesity and hyperphagia exists amongst 
homozygous Ob/Ob animals, in which no leptin is produced. (Rohner-Jeanrenaud and 
Jeanrenaud, 1996) Administration of leptin results in cessation of over-eating and loss of 
weight. In most obese humans, however, no such genetic mutation exists and leptin levels 
are actually elevated. (Schwartz et al., 1996)  
The hyperleptinaemia in obesity shows strong positive correlations with body fat mass. In a 
study of 136 lean and 139 obese people, not only was this correlation demonstrated, but the 
Ob messenger ribonucleic acid (mRNA) content was approximately twice as high in 
overweight as compared to normal weight subjects, suggesting that changes in body fat are 
translated into changes in serum leptin at the level of Ob gene expression. (Considine et al., 
1996) The relationship between body fat and leptin suggests that sensitivity to the actions of 
leptin is reduced in obesity; adipocytes produce more leptin when adipose tissue mass is 
greater, yet this results in the increased adipose tissue mass being maintained. In other 
words, leptin resistance could explain the failure of obese individuals to respond to their 
elevated leptin levels.  
A number of leptin receptors have been identified, with many isoforms, including a soluble 
receptor which can be measured by enzyme-linked immunosorbent assay (ELISA.) (Meier 
and Gressner, 2004) Levels of this soluble receptor, which acts as one of several leptin 
binding proteins, have also been shown to increase with increasing BMI. In lean people, 
most of the leptin circulates in the bound form, but in the obese, levels of free leptin are 
significantly increased. Total concentrations of leptin thus show less of a difference between 
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slim and overweight individuals than if free concentrations are measured. Leptin also 
exhibits circadian variation, rising to its highest levels during the night.  
Caloric restriction reduces the serum leptin and the amount of adipocyte mRNA, whilst re-
feeding increases these levels. (Considine et al., 1996; Rohner-Jeanrenaud and Jeanrenaud, 
1996) A reduced calorie diet, resulting in weight loss, has been shown to significantly reduce 
serum leptin concentrations as well as levels of the soluble leptin receptor amongst healthy 
humans. (Wolfe et al., 2004) The leptin responses to changes in eating patterns are too rapid 
to be fully explained by changes in adipose mass. Acute fasting depletes the serum leptin 
concentrations and massive overeating has the opposite effect, both within about seven 
hours and despite little or no change in fat mass. (Fried et al., 2000) Acute signals must also 
be involved in regulating the rate of leptin secretion. The actions of leptin are to suppress 
food intake and to increase energy expenditure and one link between leptin and food intake 
is said to be the hypothalamic appetite-stimulating hormone, neuropeptide Y (NPY). 
(Rohner-Jeanrenaud and Jeanrenaud, 1996) Leptin is able to cross the blood-brain-barrier 
and binds the Ob-Rb receptors in the arcuate, ventromedial, paraventricular and 
dorsomedial nuclei of the hypothalamus, signalling satiety via neurons expressing NPY as 
well as agouti-related peptide. (Mercer et al., 1996) Thus peripheral hormonal signals are 
translated into the neural messages that alter appetite. (Seckl, 2004) Figure 1.13 shows a 
diagrammatic representation of this hypothalamic appetite regulation. Studies of severely 
obese rats with a genetic absence of leptin receptors showed that signalling within the 
arcuate nucleus limits food intake on a meal-to-meal basis, by regulating the hindbrain 
response to short-acting satiety signals. (Morton et al., 2005) Such a mechanism could 
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explain how changes of body adiposity relate to modifications in the intake of energy during 
individual meals.  
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Figure 1.13: Hypothalamic appetite regulation by leptin. The arcuate nucleus is the main target of 
leptin, a peripheral anorexigenic signal secreted from adipose tissue. Leptin decreases NPY release 
to suppress appetite and body weight. Ob-R = leptin receptor, AgRP = agouti-related peptide. 
 
Measurement of leptin in the CSF is possible, and gives an indication of how the adipose-
secreted hormone is transported into the brain, although some leptin may be produced 
centrally. (Meier and Gressner, 2004) CSF leptin concentrations increase with higher values 
of BMI, but the correlation is not as strong as that seen with plasma levels. (Caro et al., 1996) 
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CSF leptin also does not appear to show a circadian rhythm; a study in which CSF was 
sampled from 9 volunteers, every 30 minutes over a 24-hour period, failed to show diurnal 
variation in the levels. (Wong et al., 2004) Schwartz et al (1996) demonstrated that whilst 
CSF leptin, in 53 human subjects, correlated positively with plasma levels, the relationship 
was non-linear and the ratio of CSF to plasma leptin was lower amongst people with the 
highest plasma leptin concentrations. Caro et al (1996) found that 23 lean subjects had a 
mean CSF to serum ratio over four-fold higher than their eight obese counterparts, who had 
only a 30% increase in their CSF leptin, despite a mean serum level 318% higher. A similar 
study found a 2.3 times higher ratio of CSF to serum leptin in 14 normal weight than 16 
obese women, and also showed that after significant weight loss, both CSF and serum levels 
were reduced. (Nam et al., 2001) Others have documented a negative association between 
the ratio of CSF to serum leptin and both BMI and serum leptin. (Rodrigues et al., 2002) It 
would appear that the relationship between CSF and plasma leptin is not a straightforward 
one. It can be described logarithmically, and may reflect a reduction in the efficiency of 
leptin’s delivery into the brain in obese individuals. Some authors have argued for the 
presence of a saturable transport system or even a separate mechanism in response to the 
hyperleptinaemia of obesity. (Schwartz et al., 1996; Hagan et al., 1999)  
Although the amount of leptin is dependent upon the mass of its secretory organ, the 
adipose tissue, some people exhibit lower or higher levels than predicted from their body fat 
and there is considerable inter-individual variation. Age, ethnicity, and basal glucose 
concentrations do not influence circulating leptin concentrations, but levels do show a 
sexual dimorphism. Leptin levels are greater in women than men, even when corrected for 
absolute measures of fat mass. (Rosenbaum et al., 1996; Rosenbaum and Leibel, 1999) In 
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vitro adipose tissue cultures have shown that secretion of leptin by samples from female 
donors is significantly higher than those from males, despite no gender differences in 
adipocyte number or size amongst the omental tissue samples. (Casabiell et al., 1998; 
Menendez et al., 2000) The secretion of leptin by the omental fat in these studies was not 
correlated with the BMI of the donors. Furthermore, the pulse amplitude of leptin release 
has been shown to be two to three times higher in women than men, although there was no 
apparent sex difference in the frequencies of leptin pulses. (Rosenbaum and Leibel, 1999) 
There are associations between leptin and sex hormones. Leptin receptors occur in the 
peripheral reproductive organs and are also found on hypothalamic neurones that control 
reproductive function, as well as energy balance. (Casabiell et al., 2001) Leptin appears to 
integrate systems of energy homeostasis with those controlling the hypothalamic-pituitary 
axis, via complex and reciprocal interactions. (Rosenbaum and Leibel, 1999) There is 
evidence that it regulates the synthesis and secretion of GnRH, gonadotrophins and sex 
steroids and that its reduction during periods of fasting mediates the suppression of 
reproductive hormones. (Ahima, 2004)  
Adipose tissue contains oestrogen, androgen, and progesterone receptors and the gonadal 
steroids account for differences in the distribution and amount of adipose tissue between 
males and females. (Rosenbaum and Leibel, 1999) Whilst leptin and oestradiol appear to 
interact to affect fat metabolism, there is evidence that oestradiol’s regulation of the 
secretion or action of leptin is not a direct effect, and that the converse is true. 
(Pelleymounter et al., 1999) Adipocytes from male donors, studied in vitro, appear to be 
refractory to the action of steroid hormones in terms of leptin secretion. (Casabiell et al., 
2001) In samples from female donors however, leptin levels have been shown to rise 
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significantly in response to oestrogen, and secretion seems to be inhibited by 
androstenedione, dihydrotestosterone and dehydroepiandrostene sulphate (DHEA). 
There appears to be a dynamic relationship between leptin and the reproductive system, 
with leptin behaving as a hormonal messenger, coordinating nutritional status and 
reproductive function. It may thus act as an afferent signal, carrying information about 
somatic energy stores, whilst itself being influenced by adipose mass and sex hormones. 
(Rosenbaum and Leibel, 1999) Homozygous Ob/Ob mice, which cannot produce leptin, 
remain in a pre-pubertal stage and are sterile, despite a normal early sexual differentiation. 
(Casabiell et al., 2001) The situation can be reversed if pure, recombinant leptin is repeatedly 
administered. Leptin concentrations vary throughout the normal menstrual cycle; levels in 
the luteal phase are significantly higher than in the follicular phase and there is some 
experimental evidence to suggest that in the presence of pre-ovulatory levels of oestrogen, 
progesterone can stimulate leptin secretion. (Messinis et al., 2001) In studies of elite female 
athletes, low oestradiol levels accompanied reduced plasma leptin levels, which themselves 
were more markedly low amongst amenorrhoeic than cyclical women. (Thong et al., 2000) 
Administration of recombinant human leptin can reverse features of hypothalamic 
amenorrhoea. (Welt et al., 2004) In pregnant women plasma leptin levels are elevated, in 
the absence of increased food intake, which suggests there may be a temporary, acquired 
resistance to its effects. (Casabiell et al., 2001) The precise role of leptin in pregnancy and in 
the menstrual cycle is unclear, but the relationship between BMI and leptin is certainly 
altered during pregnancy and throughout the normal menstrual cycle. (Hardie et al., 1997) It 
has been suggested that the apparent leptin insensitivity seen amongst pregnant women 
may function to encourage increased energy intake during gestation. 
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Leptin also shows an interaction with corticosteroids. Cortisol, the major glucocorticoid 
synthesised and released by the human adrenal cortex, has a variety of effects upon 
metabolism. A significant positive association has been demonstrated between 24-hour 
urinary free cortisol and concentrations of leptin in CSF and to a lesser extent plasma. 
(Hagan et al., 1999) There is evidence from animal experiments that leptin can act at the 
level of the adrenal gland to inhibit the production of cortisol. (Bornstein et al., 1997) In 
addition, glucocorticoids affect the release of leptin. A study of 52 human subjects showed a 
significant increase in plasma leptin levels following treatment with the synthetic 
corticosteroid dexamethasone compared to placebo. (Dagogo-Jack et al., 1997) High levels 
of glucocorticoids are known to be associated with hyperphagia and weight gain and may 
exert their effects on fat deposition via the production of, or sensitivity to, leptin. 
A receptor for the hormone leptin has been cloned from the site of CSF production, the 
choroid plexus. (Tartaglia et al., 1995) There has been speculation that patients with IIH may 
have disturbed leptin function, or that the adiposity-related hormone may have a role in the 
pathogenesis of IIH. In a study by Lampl et al (2002) serum leptin concentrations of 15 
patients with IIH were measured under conditions of food restriction. All the patients were 
female and obese. Results were compared to those from 16 obese and 15 non-obese, female 
controls. The patients with IIH had significantly higher serum leptin concentrations than 
either control group. As expected, the serum leptin levels were significantly associated with 
BMI amongst the control subjects, but in patients with IIH this association did not persist. 
The authors propose that additional factors may be involved in the hyperleptinaemia in IIH, 
beyond obesity, possibly hypothalamic in origin. In the study primarily examining ghrelin in 
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IIH, Subramanian et al (2004) also measured fasting serum leptin, and found that patients 
had significantly higher levels than controls.  
Mysteries surround the pathogenesis of IIH and its relation to obesity and female gender. 
Not all obese females develop IIH, and the condition can occur in males, children and 
individuals of normal weight. However, the consistent predominance of overweight women 
of reproductive age amongst cohorts of patients with IIH demands explanation, and possible 
links with sex hormones and leptin warrant further study. 
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 CHAPTER 2 CYTOKINE PROFILES IN IIH 
2.1 Background 
Although the pathophysiology of IIH remains unknown, it is not traditionally regarded as an 
inflammatory disorder. The majority of patients with IIH are overweight, however and can 
be expected to exhibit the low-grade, chronic inflammatory response of obesity.  Cytokines 
and other immune mediators have not been studied in IIH, with the exception of leptin, as 
discussed in chapter 1. The hypothesis that IIH may be defined by a pro-inflammatory 
cytokine profile in both serum and CSF is worthy of exploration. Additionally, adipokine 
dysregulation may represent a causative factor in the underlying IIH disease processes 
including the raised intracranial pressure.  
In order to investigate this, adipokines and inflammatory cytokines were analysed in paired 
serum and CSF from patients with IIH and compared to samples from patients with other 
neurological disorders. 
2.2 Methods 
2.2.1 Patients 
Patients with IIH and control subjects were recruited at University Hospital Birmingham NHS 
Foundation Trust and Sandwell & West Birmingham Hospitals NHS Trust. All patients 
underwent lumbar puncture as part of their routine clinical care. Patients with IIH were 
recruited at the time of initial presentation, following the confirmation of elevated CSF 
opening pressure at lumbar puncture. A small number of patients were included who had 
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established IIH and were being investigated following a clinical deterioration. All patients 
were diagnosed according to the updated criteria. (Friedman and Jacobson, 2002)  
Control subjects consisted of a heterogeneous group of patients under investigation for 
neurological illnesses. Patients were invited to take part in the study when having an elective 
lumbar puncture as part of their routine clinical care. A subset of control subjects were 
matched with IIH patients for gender, age (±5 years) and BMI (±2 kgm-2).  Patients with acute 
infections or relapse of known disease were excluded and controls were screened for signs 
or symptoms of IIH. Subjects were also excluded if aged less than 16 years or if unable to 
give written informed consent.   
Permission for the study was obtained from the North West Multi-Centre Research Ethics 
Committee and all participants gave written informed consent. 
Clinical details including medical history, current medication and results of imaging were 
noted for each subject.  The following anthropological measures were recorded: weight, 
height, waist and hip circumference. BMI was calculated as weight in kg/ height in m2. 
2.2.2 Samples 
All lumbar punctures were carried out with the patient in the left lateral position, whilst 
breathing regularly. (Neville and Egan, 2005) CSF opening pressure was measured to the 
nearest 0.5cm by direct manometry. CSF and blood samples were collected at the time of 
lumbar puncture and transported on ice before being promptly centrifuged at 1500 rpm for 
10 minutes and aliquoted. All samples were stored at -80˚C and analysed after a maximum 
of one freeze-thaw cycle. 
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2.2.3 Multiplex immunoassay 
Cytokines were measured using multiplex detection immunoassays. This is a validated 
method enabling quantitative determination of several cytokines. (Ooi et al., 2006)  
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Figure 2.1: Method of LuminexTM technology for multiple assays 
 
The technology involves a process that dyes latex microbeads with a blend of different 
fluorescent intensities of two dyes.  Using precise ratios, numerous different bead sets are 
created, each one being unique and distinguishable in a laser beam, based on the "colour 
code" that results from the ratio of the two dyes. These beads are the foundation for the 
immunoassay.  Capture antibody for a specific molecule is coupled to a specific bead set.  
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After an analyte is bound to the capture antibody on the bead, a detector antibody is used 
as a reporter. The detector antibody is coupled to phycoerythrin, a red protein from the 
light-harvesting phycobiliprotein found in some bacteria and algae.  The end result is an 
antibody sandwich assay on the colour coded microbead.  The beads and the reporter 
molecule are read on a LuminexTM 100 instrument using a dual laser system as they pass 
through a flow cell.  One laser detects the beads (the colour code for an assay) and the other 
laser detects the reporter signals. This is summarised in Figure 1.1. 
By using multiple bead sets, multiple assays can be conducted simultaneously.  Each unique 
assay is identified by the colour code for the bead on which the assay is built, and the 
amount of the analyte is determined by the reporter signal.  The LuminexTM 100 instrument 
has advanced optics to capture the colour signals, and translate them into real time 
quantitative data for each reaction.  
2.2.4 Cytokines 
Two commercial kits were used (Linco Research, Millipore, Billarica, USA), each measuring a 
panel of adipokines as shown in table 2.1. Panel A contained a mixture of three bead 
populations with distinct fluorescence, coated for antibodies specific for resistin, adiponectin 
and plasminogen activator inhibitor-1 (PAI-1). Panel B contained nine bead populations 
specific to the adipokines listed, including leptin. 
Serum samples were diluted x400 with assay buffer for the measurement of resistin, 
adiponectin and PAI-1 due to the higher reference concentrations of these adipokines in 
humans. The precision of the assay was defined by a quoted intra-assay variation of 1.4 – 
7.9%.  
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Table 2.1 Human Adipokine Panels with detection ranges 
 Adipocytokine Abbreviation Detection Range pgml-1 
Panel A Resistin  3 – 12500 
Adiponectin  1600-10
8
 
Plasminogen activator inhibitor PAI-1 10-100000 
Panel B Leptin  100-62500 
Interleukin 1-beta IL-1 0.6 – 625 
Interleukin 6 IL-6 0.6 – 2500 
Interleukin 8 IL-8 0.6 – 2500 
Tumour necrosis factor alpha TNF 0.6 – 2500 
Monocyte chemotactic protein 1 MCP-1 20 – 1000 
Hepatocyte growth factor HGF 100-2500 
Nerve growth factor NGF 20-4000 
Insulin  100-10000 
 
For all assays, 25 μl samples were incubated with antibody-coated capture beads for two 
hours at room temperature. Beads washed with assay buffer were further incubated with 
biotin-labelled anti-human cytokine antibodies for 30 minutes followed by streptavidin–
phycoerythrin for 30 minutes. Samples were analysed using a Luminex 100TM (Luminex, 
Austin, Texas, USA) with StarstationTM software (Applied Cytometry Systems, Sheffield, UK). 
Identified reactions were recorded as numbered events for each analyte. Standard curves of 
known concentrations of recombinant human cytokines were used to convert fluorescence 
units to cytokine concentration. (Curnow et al., 2005)  
A 
 
B 
 
Figure 2.2 A: LuminexTM 100 machine used for the multiplex assays, B:  PC monitor with 
StarstationTM software processing the event data for one of the analytes, IL-1 
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2.2.5 Statistical Analysis 
Statistical analysis was performed using SPSS version 14 (SPSS Inc., Chicago, IL, USA) and 
Prism for Windows Version 5.0 (GraphPad Software Inc, San Diego, CA, USA) software 
packages. Continuous data were summarised using means and standard deviations (or 
medians and ranges for non-normally distributed data).  
Cytokine levels in the IIH group and in controls were compared using a two-tailed, non-
parametric t-test (Mann-Whitney U). Cytokine levels in the separate diagnostic groups were 
compared using a one-way ANOVA, with Dunnett’s post hoc test for parametric data, or a 
Kruskal-Wallis analysis with Dunn’s test for non-parametric data. Multivariable regression 
models were used to examine the effects of variables age, gender, BMI and diagnostic group 
on cytokine levels. Associations between cytokine levels and clinical parameters were 
analysed using Pearson correlation for parametric data and Spearman rank correlation for 
non-parametric data. The level at which the results were judged significant was p < 0.05. 
2.3 Results  
2.3.1 Patient characteristics 
Serum and CSF specimens were collected from 88 patients. Patient characteristics are shown 
in Table 2.2.  Of the 26 patients with IIH, 22 were newly diagnosed cases and four patients 
had established or previous IIH, with worsening symptoms as the indication for lumbar 
puncture.  
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Table 2.2: Patient characteristics.  
 
 IIH 
(n=26) 
Controls 
(n=62) 
 
p value 
 
Age a 
 
28.7 7.73 
 
47.9 13.64 
 
<0.0001 
 
BMI a 
 
35.1 5.5 
 
28.2 7.3 
 
<0.0001 
 
Female (%) 
 
100 
 
64 
 
<0.0001 
 
Waist circumference a (cm) 
 
99.1 16.2 
 
94.9 17.1 
 
0.2 
 
Waist-hip ratio a 
 
0.87 0.08 
 
0.91 0.11 
 
0.12 
 
Opening Pressure a (cm CSF) 
 
35.3 6.7 
 
18.5 7.6 
 
<0.0001 
    
a
mean  standard deviation    
 
The IIH patients were younger (p < 0.0001), had higher BMI (p < 0.0001) and higher CSF 
opening pressures (p < 0.0001) than subjects in the control group. The control subjects 
comprised patients with a confirmed diagnosis of multiple sclerosis (MS) (12), from whom 
samples were collected during disease remission, cerebrovascular disease (CVS) (10) and 
mixed neurological diseases (MIX) (28). In addition, 12 patients who had presented with 
functional neurological symptoms for which investigation of CSF was clinically justified, but 
who had no neurological diagnosis and normal neurological investigations two years after 
recruitment, were included as controls (N). Table 2.3 shows the characteristics amongst the 
individual diagnostic groups. Table 2.4 shows the primary diagnoses amongst the MIX 
control group. 
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When the diagnostic groups were considered separately, patients in the IIH group were 
significantly younger, more overweight and had higher CSF opening pressure than patients in 
all of the control groups (N, MS, CVS and MIX groups.) 
 
Table 2.3: Patient characteristics by diagnostic group 
 
Table 2.4: Primary Diagnoses amongst controls with ‘mixed neurological conditions’ 
 
Clinical diagnosis 
 
Number 
 
Headache or migraine 7 
Peripheral neuropathy 4 
Motor neurone disease 3 
Cervical neuropathy 3 
Spastic paraperesis 2 
Alzheimers disease 2 
Aseptic meningitis 1 
Cerebral vasculitis 1 
Metastatic carcinoma 1 
Mixed connective tissue disease 1 
Uveitis 1 
Unexplained optic neuropathy 
Unknown 
1 
1 
Total 28 
 
 
 IIH 
(n = 26) 
N 
(n = 12) 
MS 
(n = 12) 
CVS 
(n = 10) 
MIX 
(n = 28) 
Agea 28.7  7.7 42.2  2.6 38.0  10.4 56.1  9.8 51.6  14.6 
Female (%) 100 75.0 75.0 40.0 64.3 
BMIa (kgm-2) 35.1  5.5 30.2  10.5 27.2  5.9 27.0  4.6 28.1  7.1 
Waist-hip ratioa 0.87  0.08 0.90  0.09 0.88  0.10 0.99  0.15 0.91  0.09 
Opening pressurea (cm CSF) 35.3  6.7 18.1  7.2 17.1  3.5 20.4  7.7 18.3  8.8 
a
mean  standard deviation 
N = normal investigations, MS = multiple sclerosis, CVS = cerebrovascular disease, MIX = mixed neurological diseases. 
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2.3.2 Cytokine analysis 
Cytokines were detected in the CSF and serum of subjects to varying degrees. Table 2.5 
shows the proportion of cytokines detected above minimum concentration in each 
diagnostic group as a percentage of the total number of assays for each cytokine (i.e. 
[number detected] / [number detected + number not detected] %, or [positive assays] / 
[positive assays + negative assays] %). 
Table 2.5: Rate of detection of cytokines (%) 
 Serum Cerebrospinal fluid 
Cytokine IIH N MS CVS MIX IIH N MS CVS MIX 
IL-1 4 0 0 10 6 0 0 0 0 0 
IL-6 12 25 7 22 13 86 71 75 75 74 
IL-8 20 31 40 60 25 100 100 100 100 95 
Leptin 100 100 93 100 100 100 87 81 100 95 
TNF 50 77 50 50 81 0 0 0 0 5 
MCP-1 96 92 100 100 100 100 100 100 100 95 
HGF 27 33 33 40 63 95 93 81 83 89 
Insulin 38 33 15 50 25 0 0 0 0 0 
NGF 35 17 13 30 38 0 0 0 0 0 
Adiponectin 100 100 100 100 100 100 100 94 100 95 
Resistin 96 100 100 91 100 100 100 94 100 95 
PAI-1 100 100 92 90 100 100 100 93 100 100 
 
All cytokines in the panel were detected in at least some of the samples (i.e. present at 
concentrations above the minimum level of sensitivity for the assay) with the exception of 
IL-1β, NGF and insulin, which were not detected in any CSF sample.  
The range in concentrations of cytokines in the serum and CSF samples are shown in table 
2.6. 
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The concentrations of cytokines amongst the IIH patients were compared to those amongst 
the whole control population, for all assays in which the detection rate was above 50%. 
There were no significant differences between IIH patients and controls in serum resistin, 
PAI-1, TNFα, HGF and CSF IL-8, MCP-1, resistin, PAI-1, HGF and IL-6 (figure 2.3). Serum 
concentrations of IL-8 and MCP-1 were higher in the control group than the IIH patients 
(p=0.04 and p=0.008 respectively.) 
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Table 2.6: Cytokine concentration ranges in serum and CSF (pgml-1 unless stated) 
 
   Control 
  IIH N MS CVS MIX 
Serum IL-1b <0.6 - 0.71 all < 0.6 all < 0.6 <0.6 - 0.62 <0.6 - 1.43 
 
IL-6 <0.6 - 10.4 <0.6 - 9.05 <0.6 - 2.16 <0.6 - 1.36 <0.6 - 2.16 
 
IL-8 <0.6 - 1.18 <0.6 - 2.20 <0.6 - 1.2 <0.6 - 2.63 <0.6 - 3.19 
 
Leptin (ngml
-1
) 1.10 - 21.88 0.13 - 6.11 <0.1 - 5.84 0.43 - 5.57 0.32 - 12.56 
 
TNFa <0.6 - 3.74 <0.6 - 3.17 <0.6 - 3.1 <0.6 - 5.3 <0.6 - 4.71 
 
MCP-1 <20 - 434.8 <20 - 310.9 24.1 - 397.6 119.1 - 340 100.0 - 405.8 
 
HGF <0.6 - 1,639.5 <0.6 - 1,066.5 <0.6 - 981.6 <0.6 - 1,114.8 <0.6 - 1,769.0 
 
Insulin <30 - 366.4 <30 - 93.8 <30 - 400.4 <30 - 184.4 <30 - 159.7 
 
NGF <20 - 110.8 <20 - 248.0 <20 - 70.4 <20 - 42.4 <20 - 149.3 
 
Resistin (ngml
-1
) <0.003 - 77.1 2.9 - 75.3 6.8 - 53.7 <0.003 - 62.2 3.6 - 100.9 
 
Adiponectin (gml
-1
) 0.261 - 58.9 4.88 - >100 0.40 - >100 0.529 - >100 3.298 - >100 
 
PAI-1(ngml
-1
) 3.1 - 130.8 8.2 - 152.6 <0.01 - 141.2 <0.01 - 43.5 5.7 - 138.9 
 
                
CSF IL-1b all < 0.6 all < 0.6 all < 0.6 all < 0.6 all < 0.6 
 
IL-6 <0.6 - 20.3 <0.6 - 9.28 <0.6 - 27.7 <0.6 - 24.2 <0.6 - 112.5 
 
IL-8 4.06 - 24.7 4.78 - 25.2 3.08 - 52.1 4.15 - 31.9 <0.6 - 55.2 
 
Leptin (ngml
-1
) 1.10 - 5.87 <0.1 - 4.02 <0.1 - 2.42 0.14 - 5.61 <0.1 - 2.62 
 
TNFa all < 0.6 all < 0.6 all < 0.6 all < 0.6 all < 0.6 
 
MCP-1 148.3 - 886.0 160.9 - 750.8 134.1 - 1324.9 141.2 - 1274.6 <20 - 1461.0 
 
HGF <100 - 686.0 <100 - 388.2 <100 - 645.3 <100 - 624.9 <100 - 726.6 
 
Insulin all < 100 all < 100 all < 100 all < 100 all < 100 
 
NGF all < 20 all < 20 all < 20 all < 20 all < 20 
 
Resistin  35.0 - 550.0 49.2 - 522.3 <3 - 372.0 34.2 - 2,943 <3 - 1,832 
 
Adiponectin (ngml
-1
) 2.97 - 10.48 3.70 - 25.14 <2 - 26.03 3.70 - 25.14 <2 - 109.08 
 
PAI-1 27.0 - 254.3 24.4 - 154.0 <10 - 227.9 54.9 - 255.9 <10 - 505.3 
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Figure 2.3: Scatter plots of cytokine concentrations in IIH patients and controls, medians shown 
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Serum adiponectin concentrations were lower in the IIH patients, although the difference 
was not significant. CSF adiponectin was significantly lower in the IIH group (p=0.0005). 
Serum leptin was higher amongst patients with IIH than controls, as was CSF leptin (both 
p<0.0001.) The results are summarised in figure 2.4. 
Serum Adiponectin CSF Adiponectin 
 
 
 
 
Serum Leptin 
 
CSF Leptin 
 
 
 
 
Figure 2.4: Serum and CSF adiponectin and leptin concentrations in IIH patients and controls. 
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2.3.3 Regression Analyses 
To examine whether the differences observed were an effect of the diagnostic group itself 
(IIH or control), or due to other characteristics such as BMI, regression analyses were carried 
out. CSF adiponectin was significantly influenced by age in the multivariate regression 
analysis (p=0.017). The correlation of adiponectin with age was confirmed separately 
(Spearman r=0.46, p<0.0001). Once the regression analysis was carried out to correct for 
age, gender and BMI, the CSF adiponectin was no longer significantly lower in the IIH group.  
Serum leptin was not significantly higher in IIH patients after correction for age, gender and 
BMI.  Serum leptin was positively influenced by BMI (p < 0.0001) and gender (levels being 
higher in females, p < 0.0001) in the multivariate regression (table 2.7).   
  
 
P value 
 
 
B value 
 
Standard 
Error 
95% Confidence Interval 
Lower Bound Upper Bound 
Diagnostic group 0.82 0.193 0.109 -0.025 0.411 
Age 0.511 0.002 0.003 -0.004 0.009 
BMI <0.0001 0.029 0.006 0.017 0.040 
Gender <0.0001 0.458 0.104 0.251 0.664 
Dependent variable Log 10 transformed serum leptin. R squared = 0.550 
Table 2.7: Regression model data for serum leptin 
 
CSF leptin was significantly influenced by BMI (p<0.0001) and gender (p<0.0001). However, 
CSF leptin levels remained higher in the IIH group compared to controls following regression 
analysis to correct for these factors (p=0.001) (table 2.8).  
  
 
P value 
 
 
B value 
 
Standard 
Error 
95% Confidence Interval 
Lower Bound Upper Bound 
Diagnostic group 0.001 0.343 0.098 0.147 0.538 
Age 0.178 0.004 0.003 -0.002 0.10 
BMI <0.0001 0.028 0.005 0.018 0.038 
Gender <0.0001 0.421 0.089 0.244 0.598 
Dependent variable Log 10 transformed CSF leptin. R squared = 0.593 
Table 2.8: Regression model data for CSF leptin 
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Using the correction factors identified by the regression analysis, corrected CSF leptin values 
were compared between IIH patients and controls as shown in figure 2.5.  Also shown in 
figure 2.5 is a scatter plot of CSF leptin values in ten IIH patients and ten controls matched 
for age, gender and BMI. CSF leptin was significantly elevated in the ten patients (p = 0.023) 
when compared to this matched control cohort. 
 
Corrected CSF Leptin CSF leptin in matched patients 
  
Figure 2.5: CSF Leptin after correction or matching for age, gender and BMI 
 
 
2.3.4  Correlations 
To further investigate the CSF leptin result, its relationship with CSF opening pressure was 
examined. A significant positive correlation of CSF leptin with CSF opening pressure was 
identified in the total cohort (Spearman r = 0.47; p < 0.0001) (Figure 2.6).  However, when 
IIH patients and controls were analysed separately, the correlation was significant for the 
control population (r=0.42, p=0.005) but not for the IIH cohort (r=0.11, p=0.62).  
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Figure 2.6: Relationship between CSF opening pressure (CSF OPP) and CSF leptin, line of best fit 
 
The correlations between BMI and leptin concentrations were compared between IIH 
patients and controls. In the total control population cohort, BMI was significantly positively 
correlated with serum leptin (r = 0.34; p = 0.007) and CSF leptin (r = 0.51; p<0.0001), figure 
2.7. This was not the case amongst the IIH population (serum leptin r = 0.09; p=0.67, CSF 
leptin r = 0.21; p = 0.34).  
Serum leptin and BMI CSF leptin and BMI 
  
Figure 2.7: Relationship between serum and CSF leptin and BMI showing lines of best fit for control 
cohort 
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Adiponectin showed a negative correlation with BMI amongst the whole cohort. The 
correlation between serum adiponectin and BMI was weakly significant (r=-0.24, p=0.04) as 
was that between CSF adiponectin and BMI (r=-0.27, p=0.015.) When the correlations were 
examined with the subjects split by diagnostic group (IIH and all controls), the significance 
was lost. 
All cytokines were examined for correlations between serum and CSF levels and BMI as well 
as waist circumference and waist:hip ratio. Other significant findings were negative 
correlations between serum IL-8 and BMI (r=-0.38, p=0.0004) and serum NGF and BMI (r=-
0.22, p=0.04.) Waist circumference showed significant positive correlation with CSF IL-6 (r = 
0.31; p = 0.01), CSF PAI-1 (r = 0.26; p = 0.04), CSF resistin (r = 0.26; p = 0.04), CSF leptin (r = 
0.35; p = 0.006) and serum leptin (r = 0.37; p = 0.006). 
2.3.5 Further Analyses 
The ratio of CSF:serum concentrations were examined for IL-8, MCP-1, HGF, resistin, PAI-1, 
adiponectin and leptin. The ratios were not significantly different between IIH patients and 
controls for any adipokine. When correlations between the serum and CSF concentrations 
were examined for each of these seven adipokines, only leptin and resistin showed a 
correlation between serum and CSF levels. In the case of leptin, the serum and CSF 
concentrations were correlated amongst the whole cohort (r=0.66, p<0.001) and the total 
control cohort (r=0.68, p<0.001), but not the IIH patient cohort (r=-0.35, p=0.12). Similarly, 
the serum and CSF resistin levels were significantly correlated when the whole cohort was 
considered (r=0.26, p=0.03), but this was not the case for the IIH patients (r=0.32, p=0.17) or 
for the control subject cohort (r=0.25, p=0.08). 
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Further sub analysis was performed by considering the controls according to the four 
diagnostic groups (MS, CVS, MIX and N). Of all the separate analyses, only CSF IL-8 showed a 
significant difference, with higher concentrations in the MS cohort (p=0.02). Regression 
analysis confirmed this to be an effect of disease group as age, gender and BMI did not 
significantly influence the result. Finally, the data was explored with subjects considered in 
three groupings, IIH patients, ‘disease controls’ (MS+CVS+MIX) and patients with normal 
investigations (N). This did not affect the results significantly, with the exception of serum IL-
8 which was identified as being higher amongst disease controls than patients in the IIH and 
N diagnostic groups. 
2.4 Discussion 
Profiles of adipokines and inflammatory cytokines have not previously been compared 
between IIH and other neurological diseases. Although a distinct IIH-specific cytokine profile 
has not been identified, the adipokine leptin appears to be significantly dysregulated in the 
CSF of patients with IIH. 
A significant elevation of serum leptin levels amongst patients with IIH was found in this 
study, but this significance was lost when levels were adjusted for age, gender and BMI. 
Previous studies have reported elevated serum leptin in IIH compared with control groups. 
(Lampl et al., 2002; Subramanian et al., 2004) However, the two studies concerned did not 
carry out multivariable regression analysis and the confounding effect of elevated BMI may 
not have been excluded. The serum leptin results in this study do mirror previous studies 
documenting sexual dimorphism, with levels higher in women than men, and a positive 
correlation with age and BMI. (Ostlund et al., 1996; Schwartz et al., 1996; Nam et al., 2001)  
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It should be noted that subjects were not fasted prior to the collection of blood and CSF 
samples. Serum leptin levels can reportedly be influenced by fasting, (Weigle et al., 1997) 
although acute alterations in food intake have been shown not to affect circulating levels. 
(Korbonits et al., 1997) Data from the study by Wong et al (2004) suggests that there is very 
little variation in the levels of CSF leptin over a 24 hour period or in response to food intake. 
It is unlikely that the lack of fasting amongst the patients in this study had a major effect on 
the results. 
An important and novel finding was the elevated CSF leptin in patients with IIH, which 
remained significantly raised after adjustments for age, gender and BMI. The CSF leptin 
levels in this study were higher than previously published values, possibly reflecting 
differences in the recombinant leptin used to standardise the assays. (Caro et al., 1996; 
Schwartz et al., 1996; Meier and Gressner, 2004; Wong et al., 2004) The use of control 
subjects from a neurological disease population, where permeability of the blood brain 
barrier may be affected, may also be relevant. CSF leptin levels vary very little when 
measured over a 24 hour period, (Wong et al., 2004) but levels can be influenced by drug 
therapy. (Rodrigues et al., 2002) There were no consistent trends regarding prescribed 
medication amongst the subjects in this study. Only four patients with IIH were taking 
acetazolamide and four patients in the whole group were using hormonal contraceptives.  
Medication use is unlikely to have significantly contributed to the results seen.   
CSF leptin was noted to significantly correlate with intracranial pressure, but analysis 
confined to the IIH cohort failed to identify a linear correlation. This may possibly reflect a 
more complex relationship between leptin and CSF opening pressure at higher intracranial 
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pressures. The role of CSF leptin and how it may be involved in intracranial pressure 
homeostasis or the pathogenesis of IIH remains to be explored. 
It is interesting that despite high levels of CSF leptin and the potential for hypothalamic 
signalling to indicate satiety, IIH patients remain overweight.  In obesity, levels of serum 
leptin are elevated but there is an apparent resistance to its appetite suppressing effects. 
(Schwartz et al., 1996) This has been postulated to occur as a result of either impaired 
transport of leptin across the blood-brain-barrier, or impaired leptin signalling at the 
hypothalamus. (Flier, 2004) In support of the impaired transport theory, CSF:serum leptin 
ratios are reduced in obesity. (Caro et al., 1996) In addition, infusion of leptin into the CSF of 
overweight leptin-deficient rats has been shown to cause weight loss. (Van Heek et al., 1997) 
The elevated CSF leptin seen in our cohort of patients with IIH may suggest that the 
aetiology of the obesity in IIH is failed leptin signalling at the hypothalamus. 
The origin of the CSF leptin in IIH is of interest.  This study found that neither CSF nor serum 
leptin levels correlated with BMI in subjects with IIH, yet both correlated significantly with 
BMI in the control population. A similar finding was reported by Lampl et al (2002) who 
showed a significant association of leptin with BMI in the serum of healthy control subjects, 
including an obese cohort, but not in a cohort of 15 IIH patients. Furthermore, the 
relationship between serum and CSF leptin in this study was not significant for the IIH 
patient cohort, (r=-0.35, p=0.12) but showed a significant positive correlation amongst all 
patients together (r=0.66, p<0.001) as well as the control group (r=0.68, p<0.001). When 
CSF:serum ratios were compared for all adipokines, no differences were identified between 
the diagnostic groups. However, CSF:serum leptin ratios showed a trend towards higher 
values in the IIH cohort  (0.61 compared to 0.39 in the control population, p = 0.075). These 
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findings suggest that, in contrast to the situation in normal obese individuals, transfer of 
leptin across the blood brain barrier in IIH is not impaired and may even be enhanced. 
Alternatively, up-regulation of leptin secretion from central nervous system locations may 
explain why CSF leptin levels are significantly elevated in IIH; extra-adipose sites of leptin 
secretion have been previously documented in the stomach, heart, pituitary and 
hypothalamus. (Green et al., 1995; Bado et al., 1998; Morash et al., 1999) It remains unclear 
whether elevated CSF leptin is a cause or a consequence of the pathogenic process 
underlying IIH. 
Obesity was characterised by an inflammatory cytokine profile (CSF IL-6, CSF PAI-1, CSF 
resistin, CSF leptin and serum leptin) in this neurological patient cohort, although not all the 
cytokines previously documented in obesity were dysregulated. (Maedler et al., 2002; 
Straczkowski et al.; 2002, Sartipy and Loskutoff; 2003; Park et al., 2005; Straczkowski et al., 
2006) Levels of adiponectin, an adipokine with seemingly antagonistic effects to leptin, were 
reduced in both the CSF and serum in IIH patients compared to the control group, but this 
did not reach statistical significance when age and BMI were taken into account. The results 
did not identify significantly deranged cytokine profiles in IIH patients compared with 
controls, although IL-8 and MCP-1 were present at higher concentrations in the control 
group as a whole, a likely effect of the inclusion of control subjects with inflammatory 
disease.  Sub-analysis of the results by individual diagnostic groups did not identify any 
disease-specific inflammatory cytokine profiles, with the exception of CSF IL-8, which was 
elevated in the MS cohort, as has been shown by other studies. (Cannella and Raine, 1995; 
Ishizu et al., 2005) Very little is known about the transfer of certain cytokines across the 
blood brain barrier and their role in many neurological conditions. Thus, the lack of 
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significant cytokine abnormalities and specific profiles in this study does not exclude their 
involvement in the pathogenesis of IIH.  
 
2.5 Summary 
No previous studies have characterised cytokine levels in the serum and CSF of patients with 
IIH. The findings of this study appear to indicate that IIH is not an inflammatory condition as 
may have been predicted from the associated obesity phenotype. A novel finding of 
significantly elevated CSF leptin in IIH has been demonstrated, independent of BMI. 
Additionally levels of CSF leptin positively correlate with intracranial pressure in control 
subjects but not in patients with IIH. These findings suggest that failure of leptin signalling at 
the hypothalamus may be important in the pathophysiology of the obesity seen in patients 
with IIH. In addition, increased CSF leptin may be important in the underlying pathogenic 
processes that lead to the development of IIH. Further study of the central actions of leptin 
and its possible role in the regulation of intracranial pressure and satiety may shed light on 
the mechanisms underlying IIH. 
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CHAPTER 3 THE IIH TRIAL PILOT 
 
A PRAGMATIC RANDOMISED CONTROLLED TRIAL OF 
TREATMENT FOR IDIOPATHIC INTRACRANIAL HYPERTENSION 
 
3.1 Background 
Evidence of the effectiveness of treatments for IIH is poor, with most of the data coming 
from small retrospective case series. Even the largest prospective studies have involved only 
35, (Rowe and Sarkies, 1998) 50 (Wall and George, 1991) and 81 patients. (Radhakrishnan et 
al., 1993) A Cochrane systematic review in 2005 failed to find a randomised controlled trial 
of any treatment option in this disease area. (Lueck and McIlwaine, 2005) Acetazolamide is a 
widely used treatment, but with the exception of one small study, (Celebisoy et al., 2007) 
has not been formally evaluated in IIH. There is increasing belief that weight reduction is 
beneficial and possibly even curative, but this too needs further investigation. Thus, 
controversies abound in the management of IIH and there is an urgent need for well 
designed clinical trials. 
Similarly, there is no consensus regarding the best way to monitor patients with IIH. There 
are uncertainties surrounding the natural history of the condition and the identification of 
those most at risk of visual loss. In clinical practice, routine reviews tend to combine the 
assessment of symptoms with ophthalmological examination and measurement of visual 
function, giving an overview of the patient’s presentation. Assessments of disease status are 
subjective and no agreed grades of IIH severity exist. There are no specific criteria to guide 
the clinical decision-making and the timing of any intervention is left to the judgement of the 
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treating clinician. Even the concept of ‘cure’ in IIH is fraught with difficulty.  Resolution of all 
symptoms and abnormal signs indicates remission of the condition, but in many instances, 
headache or minor changes in the appearance of the optic discs or visual fields can persist, 
suggesting the presence of residual disease. It can be difficult to ascertain whether a 
patient’s discs have returned to normal or to be certain that a patient’s headache is actually 
due to raised intracranial pressure. Thus whilst a definition of cure may be straightforward 
and easily agreed, applying that definition to a particular patient can be problematic. 
Clinical experience suggests that several factors are considered in deciding whether a patient 
with IIH is improving or deteriorating. A variable combination of symptoms, signs and visual 
parameters appears to dictate the management strategy. Some studies have highlighted the 
relative importance of visual field assessment in predicting outcome (Wall and George, 1991; 
Rowe and Sarkies, 1998) and this is often reflected in current practice, but treatment is also 
guided, to a greater or lesser degree, by presenting symptoms, papilloedema and 
performance on other tests of vision. Studies in IIH must acknowledge this multi-factorial 
approach to disease evaluation. Striving towards a single measure of outcome in IIH may be 
futile; instead a composite outcome may perform better as a measure of disease status and 
warrants further study. 
Since so little is known about the effects of different treatments and the most appropriate 
outcome measures in IIH, large scale clinical trials cannot be properly planned. A pilot study 
is required to explore the feasibility of such trials as well as provide data to inform sample 
size and power calculations in their design. 
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3.1.1 Objectives 
This pilot study was designed to prospectively evaluate a cohort of newly diagnosed patients 
with IIH, with the following aims: 
 To examine the feasibility of a randomised controlled trial of treatment for IIH  
 To obtain data upon which to base future calculations of sample size and anticipated 
treatment effect for a large scale trial 
 To observe the use of acetazolamide and its effect upon various measures of disease 
status in IIH 
 To observe the effects of weight reduction in patients who were overweight, by 
comparing outcomes between those who did and those who did not lose weight  
 To explore the commonly employed measures of disease status in IIH and identify 
features of the clinical assessment that most influenced the overall status of patients 
with IIH 
3.2 Methods 
3.2.1 Trial Design 
A pragmatic trial design was adopted for this study. An open-label, prospective, randomised 
controlled structure was chosen to complement normal clinical practice and maximise 
recruitment. Patients and treating clinicians were not blinded to the treatment allocation. 
Patients presenting to the neurology and ophthalmology units of the participating hospitals 
who met the inclusion criteria were informed of the study by their treating clinician and 
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invited to take part. They were provided with an information sheet and asked to give written 
informed consent for the study. 
Randomisation was performed by the University of Birmingham Clinical Trials Unit, via a 
telephone call from the treating clinician, once consent had been obtained. Allocation was 
determined by a computer-generated random list. Patients were randomised to receive 
either treatment with acetazolamide or no acetazolamide. Randomisation was based upon 
the uncertainty principle; if the supervising clinician believed that a patient should definitely 
receive or not receive treatment with acetazolamide, the patient was not eligible for 
inclusion in the study. 
Acetazolamide was used within licence, according to the Summary of Product Characteristics 
(SPC). The dosing schedule was left to the discretion of the treating clinician, in accordance 
with their normal clinical practice. Regardless of treatment allocation, all overweight 
patients were advised to follow a weight reduction programme. Overweight patients were 
referred for assistance with weight reduction, such as advice from a dietician, in keeping 
with the normal policy of the treating centre.  
It was anticipated that some patients would deteriorate regardless of initial treatment. 
Supervising clinicians were advised to use their normal judgement to decide if and when 
patients should receive additional intervention. The supervising clinician was able to initiate 
changes to the dosing schedule of acetazolamide in those patients randomised to receive it 
and to commence treatment with acetazolamide in patients allocated not to receive it. The 
decision to refer patients for further or urgent intervention, such as surgery, was also left to 
the discretion of the treating clinician. 
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The duration of the study period was 12 months from randomisation. Data was collected at 
baseline and at 3, 6, 9 and 12-months, totalling five visits. It was customary for some centres 
to schedule reviews at additional time points within the one year period; where this was the 
case, abbreviated data was collected as “additional visit” information. Data was recorded on 
visit-specific forms, provided as a trial pack for each patient (see Appendix 1) Various 
measures were documented by the treating clinician at each visit, with patient 
questionnaires completed at visits 1 (baseline), 3 (6 months) and 5 (12 months). All of the 
documented information from a single visit was returned by post to the trial coordinator for 
entry onto the trial database. 
Approval for the study was granted by the North West Multicentre Regional Ethics 
Committee. The Medicines and Healthcare products Regulatory Authority (MHRA) approved 
the use of acetazolamide in this trial. The trial was registered with the European Clinical 
Trials Database (European Union Drug Regulating Authorities Clinical Trials, EudraCT number 
2004-001595-40). 
3.2.2 Trial Centres 
Patients were recruited from six neurology and ophthalmology units in the Midlands area of 
the UK. The main trial centre was in Birmingham, within the Neurology department of City 
Hospital (Sandwell and West Birmingham NHS Trust) and the adjoining Birmingham and 
Midland Eye Centre, which is a regional tertiary referral centre for neuro-ophthalmology in 
the West Midlands. Additional sites were identified by the Trial Steering Committee and 
chosen on the basis of availability of interested senior clinicians, appropriate facilities and 
local neuro-ophthalmology expertise.  
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Site-specific local research ethics committee approval was granted for the following 
additional centres:  
 University Hospital Birmingham NHS Foundation Trust 
 Royal Wolverhampton Hospitals NHS Trust 
 University Hospitals Leicester NHS Trust 
 Sheffield Teaching Hospitals NHS Foundation Trust 
 United Lincolnshire Hospitals NHS Trust 
 University Hospital North Staffordshire NHS Trust 
 
All sites were coordinated through the main trial centre and the same trial manager 
performed the site visits, training and data entry for all of the centres. 
3.2.3 Patients 
Clinical audit in 2004 showed that approximately 50 cases of IIH present to the Birmingham 
and Midland Eye Centre and the neurology and ophthalmology services of City Hospital and 
University Hospital each year. By increasing the area covered by the pilot study to the above 
centres, it was anticipated that 50 patients could be recruited in a 12-month period. 
3.2.3.1 Inclusion Criteria 
 New diagnosis of IIH according to modern criteria (Friedman and Jacobson, 2002)  
 Normal imaging (cerebral MRI and MR venogram or CT venogram normal) 
 Documented elevation of CSF opening pressure above 25cm at lumbar puncture 
 Normal CSF constituents 
 Normal routine haematology and biochemistry (no abnormalities of full blood 
count or urea and electrolytes) 
 Willing and able to give written informed consent 
 Able to complete trial documentation 
 Randomising clinician uncertain about the treatment the patient should receive 
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3.2.3.2 Exclusion Criteria 
 Intracranial hypertension due to cerebral venous sinus thrombosis, structural, 
metabolic or other cause 
 Contraindication to acetazolamide: hypokalaemia, hyponatraemia, metabolic 
acidosis, severe hepatic or renal impairment, sulphonamide sensitivity 
 Pregnancy or planned pregnancy 
 Randomising clinician certain about the treatment the patient should receive 
3.2.4 Outcome Measures 
No single or main outcome could be chosen, since a principal aim of this pilot was to explore 
a variety of measures of IIH status. The data collected can be summarised as: 
1. Demographic data 
2. Pragmatic outcome measures 
a. Presence or absence of symptoms 
b. Headache visual analogue score (VAS) 
c. Intervention 
i. Changes to acetazolamide 
ii. Surgery 
3. Visual Function 
a. Acuity 
b. Visual Field 
c. Contrast Sensitivity 
d. Optic disc appearance 
4. Health related quality of life / mood 
a. Short Form 36 
b. Hospital Anxiety and Depression Score 
c. EuroQoL EQ-5D 
 
In addition, serious unexpected suspected adverse reactions (SUSARS) were monitored 
throughout the trial. 
3.2.4.1 Demographic data 
The following data were recorded at baseline: 
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 Hospital identification number and recruiting centre 
 Date of birth, ethnic group 
 Height (metres) and weight (kilograms; to nearest 0.5kg) 
 Any pre-existing neurological or ocular disease 
 Current medication 
 Prior use of antibiotics (in previous 6 months), hormonal medication, lithium or 
vitamin A or its derivatives 
 Any other relevant medical or surgical history 
 Documented CSF opening pressure in cm 
3.2.4.1 Pragmatic outcome measures 
3.2.4.1.1 Symptoms 
At baseline, as well as at each subsequent visit, patients were asked about the presence or 
absence of the following symptoms: 
 headache  
 tinnitus  
 visual loss 
 transient visual obscurations  
 diplopia  
 any other symptom 
 
Space was provided for the assessing clinician to elaborate on any of the items using free 
text entries. Headache was rated on a 10 point scale by the patient. They were asked to 
choose a score from 1 to 10 to describe their current headache, with 1 indicating no 
headache and 10 being the worst headache imaginable.   
3.2.4.1.2 Intervention: Acetazolamide 
A series of questions relating to the treatment allocation was included at each visit. 
 For the acetazolamide group the questions were: 
1. Is the patient still taking acetazolamide? 
2. Current dose of acetazolamide 
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3. Has the dose been changed? 
4. Reason for dose change (if known) 
5. Reason(s) for stopping acetazolamide from a choice of any or all of: 
a. Adverse effects of medication   
b. Patient preference 
c. Pregnancy or planned pregnancy 
d. Other reason 
 
 For the control group the questions were: 
1. Has acetazolamide been added? 
2. Date commenced acetazolamide (if applicable) 
3. Current dose (if applicable) 
4. Reasons for adding acetazolamide from a choice of any or all of: 
a. Worsening visual field 
b. Worsened disc appearance  
c. Reduced acuity  
d. Development of afferent pupillary defect  
e. Headaches failing to resolve  
f. New visual obscurations  
g. Worsening tinnitus  
h. Worsening impairment of colour vision  
i. Other 
 
3.2.4.1.3 Intervention: Surgery  
At each visit, clinicians were asked whether surgery was indicated for the patient and if so, 
to document the reason for surgery. Space for free text was provided on the forms. 
3.2.4.2 Visual Function measures 
3.2.4.2.1 Visual acuity 
Visual acuity was measured at each visit after refraction on standard LogMAR charts (Figure 
3.1) with uniform illumination at a distance of 4 metres. LogMAR is the logarithm of the 
minimum angle of resolution (MAR). Two charts are available, the Bailey-Lovie and the 
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Lighthouse charts. (Holladay and Prager, 1989) The MAR relates to the resolution required to 
resolve the elements of a letter. (Bailey and Lovie, 1976) Thus Snellen acuity 6/6 equates to 
a MAR of one minute of arc, 6/12 equates to two minutes of arc and so on. LogMAR is the 
Log10 of the MAR (See table 3.1). Snellen charts have irregular progression of letter size, 
variation in number of letters per line, difference in legibility of letters and the spaces 
between letters and rows have no relationship. In contrast, LogMAR charts have logarithmic 
progression in letter and row size, equal numbers of letters per line and letters of equal 
legibility. Therefore the only parameter likely to influence visual acuity levels is the letter 
size. (Bailey and Lovie, 1980) Each letter on a line is equal to log 0.02. If the patient is unable 
to read the whole line, 0.02 for each letter on the line read correctly is subtracted from the 
value of the last whole line read, for values below 0.0, or added, for values better than 0.0. A 
lower number equates to a better visual acuity. 
Table 3.1 Snellen to LogMAR comparisons 
  
Snellen LogMAR 
6/120 1.3 
6/60 1.0 
6/24 0.6 
6/9.5 0.2 
6/6 0.0 
6/4.8 -0.1 
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  Figure 3.1 LogMAR acuity chart    
 
3.2.4.2.2 Visual fields  
Visual fields were recorded at each visit. Humphrey automated perimetry was used. The 
programme used was a central 24-2 SITA test (Swedish Interactive Threshold Algorithm) with 
Statpac software. Visual thresholds were established at loci separated by six degrees 
throughout the central 24 degrees of the visual field. The starting stimulus light intensity was 
6 dB brighter than the age-matched standard for each location and the stimulus had 
duration of 0.02 seconds. The 24-2 programme was chosen as it is most commonly used in 
the assessment of optic nerve disease and was available at all trial centres. In addition, 
effective screening is achieved with minimal testing time and patient fatigue. 
The mean deviation (MD) value, a measure of the average amount by which the measured 
threshold differed from the age corrected normal, was recorded in decibels. In addition, the 
pattern standard deviation, a measure of localised non-uniformity, was recorded. If any of 
the global incides fell outside the expected range of normal, they were flagged with a p 
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value. The numbers of fixation losses were recorded as well as the percentages of false 
positive and false negative errors, so that unreliable recordings could be excluded from later 
analysis. 
3.2.4.2.3 Contrast Sensitivity 
Where available, contrast sensitivity was assessed for both eyes individually, as well as for 
binocular vision, using a Pelli-Robson chart under standard illumination. Patients were tested 
three times, each eye separately and both eyes together, wearing their normal distance 
correction, if any.  
Scoring grids were provided, so that the log contrast sensitivity for the faintest triplet for 
which two of the three letters were named correctly could be recorded. (Figure 3.2) The log 
contrast sensitivity is given by the number on the grid nearest to the letter triplet. Two 
different sets of letter sequences were available on charts which were otherwise identical, 
to vary the letters in case patients had memorised them. Patients were encouraged not to 
give up too soon and to make a guess even when they believed the letters to be invisible. 
The reliability of the results was dependent upon the allowing sufficient time and only 
stopping the test once the patient had guessed incorrectly two of the three letters in a 
triplet. (Pelli et al., 1988)  
 
LEFT  EYE 
 
RIGHT EYE 
 
BINOCULAR 
0.00 H S N D S N 0.15     0.00 H S N D S N 0.15  0.00 H S N D S N 0.15 
0.30 C K R Z V R 0.45  0.30 C K R Z V R 0.45  0.30 C K R Z V R 0.45 
0.60 N D C O S K 0.75  0.60 N D C O S K 0.75  0.60 N D C O S K 0.75 
0.90 O Z K V H Z 1.05  0.90 O Z K V H Z 1.05  0.90 O Z K V H Z 1.05 
1.20 N H O N R D 1.35  1.20 N H O N R D 1.35  1.20 N H O N R D 1.35 
1.50 V R C O V H 1.65  1.50 V R C O V H 1.65  1.50 V R C O V H 1.65 
1.80 C D S N D C 1.95  1.80 C D S N D C 1.95  1.80 C D S N D C 1.95 
2.10 K V C O H R 2.25  2.10 K V Z O H R 2.25  2.10 K V Z O H R 2.25 
  
Figure 3.2: Scoring grids for Pelli-Robson Contrast Sensitivity.  
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3.2.4.2.4 Papilloedema 
Papilloedema was documented as present or absent for each eye by the examining clinician.  
Photographs of both optic discs were taken with pupils dilated using a Topcon Trc 50IX© 
digital fundus camera (Topcon Corporation, Japan). Clinicians were not asked to assign a 
grade to or comment on the severity of the disc appearances. Digital images were stored for 
use in a later study (see Chapter 4). 
3.2.4.3 Health related quality of life and depression 
All patients were asked to complete a questionnaire at baseline, 6 months and 12 months, 
comprising three validated measures. (Appendix 2) 
3.2.4.3.1 Short Form 36 (SF36) 
The multi-purpose Short Form 36 health survey is a generic measure used in surveys of 
general and specific populations, comparing the relative burden of diseases and 
differentiating the health benefits produced by different treatments. Comprising 36 
questions, it yields an eight scale profile of functional health and well-being as well as 
psychometrically-based physical and mental health summary measures. The following eight 
health concepts are measured, which are relevant across age, disease and treatment groups: 
physical functioning, role limitations due to physical health problems, bodily pain, general 
health, vitality (energy/fatigue), social functioning, role limitations due to emotional 
problems and mental health (psychological distress and psychological well being). The survey 
uses a standardized scoring system, producing two summary measures and a self-evaluated 
change in health status in addition to the eight health scores.  Higher scores are indicative of 
more positive quality of life. 
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3.2.4.3.2 Hospital Anxiety and Depression Scale (HADS)  
Psychological well-being was assessed by the Hospital Anxiety and Depression Scale (HADS). 
(Zigmond and Snaith, 1983) This is a brief self-report measure that provides two separate 
scores for anxiety and depression. It was designed to assess milder forms of mood disorder 
in non-psychiatric hospital outpatients. Scores range from 0 to 21, with higher scores 
indicative of more anxiety and greater depression. Score of 0-7 is in the normal range, 8-10 
borderline and 11-21 is the abnormal range.  
3.2.4.3.3 The EuroQoL EQ-5D 
Patient rated health status was assessed using EuroQoL EQ-5D (©1990 EuroQol Group), a 
standardised instrument measuring health outcome. Applicable to a wide range of health 
conditions it provides a descriptive profile (i) and single index (ii) for health status. It was 
designed as a simple generic measure of health for clinical and economical appraisal.(Brooks 
et al., 2003)  
(i) The EQ-5D descriptive system has five dimensions: mobility, self care, usual activities, 
pain/ discomfort and anxiety / depression. There are three levels for each dimension: no 
problems, some problems, severe problems. Health states are then referred to in 5-digit 
code, where ‘11111’ represents no problems and ‘33333’ represents severe problems in all 
dimensions. Weights are used to score the responses to the 5 domains, with scores ranging 
from 0 to 1 (where a score of 1 represents a perfect state). Utilities or societal valuations 
placed on each state are based on a UK sample of 3,235 persons using time trade off to 
determine valuations. (Dolan et al., 1995)  
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(ii)The EQ-VAS (visual analogue score) is from 0 (worst) to 100 (best). Respondents rate their 
own health on a vertical ‘thermometer’ scale labelled ‘best imaginable health state’ and 
‘worst imaginable health state’.  
3.2.4.4 Composite Outcome Measures  
3.2.4.4.1 Final Status Score 
At the final (12-month) visit, treating clinicians were asked to describe each of the patient’s 
headache, tinnitus and visual obscurations as  absent (0 points),  present, - stable (1 point) or 
deteriorating (2 points),  along with visual acuity, visual field and optic disc appearance as 
normal (0 points), abnormal, - stable (1 point) or deteriorating (2 points). Summation of each 
item produced a Final Status Score ranging from 0 for the best outcome to 12 for the worst 
(Table 3.2) 
3.2.4.4.2 Final Outcome 
Also at the 12-month visit, clinicians were asked to choose which term best described the 
patient’s IIH at that visit, from a choice of four: 
1. IIH in remission    
2. Active IIH improving   
3. Active IIH but stable  
 4. Active IIH deteriorating  
 
 
 
 130 
 
Table 3.2: Scoring system for IIH Final Status Score 
 
Item Description Select 
one ( ) 
 
Score 
1. Headache 
Absent [  ] 0 
Present, stable [  ] 1 
Deteriorating [  ] 2 
    
2. Tinnitus 
Absent [  ] 0 
Present, stable [  ] 1 
Deteriorating [  ] 2 
    
3. Visual obscurations  
Absent [  ] 0 
Abnormal, stable [  ] 1 
Deteriorating [  ] 2 
    
4. Visual Acuity  
Normal [  ] 0 
Abnormal, stable [  ] 1 
Deteriorating [  ] 2 
    
5. Optic Disc 
Normal [  ] 0 
Abnormal, stable [  ] 1 
Deteriorating [  ] 2 
    
6. Visual Field 
Normal [  ] 0 
Abnormal, stable [  ] 1 
Deteriorating [  ] 2 
 Total maximum score: 12 
  
3.2.5 Statistical analysis 
Statistical analyses were performed using SAS (Statistical Analysis Software, SAS Institute 
Inc.,Cary, NC) and SPSS 17.0 (Statistical Package for Social Sciences, SPSS Inc., Chicago, IL.) 
Graphs were produced using Microsoft Excel 2007 and GraphPad Prism 5 (GraphPad 
Software Inc., La Jolla, Ca.) 
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Being a feasibility study, the trial was not powered to provide definitive efficacy results. 
Intention-to-treat point estimates and confidence intervals (CI) were calculated for clinical 
outcomes. Differences between dichotomous variables were analysed as Peto odds ratios to 
examine treatment effect; for continuous variables, the mean values were compared. 
Repeated measures analysis was applied to longitudinal data. Continuous and ordinal non-
parametric variables were compared between groups using the Mann-Whitney U test, or 
Cuzick’s test for trend if they were measured across three or more ordered groups. The tests 
were two-tailed with significance set at 5%. Association between categorical variables was 
measured using Somers' D, an asymmetric measure of the effect of a given predictor 
variable on outcome.  
 
3.3 Results 
 
3.3.1 Recruitment 
The first of a total of 50 patients was recruited in February 2005 and the last, in December 
2006. Five of the approved centres recruited patients to the trial: The Birmingham and 
Midland Eye Centre (Sandwell and West Birmingham NHS Trust), Leicester Royal Infirmary, 
Sheffield Teaching Hospitals NHS Trust (Royal Hallamshire Hospital), University Hospital of 
North Staffordshire, (Stoke on Trent) and United Lincolnshire Hospitals NHS Trust.  
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Figure 3.3: Total numbers of patients recruited by each centre in the IIH Trial 
 
Figure 3.4: Patients randomised, by centre, during each month of the total recruitment period 
3.3.2 Ineligible patients 
For the Birmingham centre only, data was available for all patients screened for inclusion. 
From a total of 84 patients screened, 34 were ineligible for a variety of reasons (table 3.3) In 
the majority of cases, patients were ineligible because they had been prescribed 
acetazolamide during their acute hospital admission, immediately following the diagnostic 
lumbar puncture and prior to neuro-ophthalmology assessment and invitation to the trial. 
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Amongst the six patients who declined consent, three expressed concern about the concept 
of randomisation, two indicating a strong preference for receiving medication and one 
preferring not to receive any. One of the other three patients had concerns about travel to 
appointments in Birmingham; the other two did not cite specific reasons. 
Table 3.3 Reasons for ineligibility of screened patients 
Acetazolamide already commenced 9 
Declined consent 7 
Anaemia 5 
Referred for surgery 3 
Acetazolamide contraindicated 3 
Absent papilloedema 3 
CSF abnormalities 2 
Unable to give consent 1 
Borderline CSF pressure 1 
Total 34 
 
Four women and one man were found to be anaemic during screening. The haemoglobin 
values ranged from 5.5gdl-1 to 9.0 gdl-1 amongst the women (normal range 11.5 to 16.0gdl-1); 
in the male patient it was 9.2gdl-1 (Normal range 13.5 to 18.0gdl-1). As discussed in chapter 
one, all patients had a microcytic blood picture and all had improvement of their intracranial 
hypertension symptoms when the anaemia was treated. 
Three patients presented with visual loss and clinical findings that were felt to warrant 
immediate surgical intervention. All three underwent insertion of lumboperitoneal (LP) or 
ventriculoperitoneal (VP) shunt in the neurosurgical unit, within five days of their initial 
presentation. 
Acetazolamide was contraindicated in two patients, one due to current pregnancy and one, 
planned pregnancy. A third patient was assessed by the treating clinician as having disease 
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which definitely did not require drug treatment, hence was ineligible according to the 
uncertainty principle.  
Three patients appeared to have papilloedema upon initial presentation, which led to a 
series of investigations for IIH, but were subsequently found not to have papilloedema when 
neuro-ophthalmology review including slit lamp examination was carried out. One of the 
patients was found to have optic nerve head drusen, with a similar appearance to 
papilloedema. Although this patient had an opening CSF pressure of 34cm, there were no 
symptoms or signs of raised intracranial pressure, the patient having undergone 
investigations due to the appearance at fundoscopy of their optic discs.  No diagnosis of IIH 
was made and the patient was simply kept under review. In the case of the other two 
patients, in whom the optic discs appeared normal, no consensus of opinion about the 
diagnosis could be reached.  
Two patients were found to have CSF pleocytosis which precluded the diagnosis of IIH and 
were referred for further investigation. One patient had a CSF opening pressure of 21cm and 
was excluded. One patient had learning difficulties and was unable to give informed consent. 
3.3.3. Demographics 
50 patients fulfilled the inclusion criteria for inclusion and were recruited. The characteristics 
of these patients are shown in table 3.4. There were 25 patients in each randomisation arm. 
Overall, 46 patients were female and the mean age was 31 years (range 18 to 66 years). The 
recorded opening pressure at diagnostic lumbar puncture ranged from 25.0 to 78.0cm. 
Baseline weight amongst the 50 patients ranged from 72.5 to 146.0 kg, with corresponding 
values of body mass index (BMI) from 23.7 to 60.6 kgm-2. As expected there were no 
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significant differences between the allocation arms; the Mann Whitney two-tailed p values 
for age, BMI and CSF pressure were p = 0.57, 0.12 and 0.66 respectively (figure 3.5.) 
Table 3.4 Characteristics of patients by allocation. Medians and ranges are given. OP = opening 
pressure at diagnostic lumbar puncture 
 Acetazolamide No Acetazolamide 
N 25 25 
Age  29 (18-66) 33 (18-63) 
F:M 22:3 24:1 
CSF OP cm 38.5 (26.5-51.0) 39.0 (25.0-78.0) 
BMI kgm-2 38.4 (29.8-60.6) 34.1 (23.7-48.8) 
   
 
Figure 3.5 Baseline demographics by allocation 
 
Ethnicity was recorded as White British in 40 of the 50 patients (80%), Black Caribbean in five 
(10%), Indian in three, Pakistani in one and White Irish in one patient.  
3.3.3.1 Medical History 
Two patients had prior ocular conditions; one had recurrent IIH, having being diagnosed and 
treated 20 years previously, the other right sided amblyopia diagnosed aged 3 years. Four 
patients reported a history of migraine. One patient had a history of Bell’s palsy in 
childhood; no other prior neurological conditions were reported.  
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Systemic arterial hypertension was recorded in 8 patients (16%), two male and six female. 
The male patients were 52 and 70 years, the age range in the females was 29 -67, mean 46 
years. Two patients had a history of depression, one with associated panic disorder. 
Three patients reported menstrual dysfunction. One patient was being investigated for 
polycystic ovary syndrome for oligomenorrhoea, one reported ‘erratic’ menstrual periods 
and one patient had a combination of oligomenorrhoea and menorrhagia. One further 
patient had undergone a hysterectomy two years prior to recruitment. 
A variety of prior medical or surgical diagnoses were reported for individual patients, as 
shown in table 3.5. 
Table 3.5 Prior medical or surgical diagnoses  
Condition Number of patients % 
 
Hypertension 
 
8 
 
16 
Depression 2 4 
Migraine 4 8 
Menstrual dysfunction 3 6 
Folate deficiency 2 4 
Osteoarthritis 2 4 
Gallstones 1 2 
Eczema 1 2 
Ulcerative colitis 1 2 
HIV seropositivity 1 2 
Obstructive sleep apnoea 1 2 
Prior hysterectomy 1 2 
Prior spinal tuberculosis 1 2 
Prior varicose vein surgery 1 2 
 
3.3.3.2 Medication 
Prescribed medication other than simple analgesia was recorded in 18 subjects (Table 3.6). 
Six women were taking an oral contraceptive pill, progestogen-only in three, combined in 
three. Three further patients had progestogen contraception via subdermal implants and 
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three were taking oestrogen hormone replacement therapy (HRT). In addition, four women 
had recently discontinued oral contraceptive medication; in three cases, within eight weeks 
of recruitment and in once case, six months previously. 
Four patients were taking antihypertensive medication and one other person was receiving 
propranolol as migraine prophylaxis. Three patients were using antidepressants or mood 
stabilisers, one patient was taking warfarin for familial protein C deficiency, one 
hypertensive patient was on low-dose aspirin and one patient was on a proton pump 
inhibitor for dyspepsia. One patient had been prescribed latanoprost eye drops following an 
isolated finding of raised intraocular pressure prior to the trial; glaucoma was subsequently 
excluded and the drops discontinued. 
Table 3.6 Prescribed medications at baseline 
Medication Number of patients % 
 
Oral contraceptive pill 6 12 
Etonogestrel contraceptive implant 3 6 
Oestrogen hormone replacement therapy 3 6 
Antihypertensives 4 8 
(Labetolol 1  
Amlodipine 1  
Felodipine 1  
Bendrofluazide 1)  
Psychiatric medication 3 6 
(Citalopram 1  
Paroxetine 1  
Quetiapine 1)  
Folic acid 1 2 
Propranolol 1 2 
Omeprazole 1 2 
Warfarin 1 2 
Aspirin 1 2 
Latanoprost eye drops 1 2 
Topical hydrocortisone 1 2 
 
On specific questioning, six patients reported receiving antibiotics during the six months 
prior to recruitment, amoxycillin in three cases, metronidazole, trimethoprim, erythromycin 
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in the other three. No patients admitted ingestion of high doses of Vitamin A and none had 
received lithium. 
3.3.4 Clinical Features 
3.3.4.1 Symptoms 
Table 3.7 shows the prevalence of symptoms. Headache was present in 35 of the 50 
patients. A pain score was documented in 44 of the 50 patients, ranging from 1 (15 patients) 
to 10 (two patients), median score 3. Baseline scores amongst the allocation arms are shown 
in figure 3.6. In five patients, comment was made that the severity or frequency of headache 
had lessened following the diagnostic lumbar puncture and in a further three that it had 
resolved completely. Descriptions were provided in 14 cases, with five headaches described 
as worse on lying down or waking, four as generalised, throbbing and four as constant.  
Table 3.7 Baseline symptoms amongst the 50 patients 
Symptom Prevalence % 
Headache 70 
Transient Visual Obscurations 64 
Tinnitus 56 
Diplopia 22 
Visual Loss 26 
Other 34 
Other symptoms % 
Nausea 10 
Neck pain / stiffness 6 
Dizziness / vertigo 6 
Photopsia 4 
Photophobia 4 
Ocular pain 2 
Facial numbness 2 
Forgetfulness 2 
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Figure 3.6 Baseline headache visual analogue score (VAS) by allocation. Median values are 
indicated by shaded bars for the two groups (acetazolamide = 2, control = 5.)  
There was no difference between the two groups (p=0.21) 
 
Amongst the 32 patients for whom transient visual obscurations were recorded, the 
symptom was unilateral or highly asymmetrical in 17, described as blurring, clouding and 
black spots where stated and had an effect of postural change noted in six cases. Of the 26 
patients with tinnitus, it was bilateral in nine, unilateral or highly asymmetric in nine and not 
stated in seven. The descriptions “whooshing”, “roaring”, “pulsatile”, “thumping” and 
“mechanical” were volunteered in 11 cases. Additional comments were provided for 10 of 
the 11 patients with diplopia; it was recorded as intermittent in seven and horizontal in five. 
Comment on visual loss was recorded in 12 of the 13 patients for whom it was reported as a 
symptom, with visual blurring as the complaint in five. 
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One patient had no symptoms at all at baseline. One patient had only tinnitus and one 
patient had only blurred vision. There were two patients whose only symptom was 
headache and four patients with obscurations as their only symptom. 
3.3.4.2  Visual Function 
The visual function amongst the 50 patients at baseline is shown in table 3.8 and figures 3.7 
and 3.8. All of the 50 patients had papilloedema, which was unilateral in two cases and 
highly asymmetric in a third. A left sided relative afferent papillary defect was documented 
in one patient. Four patients were reported to have low test reliability on perimetry and 
their MD and PSD values were excluded from the analysis. 
Table 3.8 Baseline visual function. Medians and ranges are given. MD = mean deviation, PSD = 
pattern standard deviation (Humphrey automated perimetry) 
 
Papilloedema % 100 
Afferent pupillary defect % 2 
Left LogMAR acuity 0.0 (-0.20 to 0.40) 
Right LogMAR acuity 0.0 (-0.20 to 0.36) 
Left MD -2.19 (-21.15 to 0.94) 
Right MD -2.05 (-17.06 to 0.75) 
Left PSD 2.35 (1.07 to 9.68) 
Right PSD 2.11 (1.22 to 8.92) 
Left contrast sensitivity 1.65 (1.20 to 1.80) 
Right contrast sensitivity 1.65 (1.05 to 1.95) 
Bilateral contrast sensitivity 1.80 (1.20 to 1.95) 
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Figure 3.7 Baseline LogMAR acuity and Humphrey perimetry MD values, by allocation. Lines show 
median values. There were no significant differences between the groups. 
 
 
Figure 3.8 Contrast sensitivity by allocation amongst the 19 patients tested  
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3.3.5 Protocol Compliance 
Progression of the 50 patients through the trial is shown in figure 3.9.  Final visit data and IIH 
status was available for 40 patients (80%). 26 patients (52%) attended all five visits and 47 
(94%) attended three or more visits. Only one patient dropped out of the study after the 
baseline visit and was lost to all follow-up. 
 
 
 
 
 
Figure 3.9 Disposition of patients in the IIH Trial. N = number of patients, DNA = did not attend visit 
and was lost to further follow up 
N =50 
Acetazolamide 
N =25  
No acetazolamide 
N = 25 Baseline 
N = 25 N =24  3 Months 
N = 25 N = 23 6 Months 
DNA 
   1 patient 
DNA 
1 patient 
DNA 
1 patient 
N = 24 N = 23 
N = 21 
N=13 on protocol 
 
N = 20 
N=17 on protocol 
9 Months 
 
12 Months 
DNA 
 3 patients 
DNA 
3 patients 
 + Acetazolamide  
2 patients 
 NO 
Acetazolamide  5 
patients 
 NO 
Acetazolamide 3 
patients 
 NO 
Acetazolamide 3 
patients 
 NO 
Acetazolamide  1 
patient 
 + Acetazolamide  
2 patients 
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Compliance with treatment allocation is also indicated in Figure 3.9. Four patients allocated 
to no acetazolamide were subsequently prescribed it during the trial as detailed in Table 3.9. 
Table 3.9 Addition of acetazolamide during trial period 
Timing  Dose Stated reasons Notes 
Baseline + 2 
weeks 
750mg Worse visual 
field 
Persistent 
headache 
Reduced visual 
acuity 
Dose increased to 1000mg at 6-months.  
Further increase to 1500mg at 9-month visit 
 
Baseline + 12 
weeks 
250mg Persistent 
headache 
Added outside trial.  
3-month visit delayed by 5 weeks 
 
3-month visit 500mg Persistent disc 
swelling  
Blurred vision 
Patient dropped out of trial after 9-month visit 
3-month visit 500mg Persistent 
headache 
Dose increased to 750mg at 6-month visit due to 
worsening papilloedema, reduced to 500mg at 9-month 
visit 
 
In two cases it was added prior to the 3-month visit and in two cases, at the 3-month visit. 
Reasons for adding acetazolamide included persistent headaches (3), disc appearance (1), 
reduced visual acuity (1), deteriorating visual field (1) and persistent blurred vision (1). One 
patient had acetazolamide added by their neurologist outside the trial. 
Seven of the patients initially allocated to acetazolamide had their dose increased. All seven 
had starting doses of 500mg in 24 hours, increased to 1000mg in six cases and to 1500mg in 
one. The first dose increase occurred within the first three months in all cases. Overall in the 
study the dose of acetazolamide ranged from 250mg to 1500mg in 24 hours. 
In the acetazolamide group, 12 patients discontinued or never started the drug. Reasons 
documented were patient preference (4), non-compliance from the outset (3), adverse 
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effects (2), planned pregnancy (2) and insertion of VP shunt (1). One patient reporting 
adverse effects (nausea) stopped acetazolamide before the 3-month visit, restarted it at the 
6-month visit, but reduced the dose again at the 9-month visit due to further nausea. The 
other patient stopped the drug before the 3-month visit due to a the side effect of tingling 
fingers, restarted it at that visit at 250mg, discontinued it at 6-months due to pregnancy, 
which was terminated, then restarted it after the 9-month visit due to worsening headache. 
3.3.6 Outcome 
3.3.6.1 Final Outcome 
Intention-to-treat analysis of the Final Outcome at 12-months showed: in the acetazolamide 
group, nine patients were in remission, three had active – improving IIH, eight had active – 
stable IIH and none had active – deteriorating IIH (table 3.10). In the control group, eight 
patients were in remission, two had active – improving IIH, six had active – stable IIH and 
three active – deteriorating IIH.  
Table 3.10 Final Outcome by allocation: numbers of patients in each category are shown 
 Final Outcome 
 
Allocation 
Remission Improving Stable Deteriorating 
Acetazolamide 9 3 8 0 
No Acetazolamide 8 2 6 3 
 
A Mann-Whitney U test showed no significant difference between the treatment arms 
(p=0.5).  Further analysis with treatment arm determined by acetazolamide use three 
months before the final visit, also showed no significant difference (p=0.8).  
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To obtain estimated confidence intervals for the treatment effect, categories were grouped 
into remission/improving and stable/deteriorating, and the odds ratio was 0.7 in favour of 
acetazolamide (95% CI 0.2, 2.6). 
3.3.6.2 Final Status Score 
Each patient was assigned a final score based on the sum of the other final status scores 
(headache, tinnitus, visual obscurations, visual acuity, visual field and optic disc), with 0 = 
best rating, 1 = intermediate rating and 2 = worst rating. A t-test was used to compare these 
sums between the two treatment arms. The mean Final Status Score (range: 0 best to 12 
worst) was 2.6 in the acetazolamide arm compared with 2.9 in the control arm (p=0.6).  
To assess the influence of the six final status scores with the upon the assigned overall IIH 
status, Final Outcome, frequency tables were drawn up (see tables 3.11a to 3.11f.) Somers’ 
D statistic was calculated in each case, where 1 is total concordance between the variables 
and -1 is total discordance. The strongest concordance was for visual field score (D=0.66), 
followed by optic disc score (D=0.59), headache (D=0.39), tinnitus (D=0.33), visual 
obscurations (D=0.19), and visual acuity (D=0.05). 
Table 3.11a Frequencies of visual field status categories by final outcome 
 Final Outcome 
IIH in 
remission 
Active IIH 
improving 
Active IIH 
stable 
Active IIH 
deteriorating 
Fi
n
al
 V
is
u
al
 F
ie
ld
 S
ta
tu
s Normal 
15 3 4 0 
Abnormal, stable 
2 2 9 3 
Abnormal, 
deteriorating 0 0 0 0 
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Table 3.11b Frequencies of optic disc status categories by final outcome 
 Final Outcome 
IIH in 
remission 
Active IIH 
improving 
Active IIH 
stable 
Active IIH 
deteriorating 
Fi
n
al
 O
p
ti
c 
D
is
c 
St
at
u
s 
Normal 
10 3 2 0 
Abnormal, stable 
7 2 12 1 
Abnormal, 
deteriorating 0 0 0 2 
 
 
Table 3.11c Frequencies of headache status categories by final outcome 
 Final Outcome 
IIH in 
remission 
Active IIH 
improving 
Active IIH 
stable 
Active IIH 
deteriorating 
Fi
n
al
 H
e
ad
ac
h
e
 S
ta
tu
s 
Absent 
11 2 5 0 
Present, stable 
5 3 5 1 
Present, 
deteriorating 1 0 4 2 
 
 
Table 3.11d Frequencies of TVO status categories by final outcome 
 Final Outcome 
IIH in 
remission 
Active IIH 
improving 
Active IIH 
stable 
Active IIH 
deteriorating 
Fi
n
al
 T
V
O
s 
St
at
u
s 
Absent 
16 4 11 3 
Present, stable 
1 1 3 0 
Present, 
deteriorating 0 0 0 0 
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Table 3.11e Frequencies of tinnitus status categories by final outcome 
 Final Outcome 
IIH in 
remission 
Active IIH 
improving 
Active IIH 
stable 
Active IIH 
deteriorating 
Fi
n
al
 T
in
n
it
u
s 
St
at
u
s 
Absent 
12 2 3 2 
Present, stable 
4 3 9 0 
Present, 
deteriorating 1 0 2 1 
 
 
Table 3.11f Frequencies of visual acuity status categories by final outcome 
 Final Outcome 
IIH in 
remission 
Active IIH 
improving 
Active IIH 
stable 
Active IIH 
deteriorating 
Fi
n
al
 V
is
u
al
 A
cu
it
y 
St
at
u
s Normal 
15 4 11 3 
Abnormal, stable 
2 1 3 0 
Abnormal, 
deteriorating 0 0 0 0 
 
The final headache status was also compared with the final pain score, shown in table 3.12. 
Table 3.12 Final Pain Score compared to Final Headache Status 
 Final Headache Status 
Absent Present, stable Deteriorating 
Fi
n
al
 P
a
in
 S
co
re
 
1 18 0 0 
2 0 2 1 
3 0 2 0 
4 0 2 0 
5 0 2 1 
6 0 1 1 
7 0 0 0 
8 0 1 1 
9 0 0 1 
10 0 0 1 
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3.3.6.3 Individual Outcomes 
3.3.6.3.1 Clinical 
Clinical features and measured outcomes were compared as measured at baseline and at 
the final visit, shown in table 3.13. There were no differences between the two allocation 
arms. Figure 3.10 shows the change in prevalence of headache, obscurations, diplopia, 
tinnitus, visual loss and papilloedema as recorded at each trial visit. 
 
Table 3.13: Individual outcomes by allocation 
 Acetazolamide No Acetazolamide  
Baseline 
(n=25) 
Final 
(n=21) 
Baseline 
(n=25) 
Final 
(n=20) 
Difference between arms, 
(95% CI)§ 
Headache % 68 43 72 65 0.42 (0.12, 1.4) 
Headache VAS (mean) 3.5 2.3 4.9 3.7 1.0 (-1.8, 3.7) 
TVOs % 68 10 60 10 0.95 (0.12, 7.3) 
Tinnitus % 56 60 56 60 1.00 (0.29, 3.5) 
Diplopia % 16 0 28 5 0.12 (0.002, 6.2) 
Visual loss % 24 0 28 10 0.12 (0.007, 2.0) 
Papilloedema % 100 67 100 65 1.07 (0.30, 3.8) 
Left LogMAR  0 
(-0.20–0.40) 
0 
(-0.10–0.2) 
0.05 
(-0.24 –0.38) 
0 
(-0.2–0.64) 
0.03 
(-0.09, 0.15) 
Right LogMAR 0 
(-0.20–0.32) 
0 
(-0.18–0.2) 
0.01 
(-0.22–0.36) 
-0.08 
(-0.2–0.36) 
0.04 
(-0.08, 0.16) 
Left MD * -1.47 
(-7.8–0.94) 
-0.71 
(-3.98–0.67) 
-2.91 
(-10.46–0.14) 
-2.24 
(-5.91–0.78) 
0.2  
(-1.0, 1.4) 
Right MD * -1.53 
(-6.02–0.75) 
-0.29 
(-4.50–0.98) 
-2.57 
(-9.9– -0.24) 
-1.16 
(-8.04–0.72) 
0.0 
(-1.1, 1.1) 
Left CS (median only) 1.65 1.80 1.65 1.65 -0.3 (-0.6, 0.0) 
Right CS 1.65 1.80 1.65 1.65 -0.2 (-0.5, 0.0) 
Binocular CS 1.80 1.95 1.80 1.95 -0.3 (-0.7, 0.1) 
 
Unless specified, medians and ranges are given. Baseline = baseline examination; Final = 12-month 
examination;  VAS = headache pain visual analogue score (1=no pain, 10=worst); TVOs = transient visual 
obscurations; LogMAR = visual acuity as logarithm of minimum angle of resolution; MD = mean deviation on 
automated perimetry; CS = Contrast Sensitivity (Pelli Robson score); 
*Excludes outlying data from one patient with baseline MD values of -21.15 left and -17.06 right who was 
subsequently lost to follow up. 
§Differences between dichotomous variables (with % figures) are shown as Peto odds ratios based on final visit 
data, with a number <1 indicating benefit for acetazolamide.  For continuous variables, differences shown are 
means, based on change from baseline, with numbers <0 indicating benefit for acetazolamide. 
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Figure 3.10 Change in clinical features by visit and allocation  
VB=baseline visit, V2=3-month visit, V3=6-month visit, V4=9-month visit, V5=12-month, final visit. 
 
More patients were recorded as having tinnitus at the final visit than at the start of the trial. 
As shown in table 3.14, a total of 12 patients from each allocation arm had tinnitus 
documented as present at the 12-month visit.  Nine patients had no tinnitus at the start of 
the trial, but were recorded as having it by the final visit. There was a discrepancy between 
tinnitus recorded as present / absent on the symptom checklist and the final status scoring 
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sheets. When the final tinnitus status (absent, present-stable or deteriorating) was examined 
amongst the 24 patients who had the symptom tinnitus recorded as present at the 12-
month visit, the status ‘absent’ was seen in four cases.  
Table 3.14  Patients with tinnitus at the final (12 month) visit. A=acetazolamide, C=control, 
VB=baseline visit, V2=3-month visit, V3=6-month visit, V4=9-month visit, V5=final visit. 
  Allocation 
Presence / absence 
 of tinnitus Final Tinnitus Status Final IIH Outcome 
VB V2 V3 V4 V5 
1 A + + + + + Absent IIH in remission 
2 C + + + + + Absent IIH in remission 
3 C - + + + + Absent IIH in remission 
4 C + -   - + Absent Active IIH deteriorating 
5 A - - - + + Deteriorating Active IIH stable 
6 A - + + - + Deteriorating Active IIH stable 
7 A - - + + + Deteriorating IIH in remission 
8 C +   -   + Deteriorating Active IIH deteriorating 
9 A + + + + + Present, stable IIH in remission 
10 A + - - - + Present, stable Active IIH improving 
11 A - - - - + Present, stable IIH in remission 
12 A +   ? + + Present, stable Active IIH stable 
13 A +   - - + Present, stable Active IIH stable 
14 A + + + + + Present, stable Active IIH stable 
15 A - - - - + Present, stable Active IIH improving 
16 A -   +   + Present, stable Active IIH stable 
17 C + + + + + Present, stable IIH in remission 
18 C + - - - + Present, stable Active IIH stable 
19 C + + +   + Present, stable Active IIH improving 
20 C + + + - + Present, stable Active IIH stable 
21 C - + - + + Present, stable Active IIH stable 
22 C + + - - + Present, stable Active IIH stable 
23 C + + + + + Present, stable Active IIH stable 
24 C - -   - + Present, stable IIH in remission 
 
Visual fields were compared at each visit for all patients (excluding one outlier value, as 
previously). Analysis of the mean MD values from the Humphrey automated visual fields 
showed significant improvement from baseline to final visit for both left MD (p=0.017) and 
right MD values (p=0.001). Mean MD values for each eye, by allocation, are shown in Figure 
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3.11. Whilst the values in the No Acetazolamide group appear greater the difference was not 
significant (p=0.22). 
 
 
Figure 3.11 Mean MD values by visit and allocation. 
 
3.3.6.3.2 Health-Related Quality of Life 
SF-36 scores for all patients, regardless of allocation, were compared at baseline and at the 
final (12-month) visit, as shown in table 3.15. Only SF36 Pain and SF36 Change in Health 
showed significant improvement. The mean HADS anxiety and depression scores amongst all 
patients at baseline and at the final visit did not differ significantly (table 3.16). Similarly 
there was no difference between the EuroQoL self assessment and EQ5D mean scores at 
baseline and final visit (table 3.17.) 
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Table 3.15 Mean SF36 scores at baseline and final visit (all patients) 
 
Baseline visit 
n=48 
12-month visit 
n=38 
P 
Physical Function 79.9 85.0 0.36 
Role-Physical 69.5 76.0 0.16 
Role-Emotional 77.2 78.5 0.90 
Social Function 70.3 70.8 0.86 
Mental Health 64.4 68.7 0.29 
Energy Vitality 51.6 52.5 0.59 
Pain 57.8 72.2 0.02 
General Health Perception 57.6 59.8 0.64 
Change in Health 47.8 59.7 0.01 
 
Table 3.16 Mean HADS scores at baseline and final visit (all patients) 
 
Baseline visit 
n=48 
12-month visit 
n=38 
p 
Anxiety Score 7.4 6.7 0.37 
Depression Score 4.2 4.2 0.91 
 
Table 3.17 Mean EuroQoL scores at baseline and final visit (all patients) 
 Baseline visit 
n=46 
12-month visit 
n=36 
p 
EuroQoL EQ5D visual analogue 
67.0 70.8 0.5 
EuroQoL EQ5D 
0.7 0.8 0.3 
 
The scores for each measure of health-related quality of life were examined by allocation 
and by visit as shown in Figures 3.12, 3.13, 3.14, 3.15 and 3.16. There were no significant 
differences between the allocation arms at any visit for any of the measures. 
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Figure 3.12 Mean scores amongst functional status SF-36 summary scales by visit and allocation. 
VB=baseline visit, V3=six-month visit, V5=final visit 
 
 
Figure 3.13 Mean scores amongst wellbeing and health SF-36 summary scales by visit and 
allocation 
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Figure 3.14 Mean HADS scores by visit and allocation. Scores are interpreted as 0-7 normal, 8-10 
borderline and 11-21 abnormal for each 
 
 
Figure 3.15 Mean EuroQoL scores by visit and allocation. EQ VAS ranges from 0 (worst) to 100 
(best), EQ 5D from 0 to 1, where 1 represents a perfect state. 
 
 155 
 
Table 3.18 shows the number of patients with HADS scores in each of the three categories at 
the three visits. The total numbers of patients completing questionnaires at each time point 
varied, so percentages are also given. The ratio of the total number of scores in the 
borderline and abnormal categories for anxiety, to the same total for depression, was 2.3. 
 
Table 3.18  Number of patients in each category of HADS score, by allocation and visit. VB=baseline 
visit, V3= six-month visit, V5 = final visit, A = acetazolamide, C=control. 
 
 VB V3 V5 
 A C A C A C 
Anxiety: Normal 
(0-7) 
 
15 (68%) 11 (58%) 13 (76%) 11 (61%) 13 (65%) 10 (62%) 
Borderline 
(8-10) 
 
2 (9%) 3 (16%) 0 (0%) 3 (17%) 2 (10%) 3 (19%) 
Abnormal 
(11-21) 
 
5 (23%) 5 (26%) 4 (24%) 4 (22%) 5 (25%) 3 (19%) 
       
Depression: Normal 
(0-7) 
 
21 (88%) 19 (83%) 17 (94%) 15 (83%) 17 (81%) 11 (79%) 
Borderline 
(8-10) 
 
1 (4%) 1 (4%) 0 (0%) 2 (11%) 3 (14%) 2 (14%) 
Abnormal 
(11-21) 
 
2 (8%) 3 (13%) 1 (6%) 1 (6%) 1 (5%) 1 (7%) 
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3.3.6.3.3 Repeated Measures Analysis 
Repeated measures analysis  was used to examine the effects of treatment allocation on 
each of the following variables, as measured at each visit during the trial: headache pain 
score, summed number of symptoms present scored out of seven (headache, tinnitus, visual 
obscurations, visual loss, diplopia, papilloedema and other), visual acuity (right, left), 
contrast sensitivity (right, left, binocular), visual field MD (right, left), HADS score, EQ-5D 
visual analogue score, EuroQol EQ-5D score and SF-36 domains (table 3.19.) Of these 21 
comparisons, only one (contrast sensitivity, right) was significant at the p<0.05 level. 
Table 3.19 Repeated measures analysis summary 
Variable 
Advantage for 
Acetazolamide p-value 
Headache Pain Score -1.4 0.13 
Summed Number of Symptoms -0.04 0.94 
Left LogMAR -0.03 0.38 
Right LogMAR -0.01 0.80 
Left Cont. Sens 0.14 0.14 
Right Cont. Sens 0.13 0.03 
Binoc. Cont. Sens 0.18 0.11 
Left Mean Deviation -0.16 0.71 
Right Mean Deviation -0.43 0.30 
EuroQOL EQ5D visual analogue -3.1 0.67 
EuroQOL EQ5D -0.1 0.13 
SF36 Physical Function -11.9 0.09 
SF36 Role limitation / physical problems 4.0 0.65 
SF36 Role limitation / emotional 
problems 1.9 0.78 
SF36 Social Functioning -4.1 0.63 
SF36 Mental Health -1.6 0.78 
SF36 Energy / Vitality 1.5 0.84 
SF36 Pain -6.8 0.47 
SF36 General Health Perception -1.4 0.81 
HADS Anxiety score -0.04 0.97 
HADS Depression score -0.35 0.69 
Note:  treatment effect signs have been adjusted so a positive score indicates 
advantage for acetazolamide 
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3.3.6.4 Surgical Intervention 
Two patients required surgical intervention within a month of randomisation, one in each 
arm of the trial. Characteristics of the two patients are shown in table 3.20. A further patient 
had their final visit IIH status recorded as ‘active, deteriorating’ and was being considered for 
shunt insertion at the end of the trial. 
Table 3.20 Characteristics of patients receiving surgical intervention during the study 
 Patient 1 Patient 2 
Gender F F 
Age 23 28 
BMI kg m-2 44.9 32.6 
CSF OP cm 60 30 
Associated features Prescribed erythromycin within 6 
months of entry to study 
Taking steroid inhalers for 
asthma 
Baseline symptoms Headache, Visual obscurations, 
tinnitus, visual loss 
Headache, Visual obscurations  
Headache VAS 8 2 
Allocation No acetazolamide Acetazolamide 
Baseline LogMAR acuity 
(left, right) 
0.30, 0.34 0.22, 0.32 
Baseline MD (left, right) -21.15, -17.06 -1.72, -6.02 
Documented reasons for 
surgery 
 
Reduced vision 
 
Worsening papilloedema 
Worsening symptoms 
New RAPD right eye 
 
Timing of surgery  
(days post randomisation) 
2 34 
 
  
Additional information Lost to all follow-up after 3-month 
visit 
Discontinued acetazolamide 
after shunt inserted 
 
3.3.6.5 Pregnancies 
There were 5 pregnancies during the trial, summarised in table 3.21. Three patients in the 
acetazolamide group were recorded as pregnant at the nine-month visit. Two had stopped 
the medication, and two had elective termination of pregnancy, one whilst continuing to 
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take acetazolamide. In the control group, one patient was recorded as pregnant by the three 
month visit, delivering a healthy baby during the trial and another was noted to be pregnant 
at the six-month visit then in healthy pregnancy at the final assessment.  
Table 3.21 Pregnant patients during the trial. A=acetazolamide, C=no acetazolamide, T.O.P= 
termination of pregnancy, V3=6-month trial visit, V4=9-month trial visit 
 
Allocation 
Pregnancy status 
(at final visit) 
Final Status 
(Symptom 
Score) 
Final Outcome 
1 A T.O.P after V3 2 Active, improving 
2 A T.O.P after V4 1 Active, improving 
3 A 2nd trimester 1 Remission 
4 C Delivered after V4 0 Remission 
5 C 2nd trimester 4 Active, stable 
 
3.3.6.6 Weight change 
Table 3.22 Availability of weight data by visit and by total number of recorded values in trial; 
n=number of patients 
Visit 
n %  Total no. of weights 
recorded 
N % 
Baseline 50 100  1 1 2 
3 month 40 80  2 4 8 
6 month 35 70  3 9 18 
9 month 36 72  4 17 34 
12 month 38 76  5 19 38 
 
The availability of data on body weight is shown in table 3.22. There was an overall weight 
reduction in both allocation groups. In the acetazolamide group, mean weight fell from 
106.9kg at baseline to 100.7kg at the final visit (a mean loss of 6.2kg, 5.8%.) In the control 
arm, mean weight at baseline was 94.8kg and at 12-months, 91.5kg (mean weight loss of 
3.3kg, 3.5%.) The mean BMI and as well as the mean change in weight were examined by 
repeated measures analysis (figures 3.16 and 3.17) and there was no difference between the 
allocation arms. 
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Figure 3.16 Average Body Mass Index by allocation throughout the trial.  
Error bars show 95% confidence intervals 
 
  
Figure 3.17 Average change in weight by assessment and allocation.  
Error bars show 95% confidence intervals 
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Change in weight ranged from 12.5kg gain to 23.5kg loss, median 1.1kg. More patients lost 
(n= 30) than gained weight (n=19), as shown in figure 3.18. 
 
 
Figure 3.18 Overall change in weight during trial. Lines represent the difference between the last 
weight recorded and the baseline weight in kg for individual patients (n=49) 
 
In total, 38 patients had final outcome and weight at 12-month visit recorded. Amongst 12 
patients who had lost 5% weight or more by the end of the trial, eight (67%) had a final 
outcome of ‘in remission’ or ‘improving’. This compares with 6 out of 12 patients (50%) who 
had lost between 0 and 5% weight and 7 out of 14 patients (50%) who had gained weight. 
Cuzick’s test for trend was applied to the ungrouped data and revealed no significant trend 
(p=0.3). 
3.3.7 Sample Size Calculation 
One purpose of this pilot study was to inform the planning of a definitive trial. Based on the 
data for the final IIH status, preliminary calculations were undertaken in an attempt to 
predict how many patients would be required to show a treatment effect, should one exist. 
The dropout rate and protocol non-compliance were taken into account in the calculations, 
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performed by grouping the four outcome categories into two and performing a chi squared 
test. Final IIH outcome was regarded in two categories: (1) ‘in remission’ and ‘active, 
improving’ or (2) ‘active, stable’ and ‘deteriorating’. In order to detect an improvement of 
20% in the treatment arm, such that 20% more patients were in category (1), around 300 
patients in total would be required, based on 90% power and significance set at p=0.05.  
As an alternative to grouping the best two and worst two outcome categories, a Mann-
Whitney U test can be applied to the four-way outcome data to improve sensitivity. This 
shows that 240-270 patients would be required to detect a 20% difference. Approximately 
120 patients would be needed to detect a difference of 30%. The calculations are based 
upon an intent-to-treat population, such that observed improvement allows for dilution of 
any treatment effect by non-compliance.  
 
3.4 Discussion 
This study prospectively recruited 50 patients to the first randomised controlled trial in IIH. 
Whilst the small numbers in the study preclude any firm conclusions about the benefits or 
detriment of treatment, the data is informative on several issues pertinent to the study of 
patients with IIH. 
3.4.1 Recruitment 
Rates of recruitment to the study were slower than anticipated. Recruitment of 50 patients 
was projected over a 12 month period, but in reality, reaching this number of patients took 
23 months. A mean rate of two patients recruited per month seems surprising, given the 
numbers of centres enrolled in the study and resulting catchment population. No published 
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figures exist for direct comparison, although it is interesting to note that the numbers 
involved in the major published prospective studies were not dissimilar. In the Libyan case-
control study by Radhakrishnan et al, (1993) 40 patients were seen between 1987 and 1989; 
In that of Wall and George (1991), it took from 1982 to 1988 to recruit 50 patients with IIH 
who met the entry criteria. The study period in the trial of acetazolamide and topiramate in 
40 patients was just over 4 years. (Celebisoy et al., 2007) Whilst these studies had somewhat 
lower rates of recruitment than that of the current study, they were all conducted from 
single treatment centres, so the figures are probably comparable. 
Detailed information regarding patients who failed to meet the criteria for inclusion 
following initial screening was only available for the patients seen at the Birmingham 
centres. Over a quarter of patients (9 in 34) could not be randomised because they were 
already receiving acetazolamide. Wide publicity preceded and continued throughout the 
study, in the form of posters and leaflets displayed in clinical areas as well as presentations 
about the trial in professional meetings. The advice to withhold the use of acetazolamide 
prior to discussing patients with the neurology or neuro-ophthalmology teams, all of whom 
were well informed about the trial, was widely disseminated amongst the relevant acute 
hospital teams. Despite this, several patients were prescribed acetazolamide at a very early 
stage of admission and were subsequently ineligible for entry to the study. This highlights 
the common use of acetazolamide despite no evidence base for its use in IIH. 
Three patients appeared on initial assessment to be eligible for the study but were then 
found to have no papilloedema when assessed in the neuro-ophthalmology clinic. It is 
necessary to appreciate the patient pathway of entry to the trial in Birmingham to interpret 
this finding. Most patients were admitted acutely for their diagnostic investigations, 
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including scans and lumbar puncture. Some, but not all, received their detailed neuro-
ophthalmology assessment immediately following the lumbar puncture. A number of 
patients were discharged from hospital to be seen shortly afterwards in the neuro-
ophthalmology outpatients clinic, resulting in a delay between the lumbar puncture and the 
assessment of papilloedema using a slit lamp. It is possible that the diagnostic lumbar 
puncture resulted in a reduction in the intracranial pressure sufficient to reverse the optic 
nerve swelling, such that papilloedema was no longer present at follow up. Uncertainty 
surrounds the mechanism and timing of both papilloedema formation and its resolution 
upon lowering of the pressure, due to a lack of research evidence. However clinical 
experience and anecdotal reporting suggests that a subset of patients with IIH do experience 
resolution of their symptoms and clinical signs, including papilloedema, following a single 
lumbar puncture. Whether a slow leakage of CSF via needle punctures in the dura also 
contributes is unclear. An alternative explanation for the absence of papilloedema at slit 
lamp examination could simply be that the papilloedema was initially misdiagnosed, if 
ophthalmoscopy during the acute admission led to a falsely positive finding. 
Although IIH without papilloedema (IIHWOP) is now a recognised clinical entity, (Bono and 
Quattrone, 2009) no patients with absent papilloedema were recruited to this trial. The 
absence of papilloedema in the three screened patients reported was accompanied by other 
features casting doubt on the diagnosis, such that it was appropriate to exclude them from 
the study. 
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3.4.2 Patient Characteristics 
3.4.2.1 Demographics 
Age and gender characteristics of the patients in the trial were as expected. The female to 
male ratio was 12.5:1, exactly that of the study by Wall and George (1991) and similar that of 
the largest review to date, by Bruce et al (2009) of 10.1:1.  
All patients were overweight, with the exception of two (BMI 23.7 and 24.5 kgm-2). 46 of the 
patients (92%) had body mass index at baseline in the obese range (greater than 30 kgm-2) 
Opening CSF pressure ranged from 25 to 78 cm. Five patients had a pressure of 40 cm 
recorded and a further six had pressure of “greater than 40 cm” recorded. This is likely to 
reflect the method of CSF pressure measurement, using 20 cm manometers. To record 
values above 40 cm requires the use of three manometer tubes attached together. It is likely 
that for some of the six patients at least, measurement was stopped when the top of the 
second manometer was reached, instead of additional tubing recording values of greater 
than 40cm more accurately. True maximum pressures in this cohort could therefore have 
been higher. 
3.4.2.2 Associated medical conditions 
The prevalence of systemic hypertension was comparable to that of other published studies. 
Eight of the 50 patients reported hypertension, in the Wall and George study (1991) it was 
recorded in 13 of 50 patients and by 11 of 76 patients (14.5%) in that of Radhakrishnan et al. 
(1993) All the hypertensive patients in this study with the exception of one were older than 
the mean study age of 31 years, with a mean of 49.5 years. The figures are unremarkable 
given that hypertension is common, especially in association with obesity. 
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Hormonal dysfunction amongst the female patients was only evident in three cases (6.5%). 
Symptoms of polycystic ovary syndrome have been reported in over a third of female 
patients in some studies (Glueck et al., 2003) and irregular menses were reported by 30% of 
patients at presentation in the study by Radhakrishnan et al. (1993) A higher proportion of 
the patients reported current or recent use of hormonal medication. Over a quarter of 
women in the study were taking oestrogens as contraception or HRT (12 of 46 patients, 26%) 
and a further four (9%) had discontinued oral contraceptives within the preceding six 
months. A high prevalence of hormonal medication use seems likely amongst females of the 
age group reported and the study design does not permit further conclusions to be drawn 
about the significance of these values. 
The seemingly low prevalence of reported menstrual disturbance in this study is most likely 
due to under-reporting. The baseline data collection did not include specific questions 
addressing menstrual function and any positive findings relied upon patients or assessing 
clinicians to volunteer the information as part of the medical history they felt to be relevant.  
A similar explanation could account for the recording of only two instances of psychiatric 
symptoms amongst the 50 patients (depression in one, depression with panic disorder in 
another) and an isolated case of suspected obstructive sleep apnoea syndrome. The latter 
was reported in 4% of 655 women and 24% of 66 men in the study by Bruce et al,(Bruce et 
al., 2009) but the diagnosis was not specifically sought in this cohort. 
3.4.2.3 Baseline Symptoms 
Headache was present at baseline in a smaller proportion of patients than in many other 
large studies. 15 of the 50 patients had no headache on entry to the trial. Eight patients 
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noticed improvement or resolution of their headaches after the diagnostic lumbar puncture, 
thus the true prevalence of headache at presentation was somewhat higher. No specific 
features characterised the headaches reported, although four patients had headaches 
affected by posture, thought to be in keeping with raised intracranial pressure. The method 
of data collection was insufficient to provide detailed information about headaches in IIH; 
for this, specific headache questionnaires would have been required. 
The same applies for the other symptoms (transient visual obscurations, tinnitus, diplopia 
and visual loss) upon which comment was invited during the study. Collection of descriptive 
data was dependent upon the assessing clinician volunteering detailed information and was 
not sought in a meticulous fashion in this study. Robust data collection on the individual 
symptoms characteristics would require specially designed methodologies. 
There was only one completely asymptomatic patient, a 25 years black Caribbean female 
with BMI 31.1 kg m-2 and CSF opening pressure 39cm. Papilloedema was present on 
examination and it was commented that headache had been present initially but had 
resolved after the lumbar puncture. There were eight further patients who had lone 
presenting symptoms: visual loss (1), tinnitus (1), headache (2) or visual obscurations (4).  
3.4.2.4  Baseline Visual Acuity 
Median LogMAR acuity in both eyes for both allocation arms was 0 (normal). The total 
numbers of patients with LogMAR acuity of 0.2 or worse (equivalent to Snellen 6/9.5) were, 
for the left eye, 11 and the right eye, 10 out of the total of 50. Thus approximately 20% of 
the patients had some reduction of visual acuity, although in at least one patient, this was 
 167 
 
due to conditions other than IIH. No patient had a LogMAR of more than 0.4 in either eye at 
baseline. 
Corrected Snellen visual acuity was worse than 6/9 in at least one eye in eight (21%) of 42 
patients at initial and nine (24%) at the last follow up in one case note review. (Craig et al., 
2001) In the largest published review of patients with IIH, the median LogMAR acuity in 
women was 0 (normal), but significantly worse in men, with median of 0.2. (Bruce et al., 
2009) Amongst prospective studies, the best corrected Snellen acuity at the initial visit was 
abnormal in 4 (10%) of 40 patients, (Celebisoy et al., 2007) showed a moderate or severe 
decrease in 36 (24%) of 152 eyes in 76 female patients (Radhakrishnan et al., 1993) and 
worse than 20/20 in 12% of right eyes and 14% of left eyes in 50 patients. (Wall and George, 
1991) (Wall, 1991). 
Amongst the four male patients, left LogMAR values were 0, 0.04, 0.22 and 0.3, with 
corresponding right LogMAR values of 0, 0.04, 0.14 and 0.2. Thus half of the men in the 
study had acuities worse than the median value, although the numbers are too small to 
attach significance to the finding. 
3.4.2.5 Baseline Contrast Sensitivity 
Contrast sensitivity results were only available for 19 of the 50 patients studied, because the 
Pelli-Robson charts were only in use at the Birmingham trial centre. The majority of values 
were above 1.50 in keeping with normal results. Only two outlying values were seen. One 
patient had a right contrast sensitivity of 1.20, with normal left and binocular values at 
baseline. However this improved by the three month value to 1.80 and may have been effort 
 168 
 
related. A second patient had a consistently low right sided contrast sensitivity of 1.05 in a 
severely amblyopic eye. 
Contrast sensitivity measured using sinusoidal grating stimuli was shown to be abnormal in 
16 of 37 non-amblyopic eyes from 20 patients with IIH, 12 of whom had normal visual acuity. 
(Bulens et al., 1988) In the same year, Verplanck et al (1988) found abnormal contrast 
sensitivities amongst 10 of 15 patients with acute IIH, in 18 eyes in total. Nine of these eyes 
had normal visual fields as well as visual evoked potentials. The absence of published data 
on contrast sensitivity measured by Pelli-Robson charts in IIH precludes further comment on 
the values seen in this study. 
3.4.2.6 Baseline Visual Fields 
Humphrey automated perimetry was performed on all patients in this study. One patient 
had markedly abnormal visual fields at the initial visit, with mean deviation (MD) values of -
21.15 left and -17.06, right. This patient was treated with a VP shunt just two days after 
randomisation to no acetazolamide and unfortunately failed to attend for further trial visits 
or perimetry. These MD values were unusual for this study, the next highest value amongst 
other patients being -10.46. 
The range of incidences of abnormal visual fields reported in the literature is broad. Earlier 
studies have documented lower incidences of visual field abnormality than more recent 
publications, but this may reflect the assessment strategies applied. Detailed examination of 
visual fields is likely to result in detection of a greater proportion of defects.  
In the review of patients in Northern Ireland, an abnormality other than enlargement of the 
blind spot was recorded in 18 (62%) of 29 patients. (Craig et al., 2001) Rowe and Sarkies 
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(1998) noted visual field defects in 72% of 70 eyes by Goldmann perimetry and 89% of eyes 
using Humphrey automated perimetry in their prospective study.  
Some authors have reported MD values from automated perimetry. On initial diagnosis, 76 
patients in the study by Galvin and Van Stavern (2004) had mean MD values of -5.96 (right) 
and -6.58 (left), which the authors interpreted as ‘moderate’ defects.  In the large series by 
Bruce et al, (2009) median values were 5 in women and 7.7 in men at baseline and 3.7 in 
women and 4.7 in men at the final visit.  
The values recorded in this study were somewhat lower (less abnormal). Median left MD 
values at baseline were -1.47 (acetazolamide group) and -3.10 (control group), 
corresponding right MD values were -1.34 and -2.58. Overall, 37 (74%) of 50 patients had 
some finding on their baseline visual field that was determined by the perimeter software to 
be outside normal limits, (i.e. assigned a p value). Thus the prevalence of defects of any kind 
was similar to that of other studies, although the severity of the defects was probably less. 
This reflects the tendency of the trial to recruit patients with less severe IIH; patients with 
significant visual field defects were more likely to have been observed and managed outside 
the trial. 
 
3.4.3 Outcome 
3.4.3.1 Data completion 
The overall dropout rate for the trial, based on the numbers of patients with complete data 
sets or completed final visit data, was approximately 20%. For each outcome measure in the 
study, a response rate of 80% or more was typical for recorded outcomes amongst the 50 
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patients over the five trial visits. Specific examples include Visual fields, completed in 210 
out of a possible 250 cases (84%), LogMAR acuities measured in 206/ 250 (82%) and data on 
headache in 213 / 250 (85%). Contrast sensitivity was only available to 20 patients and data 
was present for 80 out of a possible 100 visits (80%). Completed questionnaires numbered 
48 at baseline, 39 at the six-month visit and 29 at the final visit, giving 126 out of a possible 
150 (84%). 
There were some discrepancies between documentation of individual clinical features and 
the subjective assessments at the final visit. For example, in four patients, papilloedema was 
documented as present on the examination section of the final visit assessment forms, but 
the final optic disc status was recorded as ‘normal’. Similar discrepancies were seen in the 
documentation of tinnitus (four patients) and obscurations (one patient), but not headache. 
Numbers of patients attending each visit were similar regardless of allocated treatment. 
Inconsistencies in the documentation were also seen in both allocation arms with equal 
frequency. Thus data omissions and discrepancies are unlikely to have affected the overall 
results. 
 
3.4.3.2 Acetazolamide compliance 
The poor compliance with acetazolamide is of interest. Almost half (12 out of 25) of the 
patients assigned to receive acetazolamide discontinued the medication during the 12-
month study period. Treating clinicians were responsible for determining the starting dose of 
acetazolamide and any subsequent dose titration. No patient received doses in excess of 
1500mg/24 hours and all of the patients who discontinued the drug were receiving lower 
 171 
 
doses than this. The high attrition rate is surprising given the widespread use of this drug in 
treating IIH and the relatively low doses employed in this study. 
The published open-label study by Celebisoy et al (2007) compared acetazolamide and 
topiramate in 40 patients. No patients in this study were reported to have discontinued their 
medication due to adverse events. The most frequently reported side effects were fatigue 
and tingling of hands and feet. Daily doses of acetazolamide ranged from 1000 to 1500mg 
and a titration schedule starting with 500mg per day was used.  
In the prospective study by Sorensen et al, (1988) ‘nearly all’ of 17 patients treated with daily 
doses of 750 to 1500mg acetazolamide had metabolic acidosis and experienced nausea and 
moderate paraesthesia of hands and feet. These side effects were reported as transient in 
most, but some patients required dose reduction and one patient had depression which 
warranted discontinuation of treatment. However, all patients received diuretic in addition 
to the acetazolamide, either furosemide 80mg or chlorthalidone 100mg daily. They were 
also all treated with potassium supplementation to overcome the hypokalaemia caused by 
diuretic. In this trial, none of the patients were receiving diuretics as well as acetazolamide; 
only one of the 50 patients was taking a diuretic (bendroflumethiazide) and they were 
randomised to the control arm. 
It is possible that the severity of IIH amongst the patients in this study had an effect upon 
their tolerance of acetazolamide. Patients may be less likely to comply with prescribed 
treatment if they have few or no symptoms. Further examination of the patients who never 
took the medication or discontinued it through choice or due to side effects shows that two 
patients were totally asymptomatic, but the remaining seven had one, two or three 
symptoms, with headache as the most common. The final outcome was recorded for seven 
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of the patients; two were in remission, two had active, improving IIH, four had active stable 
IIH and none had deteriorating disease. Small numbers preclude further analysis of this 
subgroup of patients, but the levels of non-compliance seen probably reflect the lack of 
significant morbidity. It is also conceivable that other studies have under-reported 
compliance rates. 
Amongst the patients initially allocated to receive no acetazolamide, four (16%) deviated 
from the protocol through the addition of acetazolamide. In all cases this was early on in the 
study, before or at the 3-month visit and all four patients continued the drug throughout the 
remainder of the trial period, at increased doses in two cases. Reasons for commencement 
of acetazolamide varied, although symptoms were a contributing factor in all cases, which 
may have impacted upon the patients’ likelihood of continuing the medication. 
3.4.3.3 Outcome by allocation  
Our results showed no significant difference between treatment arms in terms of final 
outcome. Whilst the odds ratio for remission / improving was slightly in favour of 
acetazolamide (0.7, 95% CI 0.2, 2.9), the confidence interval was wide and our results would 
be consistent with either a treatment benefit or detriment. A wide confidence interval was 
not unexpected, given the number of patients in this pilot study. Comparison of the 
composite final status scores, which summarised symptoms and signs at the 12-month 
assessment, also showed no difference between treatment allocations. Furthermore, 
examination of outcome variables by a total of 21 repeated measures analyses failed to 
demonstrate a treatment effect. Although right contrast sensitivity showed a p value of 0.03, 
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this one significant result is entirely consistent with what would be expected by chance 
alone when carrying out 21 separate analyses. 
In view of the relatively high level of non-compliance in the trial, additional analysis was 
carried out to examine in more detail the high dilution of the intervention effect. Patients 
were categorised into a treatment arm based on whether or not they were receiving 
acetazolamide in the three months prior to the final assessment. The results did not differ 
from the intention-to-treat analysis. A true per-protocol analysis, in which data was only 
analysed from patients receiving their allocated treatment throughout the trial, would have 
involved too few cases to be informative. Whilst all three patients described as deteriorating 
IIH at 12 months were in the deferred acetazolamide group and remained on protocol 
throughout the trial, (i.e. did not have acetazolamide added), the difference between the 
two treatment arms was not significant (p=0.5). 
The trial was conducted as an open label study and control subjects did not receive placebo. 
Subjects and treating clinicians were also not blinded to the treatment allocation. This was in 
keeping with the original aim of the study, which was to pilot a pragmatic trial which would 
complement normal clinical practice. The possibility exists that this may have allowed 
performance and detection bias to influence the results. However, the trial design was kept 
as simple as possible to maximise recruitment, reduce expense and mimic ‘real life’ as far as 
possible. Such pragmatic designs are now in common usage in other neurological fields such 
as stroke (e.g. International Stroke Trials) and Parkinson's disease (eg PD MED and PD SURG.) 
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3.4.3.4 Surgical Intervention 
Two of the 50 enrolled patients had surgical intervention during the course of the study, one 
in each randomisation arm. The surgery was carried out soon after recruitment in both (two 
days in one case and four weeks in the other). Both patients were female and obese and 
were referred for VP shunts due to concern over their visual function. One of the patients 
had MD values on initial perimetry that were considerably worse than any other values 
recorded in the whole study (left -21.15, right -17.06). Unfortunately the patient dropped 
out of the trial and did not undergo repeat perimetry. Both patients had LogMAR values 
towards the higher end of the range seen in the trial, indicative of some reduction in visual 
acuity. The patient for whom follow-up data was available showed improvement in acuity 
following surgery, from 0.22 to 0.10 in the left eye and 0.32 to 0.08 in the right. There was a 
corresponding improvement in their MD values from -1.72 and -6.02 before surgery to 0.37 
and 0.06 at the final visit. 
Three of the 34 patients screened for eligibility for the trial in the Birmingham centre were 
referred for immediate surgery and all received shunts during their initial hospital admission. 
The decision to proceed with surgery in these three cases was made by consensus amongst 
the admitting medical team, the senior neuro-ophthalmology consultants and the 
neurosurgeons regarding the risk of visual deterioration. It is not possible to extrapolate this 
data to estimate the proportion of patients with newly diagnosed IIH who have significant 
existing or threatened visual loss. Such information would be of great use, since it is 
precisely this group of patients for whom evidence based treatment is urgently needed. 
However, data on screened, ineligible patients was not collected prospectively in a 
sufficiently rigorous manner. There were undoubtedly patients with newly diagnosed IIH, 
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with varying degrees of visual loss or threat to their vision, who failed to reach the attention 
of members of the trial team during the recruitment period. 
It is thus recognised that the trial design meant patients towards the benign end of the IIH 
clinical spectrum were recruited. Patients who had more severe visual abnormalities at 
screening, felt to require urgent intervention such as surgery, failed by definition to meet 
the inclusion criteria of uncertainty of the treating clinician. This trial therefore focussed on 
individuals with milder forms of IIH, amongst whom severe visual loss is uncommon.  
 
3.4.3.5 Weight reduction 
Weight was recorded at baseline in all patients. Due to the pragmatic design of the study 
and busy clinical setting, weight was not always documented subsequently (79.6% overall 
recording rate when averaged over the five visits) and may not always have been accurate, 
due to variations in clothing and weighing scales used. In addition, missed visits resulted in 
some loss of data, but 90% of patients had at least three separate values recorded. An 
overall weight reduction was more common: 19 patients gained weight and 30 patients lost 
weight. In most patients, the overall change was slight, with more than a 10% change in just 
seven patients.  
All patients in this study were advised to follow a programme of weight reduction if they 
were overweight. It was considered unethical to include an arm in the trial in which 
overweight patients were not advised to lose weight. Whilst patients in the acetazolamide 
arm lost a little more weight, the difference was not significant. The patients had a slightly 
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higher mean BMI at the start of the trial (39.3, versus 35.5 in the deferred treatment arm) 
which may have impacted on the amount of weight lost.  
A small number of published studies have demonstrated an association between weight 
reduction and clinical improvement in IIH. In the case review by Johnson et al (1998) six 
obese female patients who lost an average 6.2% of their body weight were observed to have 
a three-grade improvement in the severity of their papilloedema. A two-grade improvement 
was seen amongst five patients who lost an average of 4.3% and even the six patients in the 
study who lost only 3.3% showed an improvement by one grade. A significant correlation 
was found between grade change and percentage weight reduction (Spearman rank 
p=0.002). Sinclair et al (2009) showed that a mean weight reduction of 5.2% was associated 
with significant reductions in intracranial pressure in 20 patients with longstanding IIH. In 
addition, symptoms and signs of disease including headache and papilloedema showed 
significant improvement amongst the patients who lost weight. 
No relationship between percentage weight reduction and Final Outcome was found in this 
pilot, in which mean weight loss overall was 4.6%, similar to that of both published studies. 
Furthermore, no significant trends were revealed when the effect of weight loss or gain 
upon the six components of IIH status was examined. This neither supports nor refutes the 
theory that weight loss in IIH is associated with improved clinical outcome, as the trial was 
underpowered to find such an association. The impact of weight loss in IIH warrants further 
investigation through specifically designed studies. 
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3.4.3.6 Pregnancies 
There were five pregnancies in the study and changes in weight of the affected patients, 
where recorded, reflected this. Two of the pregnancies were terminated before the end of 
the study, but data was available on three patients in active pregnancy. One patient, 
allocated no acetazolamide, had a healthy delivery prior to the final trial visit and was 
asymptomatic at the end of the trial as well as at the visit preceding delivery, with no 
deterioration in her visual function observed during the pregnancy. Similarly, no worsening 
of the clinical features of IIH was seen in the two patients pregnant at the final visit, both in 
the second trimester. This is in keeping with the finding of Digre et al (1984) that outcome in 
IIH is the same for pregnant as non- pregnant patients.  
The pregnancy rate in this study (10%) was perhaps surprising, given the stated exclusion 
criteria of pregnancy / planned pregnancy. There have been no well-documented reports or 
robust studies of the effects of acetazolamide upon pregnancy, (Lee et al., 2005) but the trial 
design reflected current practice of avoiding its use in pregnant patients due to concerns 
about the potential for congenital malformations.  
In addition to the effect on protocol compliance, a high prevalence of pregnancy would 
affect the data collected on body weight. This was not a major concern with the current trial, 
since roughly equal numbers of patients from each allocation arm were affected, plus the 
study was not designed specifically to examine the effect of weight change. Future trials 
seeking to reduce the prevalence of pregnancies should screen carefully for women planning 
to become pregnant and emphasise the need for contraception. 
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3.4.3.7 Individual Outcome Measures 
3.4.3.7.1. Symptoms 
Headache prevalence amongst all patients fell from 70% at baseline to 54% at the final visit. 
Figures for transient visual obscurations, diplopia and visual loss also showed an overall 
reduction (64% to 10%, 22% to 2.5% and 26% to 5% respectively.) Tinnitus was unusual, in 
that the prevalence increased between baseline and final visits (56% to 58.5%, table 3.14). 
Some data inaccuracies were apparent, with tinnitus described as absent on the final status 
score yet recorded as present on the symptom checklist in four patients. Nevertheless, 
tinnitus was present in a surprisingly high proportion of patients who otherwise had marked 
reduction in their symptoms and the prevalence remained more or less constant from the 
start to the end of the trial period. Explanations could include significant inaccuracies in data 
collection, patients misinterpreting questions about tinnitus, or a high prevalence of 
intracranial noises due to causes other than IIH in this cohort. There are no published values 
for comparison. The study by Wall and George (1991) reported intracranial noises in 60% of 
50 patients at the start of the prospective study, but no further prevalence data is provided. 
3.4.3.7.2 Optic Disc Appearance 
Papilloedema prevalence fell from 100% initially to 68% at the final visit across all patients in 
the trial according to the “is papilloedema present?” question on the examination 
documentation. Similarly, for the optic disc item on the final status score, 36.5% of all 
patients were recorded as having normal and 56% to have abnormal, stable discs, with just 
7.5% have deteriorating discs. One patient had normal optic disc status, but papilloedema 
recorded as present and one other, papilloedema absent but optic disc status abnormal, 
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stable. Otherwise there were no discrepancies in the data. The majority of patients thus had 
papilloedema at the end of the trial, with abnormal, stable disc appearances. This is in 
keeping with the clinical observation that optic disc appearances continue to show chronic 
changes in patients with IIH. 
Wall and George (1991) found a very similar reduction in papilloedema between the initial 
and final visits, from 100 to 64%. In the prospective study of 24 patients by Sorensen et al, 
(1988) complete resolution of papilloedema was seen in 50% after a combination of medical 
and, in some cases, surgical treatment, usually three to six months after the start of 
treatment.  The remainder developed chronic papillary changes (42% of patients), optic 
atrophy (4%) or still had acute papilloedema (4%) at the end of the study.  
There was no difference in papilloedema resolution between allocation arms at any time 
point and by repeated measures analysis. In the study by Celebisoy et al, (2007) 
papilloedema grades were reported to regress after a mean treatment period of 5.1 months 
in the 20 patients treated with acetazolamide and 5.1 months in the 20 treated with 
topiramate (no significant difference). No other published studies exist for comparison.  
The treating clinician’s assessment of optic disc status had strong concordance with final IIH 
outcome (D=0.59), second only to that of visual field status. This shows that the appearance 
of the optic disc had a greater influence on the clinician’s assessment of disease status than 
most other signs or symptoms, as was expected from observation of current practice. The 
use of subjective assessment is entirely justified in this study, since no recognised, validated 
measures of IIH disease status exist and management decisions are routinely made in this 
manner. The results for the influence of optic disc status on final outcome highlight the need 
to develop more objective and reliable measures of papilloedema in IIH. Many studies 
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classify optic disc appearance according to scales, such as the Frisen (1982) grading scheme 
and this is discussed in more detail in chapter 4.  
 
3.4.3.7.3 LogMAR acuity 
No patient in either allocation had their final visual acuity status assessed as deteriorating 
and it was recorded as normal in 85%. Examination of recorded LogMAR visual acuities at 
each visit did not show any significant changes throughout the trial. Of the six clinical 
features examined for their influence upon final IIH outcome, visual acuity had the lowest 
concordance (D=0.05). Acuity was thus neither a useful nor sensitive measure of visual 
function in this study population.   
Wall and George (1991) also found no significant change in Snellen acuity from initial to final 
visits and showed that acuity testing was not associated with visual loss found by perimetry 
or with papilloedema grade. In the Iowa long-term follow-up study by Shah et al, (2008) 
mean visual acuity remained stable over the period of the study, despite worsening of visual 
field being observed amongst some patients.  
Orcutt et al (1984) combined visual acuity with visual field appearance in describing visual 
loss in 68 patients with ‘benign intracranial hypertension’. A reduction in Snellen acuity of at 
least two lines, or a new field defect or field constriction of greater than 20% defined 
‘definite’ visual function loss, whilst the term ‘severe’  was reserved for acuities worse than 
6/60 or field constriction to less than 10 degrees with a 14e target on Goldmann perimetry. 
Although 49% of all eyes had definite loss of vision during the study over an average of 4.1 
years, no eye lost acuity without a visual field defect. Detailed data on individual acuities was 
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not provided. Visual acuity was also found to be insensitive to visual loss found on perimetry 
in the prospective study of 35 patients by Rowe and Sarkies. (1998) Amongst 110 eye tests 
over 3 years, abnormal visual acuity was documented in 36 tests (33%) compared to 
abnormal visual fields in 103 tests (94%). 
Whilst measurement of visual acuity is essential in clinical practice, its use as a trial outcome 
measure is limited by its sensitivity. Evidence suggests that patients observed to have 
deteriorating visual acuity will already have exhibited abnormalities on other tests of visual 
function. Visual acuity measures central visual function, reflecting retinal function in the 
central foveal area and does not indicate the condition of the peripheral or paracentral 
fields. Central vision is often spared in longstanding papilloedema, even in the presence of 
marked visual field abnormalities. More sensitive measures should be employed in studies 
where treatment effects may be small. 
 
3.4.3.7.4 Visual Fields 
At the final visit, visual fields were described as normal in 22 patients (58%), abnormal but 
stable in 16 (42%) and abnormal, deteriorating in none. There was a significant overall 
improvement in the MD values for both eyes when all patients were compared at baseline 
and at the final visit. Overall, 37% of the MD values at the final visit were determined by the 
perimeter software to be outside normal limits, compared to 74% at baseline. A learning 
effect is known to occur with perimetry, where improved performance is seen the more the 
tests are repeated. (Keltner et al., 2000) Most patients in this study completed three or more 
visual field tests, with 84% of patients completing all five scheduled examinations. It is 
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impossible to accurately assess the learning effect on the results and to reduce the impact of 
this in future studies would require tests to be repeated at each time point. Perimetry is 
time-consuming and requires specialist equipment and supervision, plus patients have to 
concentrate and tend to dislike the test, so this option is not always practicable. In this 
study, repeating the visual field tests was not felt to be in keeping with the pragmatic design.   
Only one other study has published perimetry MD values in IIH at more than one time point. 
The retrospective study by Bruce et al (2009) reported mean MD values amongst 422 
women and 66 men at their first and last visits, and values appeared to improve in both 
groups, but neither the study duration nor the significance of the changes were supplied. 
Wall and George (1991) applied their own grading criteria to visual fields in their prospective 
study. They found that 60% of patients had improvement of Goldmann visual field grade and 
50% had improvement of automated perimetry grade. The same grading system was used in 
the study by Rowe and Sarkies, (1998) in which 35 patients had at least two examinations 
over a three year period. Humphrey automated perimetry demonstrated abnormalities in 
82% of patients at the first visit and 56% at the final visit. There was a significant 
improvement in the grade of visual field loss from first to last assessment. Celebisoy et al 
(2007) also used the grading system as the main criterion to assess clinical improvement in 
their study comparing acetazolamide and topiramate. When the visual field grades at the 
beginning of the study were compared with those at the end of the third, sixth and twelfth 
months a significant improvement was demonstrated. The effect of repeated testing upon 
the results was common to all three studies, with no specific measures employed by any to 
minimise its impact. 
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Treatment allocation was found to have no effect on any measure of visual field status in 
this study. As with all other results, this reflects the sample size and trial design and no 
published data exists for comparison. Whilst other studies have demonstrated the 
superiority of perimetry as a sensitive measure of visual function, there is as yet no literature 
on its sensitivity as an outcome measure for intervention trials. Visual field status was found 
in this study to have the strongest concordance with final outcome (Somer’s D=0.66), 
suggesting that clinicians do rely most on the visual field appearance when judging IIH 
status. This should strengthen the argument for including visual field assessment in all future 
studies whilst striving to overcome the problem of the effect of learning upon the results. 
3.4.3.7.5 Contrast Sensitivity 
A mild improvement in contrast sensitivity was apparent throughout the study, in those 
patients for whom it was measured using Pelli Robson charts. As only 19 of the trial patients 
were tested and almost all of the values could be considered as falling within the normal 
range, further statistical analysis of the results is not warranted. The finding of an apparently 
significant result amongst the repeated measures analyses for right contrast sensitivity 
should be regarded as spurious. 
Wall and George (1991) reported abnormal contrast sensitivity at the initial visit in 25 (50%) 
of 50 patients. Results were abnormal at the final visit in only 38% of the patients, although 
two patients who initially had normal contrast sensitivity had abnormal results at the end of 
the study. Interestingly, contrast sensitivity was the only visual parameter to correlate with 
the symptom of visual loss (p=0.02). Different methods were used to assess the contrast 
sensitivity, namely Arden gratings for the first two years, replaced by a Vistech contrast chart 
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for the final four years of the study. Rowe and Sarkies (1998) used Pelli Robson charts in 
their prospective study of 35 patients, reporting no difference between the sensitivities of 
contrast sensitivity and visual acuity, but data on the values recorded was not provided. The 
test was shown to be significantly less sensitive than visual field assessment. Other more 
technical methods of measurement may have greater sensitivity, but are likely to be less 
widely available and more time consuming for the patient. Pelli Robson charts have the 
advantages of simplicity and low cost to recommend their use, but seem unlikely to enhance 
trials in which accurate assessment of visual field defects is undertaken. 
3.4.3.7.6 Health-related quality of life data 
The use of standardised questionnaires provided health-related quality of life data at three 
time points during the study. The SF-36 produced eight scores between 0 and 100, 
measuring three aspects of health: functional status, wellbeing and overall evaluation of 
health. In addition to the eight scales, change in health was measured by a single question in 
the questionnaire, in which patients were asked “Compared to three months ago, how 
would you rate your health in general now?” and required to choose one of five responses 
“much better”, “somewhat better”, “about the same”, ““much worse” and “somewhat 
worse.”  
There is one published study of SF-36 subscale scores in IIH. Using questionnaires at a single 
time point, Kleinschmidt et al (2000) demonstrated significantly lower (worse) scores 
amongst 28 women with IIH for all eight measures of the SF36 except energy/vitality, role-
emotional and mental health when compared to 30 age- and weight-matched as well as 30 
age-matched, normal weight, female controls. The values from this study are compared with 
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the mean values amongst the IIH trial patients, as well as published normal values from two 
adult population studies in table 3.23.  Although statistical testing of the data is not possible, 
the scores from the Kleinschmidt study appear worse across all of the eight scales. Values 
from the IIH trial appear closer to the normal scores from population studies, with the 
possible exceptions of pain and general health. This may reflect differences in the 
characteristics of the patients in the two studies, as those in the Kleinschmidt study were at 
various stages in their IIH disease and had a variety of co-morbidities. A more recent study 
by Daniels et al (2007) showed that 34 patients with IIH had lower scores for SF-36 Physical 
Components Summary (p<0.0001) and Mental Components Summary (p<0.0001) compared 
with United States norms for females, as well as with 41 patients with neuro-
ophthalmological disorders (p=0.02, Physical Components Summary only.) There are no 
other published studies of SF-36 in IIH. The finding of near-normal scores for many patients 
in this pilot is perhaps surprising, but is consistent with other results suggesting that patients 
with less severe IIH were enrolled.  
Table 3.23 Mean SF-36 scores amongst all IIH patients at baseline and mean scores from three 
published studies. *Scores are estimated to nearest 0.5 from published bar chart 
 
 
IIH Trial 
Baseline 
visit 
n=48 
IIH patients US case-
control study* 
 (Kleinschmidt) 
 n=28 
UK General 
population 
 (Garratt, 1993) 
n=542 
US general 
population 
 (Ware, 1994) 
n=2,474 
  
 
  
Physical Function 79.9 57.5 79.2 84.2 
Role-Physical 69.5 35.0 76.5 80.9 
Role-Emotional 77.2 46.5 75.0 81.3 
Social Function 70.3 51.5 78.6 83.3 
Mental Health 64.4 56.5 73.7 74.7 
Energy Vitality 51.6 29.5 61.2 60.9 
Pain 57.8 41.5 76.9 75.2 
General Health  57.6 40.0 68.7 71.9 
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When baseline scores for all patients were compared with those at the end of the study, the 
only observed differences were for SF-36 subscales pain and change in health. Mean score 
for pain improved from 57.8 to 77.8 (p=0.02). This is compatible with the clinical data for 
headache incidence, which improved from 70% to 54% overall, but it should be noted that 
the term pain in this questionnaire is specified as bodily pain, rather than headache. The 
mean score for change in health improved from 47.8 at baseline to 59.7 at 12-months 
(p=0.01). Thus more patients at the end of the study reported their overall health as better 
than three months ago than when the same question was posed at the start. It is possible 
that the time limit of three months for this question (rather than one year as used in other 
versions of the SF-36) reduces the relevance of the finding. Had the question addressed 
overall health as compared with one year previously, an even greater improvement may 
have been seen at the final visit. This should be considered in the design of future studies. 
There was little evidence of mood disturbance in this pilot. HADS scores for most of the 
patients fell within the normal range for anxiety and depression (0-7). At each visit and in 
each allocation arm, very few patients showed scores in the borderline or abnormal 
categories, as shown in table 3.18. Anxiety was more commonly reported than depression 
overall. Throughout the study, approximately one quarter of patients had scores indicative 
of abnormal levels of anxiety (score range 11-21, mean 23.2% of patients). At baseline, the 
mean score amongst all patients for anxiety (7.42) fell just outside the normal range, whilst 
for depression (4.19) it was clearly normal. By the end of the study, all mean scores were 
within the normal range, although the improvement was not significant. Furthermore, 
repeated measures analysis showed no differences between the allocation arms and no 
 187 
 
significant trend was observed when numbers of scores in each category were compared 
over time. 
In the study by Kleinschmidt et al, (2000) depression scores on the Beck Depression 
Inventory and anxiety scores on the Spielberger State-Trait Inventory were found to be 
higher (worse) in IIH patients than the normal weight controls (p<0.002 and p<0.015 
respectively) but not significantly different to weight-matched controls. No studies have 
examined the change in mood scores before and after treatment in IIH. There is a wealth of 
literature linking obesity and mental health and since all except two of the patients in this 
pilot were overweight, it is not possible to speculate about the effect of this on the 
assessment of their mental state. 
The EuroQol scoring systems (visual analogue and EQ-5D) were also not sensitive to change 
in this study. There was no improvement in scores overall from baseline to final visit, nor 
were any differences observed between the allocation arms. There are no reports at all of 
the use of EuroQol scores in IIH in the literature. Its inclusion in a pilot study such as this is 
justified on the grounds of its simplicity to administer and the potential to generate a single 
index value for health status. It was designed to complement other instruments and may 
have a role in future IIH studies in which the overall health of patients is more adversely 
affected by the disease. 
Of the three measures used in this pilot, the SF-36 appears to be the most appropriate, 
based on the observed improvement from the start to the finish of the trial in two of the 
subscales. Care is required in the interpretation of the scores when, as in this study, the 0-
100 scoring algorithm is used (based on the summated rating method), rather than the more 
recently introduced norm-based algorithm. The shapes of the profiles in figures 3.12 and 
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3.13 reflect both the impact of IIH on SF-36 health concepts as well as arbitrary differences 
in ceilings and floors of the SF-36 scales. (Ware et al., 2000) Thus the average score for each 
scale differs substantially across the profile for reasons other than IIH. It is not correct, for 
example, to infer from the profile in figures 3.12 and 3.13 that IIH has a greater impact on 
energy / vitality and general health than physical function. The use of the newer, norm-
based scoring method, in which below-average health status is indicated by a scale score 
below 50 and differences in scores more clearly reflect the impact of the disease, should be 
adopted by future trials. 
As no published studies have measured health-related quality of life before and after 
intervention in IIH, there is very little to guide which scales should be used when planning 
trials. The levels of anxiety reported in this study should not be ignored, despite the lack of 
observed changes with time or treatment. Certainly, some measure of mood, functioning 
and quality of life would seem to be important when studying the impact of IIH, particularly 
if a goal of future trials is to recruit patients with more severe disease and higher overall 
morbidity. 
3.4.3.8 Composite Outcome 
The use of a combination of commonly measured variables as an overall clinical assessment 
tool for IIH was explored by this study. This was based on the observation that decision 
making in IIH seems to depend upon the consideration of various components of the clinical 
assessment, with varying amounts of importance apparently being attached to each. As with 
many conditions and with clinical reasoning on the whole, subjective judgement by 
experienced clinicians forms the mainstay of management. Objective, reproducible, sensitive 
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and standardised measures to guide this process have obvious potential benefits and are 
essential to the design of future trials. The quest for such measures begins with an 
assessment of how clinical judgement is influenced. 
Data from the analysis of the six items for which final status was assessed by the clinician 
provided valuable information to guide the creation of a composite scoring system. Visual 
acuity had the least influence on the final IIH status and appears to be a poor measure of 
disease activity. The presence of symptoms such as headache, tinnitus and visual 
obscurations also appeared to add little to the evaluation of disease severity. The data 
suggests that perimetry and appearance of the optic disc are the most influential measures, 
as shown by their strong concordance with IIH status (Somer’s D 0.66 and 0.59 respectively).  
Combining the examination of optic discs with the perimetry findings seems to be the most 
appropriate and sensitive method of routine disease assessment and has been 
recommended as such in several publications. (Orcutt et al., 1984; Wall and George, 1991; 
Rowe and Sarkies, 1998) In future, newer techniques such as computerised optical 
coherence tomography may have a role, but remain to be formally evaluated and are not 
currently widely available. It would seem sensible therefore to prioritise visual field 
assessment and optic disc appearance in any composite measure of IIH. This leads to the 
concept of weighting the various components of the measure to reflect their apparent 
importance, with visual fields and optic disc being obvious candidates to have higher scores 
attached.  
In the scoring system piloted by this study, the theoretical maximum (worst) score was 12, 
since each of the six components scored 0, 1 or 2 according to subjectively judged severity 
and all six contributed equally to the final score. The mean value for all 50 patients at the 
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final visit was 2.75 (2.6 in the acetazolamide group and 2.9 in the control group, no 
significant difference.) Further development of composite scores could include a wider 
choice of scoring options for those components with greater influence upon overall disease 
status. Grading systems for visual field and optic disc abnormalities have been adopted by 
several major published IIH studies, (Wall and George, 1991; Rowe and Sarkies, 1998) with 
greater than three possible grades for each parameter.  Further studies could combine 
higher total possible scores for these measures with more limited ranges for disease 
features such as acuity and headache, to reflect their differing impact on the overall disease. 
One further theoretical problem with the scoring system in this study is the heterogeneity of 
its components. It includes markers of active disease (papilloedema, obscurations) as well as 
measures of damage that may be present whether or not the disease is still active (field 
defects, acuity). In addition, measures are included that may indicate either active disease or 
alternative pathology (headache, tinnitus). The assignment of lower maximum scores to 
some components, notably headache, would to some extent resolve this issue. Furthermore, 
the score in this pilot was calculated for a single time point, so no comment about the 
behaviour of the scoring system over time is possible. It would seem sensible in future to 
examine the longitudinal behaviour of the composite score, by repeating its measurement at 
multiple time points. This may also address some of the problems associated with the 
inclusion of such heterogeneous measures. 
3.5 Summary 
This is the largest trial and the only randomised controlled trial in IIH to date. 50 patients 
were recruited from five centres over a 23 month period. Patients had the typical 
 191 
 
characteristics of IIH, being predominantly obese, young females with headache as their 
most common symptom. Recruited subjects appeared to have a mild form of IIH and there 
was a low incidence of visual dysfunction at the start of and throughout the study. The 
overall dropout rate was 20%, but protocol non-compliance was seen in 16 patients (32%). 
Most patients experienced improvement of their disease, with 44% judged to have IIH in 
remission at the end of the trial and significant improvement in symptom prevalence, optic 
disc appearance and visual fields. No differences were seen between subjects allocated to 
receive acetazolamide and those allocated no medication when outcomes were compared at 
baseline and final visits or by repeated measures analysis, although the trial was 
underpowered to detect a treatment effect. The only quality of life measures reflecting 
improvement were the pain and change in health subscales of the SF-36. No patient had 
blinding visual loss, surgical intervention was required in just two patients and there were 
five pregnancies during the study. Most patients lost weight during the trial, with a mean 
loss overall of 4.6%. 
A scoring system based on common clinical features of IIH was tested and used to create a 
novel composite outcome measure. Visual fields and optic disc appearance had the greatest 
influence on IIH disease status and are the most important components of the clinical 
assessment. Future studies should incorporate weighting into composite scores to reflect 
this.  
Difficulties of recruitment and compliance with treatment have been highlighted by this 
study. In addition, a tendency to recruit only those patients with benign forms of the disease 
was observed. Future trials need to address these issues for meaningful conclusions to be 
drawn whilst maintaining a sufficiently pragmatic overall design.  
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CHAPTER 4   
THE ASSESSMENT OF PAPILLOEDEMA IN IIH 
4.1 Background 
Papilloedema, swelling of the first part of the optic nerve (the optic disc or papilla) in the 
presence of raised intracranial pressure, is almost a universal clinical finding in IIH. In the 
assessment of both newly diagnosed and more longstanding IIH, the appearance of the optic 
disc is a key measure of disease status and the effect of treatment. In addition to the 
presence or absence of papilloedema, the degree, severity and chronicity of the disc swelling 
is important to determine. 
4.1.1 Papilloedema classification  
Attempts have been made to grade and classify disc swelling. ‘The Ocular Fundus in 
Neurologic Disease: a Diagnostic Manual and Stereo Atlas’ (St Louis, CV Mosby, 1966) 
published in 1966 by neuro-ophthalmologist, William F Hoyt and photographer Diane 
Beeston, contained a classification of stages of papilloedema described as early, fully 
developed, chronic and atrophic, with serial photographic documentation of examples of 
evolving disc oedema. The book sold out almost immediately but was never reprinted. In 
1969, the Neuro-Ophthalmologist Michael Sanders published a similar temporal 
classification based on a fluorescein angiographic study of 69 cases, dividing papilloedema 
into five groups according to an estimation of its duration.(Sanders, 1970) All cases were 
under investigation at the National Hospital in London and all had elevated CSF opening 
pressure at lumbar puncture. Diagnoses were stated for 42 of the cases, as ‘Benign 
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Intracranial Hypertension’ (22), malignant tumours (13) and meningioma (7). The five groups 
were termed early, acute, chronic, vintage and atrophic and detailed descriptions of the 
features in each as well as the approximate times since onset of the process were provided, 
as summarised in table 4.1. 
Table 4.1 A summary of Sanders’ descriptive classification of papilloedema (Sanders, 1970) 
Group Duration Main features Angiographic features 
Early Hours/ days 
Hyperaemia of disc 
Blurring of disc margins 
Full tortuous veins, absent 
pulsation 
Grey colour of peripapillary retina 
above / below disc (oedema in 
nerve fibre layer) 
 
Allows dilated vessels on disc to be 
seen (may extend to retina) 
Leakage of dye mainly above and 
below disc (increased vessel 
permeability), seen as residual 
fluorescence 
 
Acute Days / weeks 
Fully developed papilloedema 
Retinal veins elevated by disc 
swelling 
Arteries often obscured 
Haemorrhages- superficial (nerve 
fibre layer), deeper, punctuate or 
more extensive, in sub-hyaloid 
space 
White areas- probable cotton wool 
spots or resolving haemorrhage 
 
Consistent with ophthalmoscopic 
appearance 
Striking appearances in residual 
photographs 
Early filling of disc capillaries  is 
followed by extensive leakage(dye 
spread widely into surrounding 
retina along nerve fibres) 
 
 
Chronic Weeks / months Less active picture 
Few haemorrhages / exudates 
Marked vascular network on 
surface of disc 
Underlying contrasting grey glial 
reaction often seen 
 
Demonstrates maximal disturbance 
often in peri-papillary plexus 
Micro-aneurysms frequent 
Massive leakage of dye 
 
Vintage Months / years 
Multiple small drusen-like bodies 
on disc surface 
May see optociliary shunt vessels 
 
Early filling of optociliary or shunt 
vessels during arteriel phase 
Venous study may demonstrate 
surrounding choroidal 
degeneration 
Atrophic Years 
Optic disc pallor 
Peri-papillary choroidal 
degenerative changes visible 
Marked attenuation of retinal 
arteries, with few branches 
No leakage of dye 
 
Sanders claimed that the category of acute papilloedema is simplest to diagnose due to the 
increase in signs from the early stage and the appearance of haemorrhages and exudates. 
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Greater difficulties arise with the diagnosis of early papilloedema, where several factors may 
influence the disc appearances at the time of examination, such as fluctuations in CSF, intra-
ocular or systemic blood pressures, so that angiographic demonstration of disc capillaries 
and leakage may be essential. The exact aetiology of the vascular changes seen in chronic 
papilloedema is not known, although it is suggested that they result from compensatory 
mechanisms to overcome disordered pressure and perfusion gradients in the region. More 
prolonged elevation of pressure can induce the degenerative changes seen in the ‘vintage’ 
variant of papilloedema. Here, as in the three previous groups, many features are reversible, 
unlike the fifth or ‘atrophic’ stage in which disc pallor is permanent and visual loss has 
occurred. 
The division of the various optic disc appearances into the five categories was entirely 
arbitrary and focussed principally on providing descriptions of the progressive development 
of papilloedema. The publication was designed to aid the ophthalmologist in judging the 
duration of a particular case of papilloedema and the possibility of visual failure. 
More recently, Lars Frisen (1982) published a numerical scheme describing stages of swelling 
of the optic nerve head according to various components of the ophthalmoscopic picture. 
The original paper reported the grading of 78 fundus photographs showing either normal 
discs or acquired disc swelling of various aetiologies, by three clinicians blinded to clinical 
information. The published paper included black and white photographic examples and 
descriptions of six distinct grades, summarised in table 4.2. The aim of the scheme was to 
provide a detailed terminology for the various components of the ophthalmoscopic 
appearance and facilitate the identification of a change in swelling in the individual case. 
Increasingly pronounced changes are seen at successive stages and short-term fluctuations 
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in appearances are said to be accommodated by sufficiently large intervals between stages 
of the scheme. Stages 1 and 2 represent early disc swelling, stage 3, moderate abnormality, 
stage 4, severe and stage 5, a transitional stage towards progressive atrophy. 
Table 4.2 Summary of the Frisen Staging Scheme (Frisen, 1982) 
 Stage Summary of ophthalmoscopic features Example 
0 Normal disc 
Radial pattern of peripapillary nerve fibre bundles 
 
1 
Disruption of the normal radial arrangement of the nerve fibre bundles  
Excessive blurring of the nasal disc border -subtle grayish halo 
Sparing of the temporal margin – temporal gap in halo 
 
2 
Halo surrounds the disc 
Nasal margin is elevated 
Concentric or radiating retinochoroidal folds may be seen 
 
3 
Additional elevation of the temporal margin, clearly enlarged disc 
diameter 
One or more segments of major retinal vessels obscured by elevated disc 
borders  
Irregular, fringed ‘circumpapillary halo’ with finger-like extensions  
4 
Elevation of the entire nerve head 
Total obscuration of a central retinal artery or vein, or 
Optic cup compressed to a slit or completely obliterated 
 
5 
Dome-shaped appearance of the nerve head - dominance of anterior 
over sideways expansion 
Halo is narrow and smoothly demarcated  
Some obscuration of vessels as they climb steeply over the dome 
 
 
Frisen highlights the major role of axonal swelling in the production of papilloedema, 
seemingly a consequence of locally arrested axoplasmic transport. Difficulties in recognising 
early changes within the disc itself are acknowledged, such that the early stages of the 
scheme refer to changes at the disc border, whilst more advanced stages reflect anterior 
expansion of the swelling nerve. The proposed scheme is applicable to a large variety of 
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conditions, except swelling of the optic nerve head by ‘elements normally foreign to the area 
(for example neoplastic cells)’ and is not specific for raised intracranial pressure. Any 
vascular components, such as venous stasis, hyperaemia, haemorrhages and infarcts are 
disregarded on the basis that various pathogeneses and ‘individual peculiarities’ lead to 
considerable variety of expression of such features.  
The results of an attempt to assess the reproducibility of the Frisen scheme were published 
alongside its original description. The 78 slides under scrutiny comprised one fundus 
photograph from each of 12 subjects with normal discs, 12 with disc abnormalities 
‘reminiscent of acquired disc swelling’ and 54 subjects with differing degrees of acquired disc 
swelling of known aetiology. No further diagnostic information was provided. The author 
plus an ophthalmology resident and a medical student assigned a stage number to each of 
the photographs, as they were projected in random order as slides with a uniform degree of 
magnification, without access to clinical information. The exercise was repeated by all, a 
minimum of four weeks later. The assigned scores were identical on re-test for 80% of the 
slides assessed by the two senior observers and 75% for the medical student. Between 
examiners, there was exact agreement for 49% of the slides and a difference of only one unit 
for 86%. For the three observers, 88 to 96% of normal discs were correctly classified and the 
fraction of abnormal discs correctly identified ranged from 93 to 100%.  
Anomalies of otherwise normal optic discs, resembling swelling, were the cause of most 
difficulties for the junior observer. Concentrating on axonal swelling as the most important 
element of papilloedema was regarded by Frisen as more reliable than using other indicators 
of disc swelling, such as the presence or absence of venous pulsations and ophthalmoscopic 
measurement of disc protrusion. It was proposed that this focus of the scheme on fine 
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details would aid the differentiation of papilloedema from innocuous normal variants, 
although it would not, nor was it intended to discriminate between the various aetiologies of 
disc swelling.  
Not only is the Frisen scheme applicable to a wide variety of pathologies besides IIH, but 
vascular changes, which may have clinical significance in IIH, are not included. Furthermore, 
the successive stages of Frisen’s scheme reflect increasing abnormalities as the degree of 
optic nerve swelling worsens; no indication is given as to how the scheme can be applied to 
the process in reverse, as papilloedema resolves. Unlike the Sanders classification, the Frisen 
scheme makes no attempt to judge the duration of the swelling. Patients with IIH frequently 
present with papilloedema over long periods of time, thus some measure of the chronicity of 
their disc swelling is desirable.  
4.1.2 Papilloedema grading in IIH Literature  
Despite its apparent limitations, the Frisen scheme, or some variant thereof, is frequently 
reported as a major outcome measure in published case series, analyses and trials in IIH. 
Some have also referred to the Sanders classification. Examples are given in table 4.3. 
Many early publications refer simply to the presence or absence of papilloedema when 
describing the clinical course of IIH. More recently, studies have provided greater detail 
regarding the severity or duration of disc swelling, particularly in relation to cases of IIH in 
which visual loss has occurred. Corbett et al (1982) described the persistence of 
papilloedema in nine of 57 patients five to 13 years after their initial symptoms, three of 
whom had severe visual loss as measured by acuity and perimetry. In addition, choroidal 
retinal folds were reported in six patients with persistently enlarged blind spots. Optociliary 
 198 
 
Table 4.3 Examples of major studies in IIH with assessment of papilloedema as a key feature 
Year 1
st
 Author Type of study n 
 
Assessment of Papilloedema 
 
2009 Bruce  Retrospective review 658 
 
Systematic review of fundus photography  
Median Frisen grade at first and last visit 
2008 Shah  Retrospective review 20 Frisen grading of stereo optic disc photographs  
Consensus of three independent observers 
Median grades at initial and final visits  
2007 Celebisoy  Prospective open-label 
study 
40 Grading of papilloedema at ophthalmoscopy 
Frisen grades reported for initial visit only 
1998 Kupersmith Retrospective review 58 Modified Frisen grading 
Mean grade as main outcome measure 
1998 Johnson Retrospective review 15 Novel Frisen-based grading of stereoscopic slides 
Consensus of three observers  
Masked review against investigators ‘gold standard’ 
1991 Wall Prospective study 50 Frisen Grade 
Average optic cup size ratio 
1988 Sorensen  Prospective study 24 Optic disc appearance described as normal, oedema / 
gliosis, or atrophy 
Disc protrusion measured in dioptres 
1984 Orcutt Retrospective review 68 Sanders classification 
Degree of disc elevation graded as low or high grade 
1982 Corbett Retrospective review 57 Absence/persistence of papilloedema on photographs 
Descriptions of features in specific cases 
 
collateral vessels were seen in three cases and, amongst patients whose papilloedema 
subsided, several features were described as sequelae of the prior disc swelling, such as 
gliosis of the disc and circumpapillary pigmentation. Two years later, Orcutt et al (1984) 
published a study of factors affecting visual loss in ‘Benign Intracranial Hypertension’ in 
which the co-author Sanders’ own classification was applied to stereoscopic fundus 
photographs from 68 patients. The chronicity of disc swelling was not seen to correlate with 
visual loss, with no significant relationship of visual deterioration with acute, chronic or 
vintage papillodema. However, the degree of oedema was also graded according to the 
actual elevation of the disc, as ‘low’ or high’ grade, where the latter had greater than 4 
dioptres of swelling measured ophthalmoscopically and this was found to be associated with 
poor visual outcome. 
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Sorensen et al (1988) also measured the degree of disc swelling in IIH. In a prospective study 
of 24 patients, ophthalmoscopy and colour fundus photography were used to subjectively 
evaluate the disc appearance as well as record the disc protrusion in dioptres. The evolution 
of changes throughout a mean of 49 months was observed. Initially all patients had 
papilloedema described as acute, which resolved completely in 50%. Development of 
chronic papillary changes was reported with gliosis of the optic discs in 42% of patients. One 
patient developed optic nerve atrophy. Patients with complete resolution of their 
papilloedema showed a rapid decrease in disc protrusion within the first months of 
treatment. 
The prospective study by Wall and George (1991) was the first major publication to report 
the use of the Frisen scheme to assess outcome in IIH. 50 patients, examined at least twice 
over an average follow up of 12.4 months, had the Frisen grade recorded at all visits 
following ophthalmoscopic examination. Stereoscopic photographs were taken at the initial 
visit and again whenever change occurred. In addition the average optic cup size ratio was 
measured, as vertical cup diameter: total vertical disc diameter, although comment was 
made that measurement was difficult when discs were elevated. The authors found a 
significant improvement in papilloedema grade in both eyes and a significant change in cup 
size ratio, in the left eye but not the right, from the initial to the final visit. Interestingly, 
neither papilloedema grade nor final cup size correlated with other measures of visual loss in 
the study. 
Kupersmith et al (1998a) used a slightly modified version of the Frisen scheme to 
retrospectively compare papilloedema in 58 patients with and without weight loss; only 
grades 0, 1, 3 and 5 were employed at one of two centres in the study. Grade 0 was assigned 
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to cases in which the papilloedema resolved. The mean grades for the worst eyes in each 
subject, as well as for both eyes, were reported for the initial visits and six months or more 
after baseline. A mean time to improve one grade in papilloedema of 4.0 months for 38 
patients who lost weight compared to 6.7 months for 20 patients with no weight loss was 
cited as evidence of the beneficial effect of weight reduction in IIH.  
In the same year, Johnson et al (1998) used a modified version of the Frisen scheme in a 
study of 15 patients, also aiming to assess the association of weight loss with resolution of 
papilloedema in IIH. Stereoscopic slides of the optic disc from the eye with the more 
advanced papilloedema from each patient were reviewed in a masked fashion by three of 
the authors and assigned a grade by comparison against ‘gold standard’ photographic 
examples. The gold standards were photographs from earlier studies for which there was 
complete agreement about the grades amongst the authors as well as by three senior neuro-
ophthalmologists with expertise in optic disc evaluation who had graded them previously. 
Four grades (0=absent; 1=mild; 2=moderate and 3=marked) described the severity of 
papilloedema. Thus the maximal change in the study was three-grade change (optic disc 
oedema changing from marked to absent). Grade 0 was equivalent to Frisen Stage 0, grade 1 
to Frisen stages 1 and 2, grade 2 corresponded to Frisen stage 3 and grade 3 to Frisen stages 
4 and 5, with vascular changes disregarded in both schemes. The results of this study, 
including a mean weight loss of 6.2% amongst 10 patients with complete resolution of 
papilloedema and a significant correlation between percent weight lost and the 
papilloedema grade change, provided further support for the role of weight reduction in IIH. 
More recently, three papers have adopted the Frisen scheme as their sole measure of 
papilloedema in IIH. Celebisoy et al (2007) reported grades of 3, 4 or 5 amongst all of 40 
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patients at the initial visit of a treatment trial comparing acetazolamide with topiramate. 
Visual field grades were chosen as the main outcome for the study and no subsequent Frisen 
grades were reported in the results, although the mean treatment period before regression 
of papilloedema grades was quoted for each group. Shah et al (2008) used the mean Frisen 
grade, determined by a consensus of three independent neuro-ophthalmolgists’ evaluations 
of stereo disc photography, to illustrate the occurrence of delayed worsening in IIH during a 
ten year observation period, although they too opted for visual field defects and not 
papilloedema as the primary visual outcome. Most recently, Bruce et al (2009) systematically 
assessed disc photographs from over 600 patients with IIH and assigned a Frisen grade at the 
initial and last visits in a review spanning 18 years in three US centres. Whilst this study also 
omitted papilloedema grade as a major outcome measure, its use illustrates the increasing 
trend in IIH literature for including the Frisen scheme in its original, unmodified form.  
4.1.3 Evaluation of the Frisen Staging Scheme 
Using all combinations of the search terms “Frisen staging scheme”, “papilloedema 
classification”, “papilloedema grading” and “optic disc swelling” a formal search of all major 
online scientific databases was carried out. With the exception of the original paper, (Frisen, 
1982) there are no publications reporting the systematic assessment of the clinimetrics of 
the Frisen staging scheme. The high sensitivity (93-100%) and specificity (88-96%) values 
published by Frisen probably reflect the broad range of diagnoses in the study as well as the 
role of the author himself as one of the graders. Despite this, the scheme is now widely 
employed as a measure of papilloedema. Some studies report attempts to substantiate its 
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use through the inclusion of more than one observer to assign the staging, but these are in 
the minority. 
In a study examining the use of optical coherence tomography in papilloedema, Karam and 
Hedges (2005) used a modified version of the Frisen scheme to grade optic disc swelling in 
32 patients with mild papilloedema or congenitally crowded optic nerves and 17 normal 
subjects. Two observers, masked to patient histories, reviewed colour and red-free 
photographs after they were mixed and shown randomly, and identified each disc as either 
normal, congenitally crowded or papilloedematous. For the latter group, they assigned 
grades of disc swelling as normal or stages 0,1,2,3 or 4, according to descriptions provided. 
There was agreement over the identification of normal, crowded disc or papilloedema in 
68% (71 photographs). As in the original Frisen paper, most of the differences occurred in 
the differential diagnosis of crowded disc versus papilloedema. Agreement by stage of optic 
disc swelling was just 62% (64 photographs). Despite the observers reportedly having 
experience in the evaluation of optic discs, there was thus considerable inter-rater variability 
when applying a slightly modified Frisen classification. Furthermore, the study included 
fewer stages in total than the Frisen scheme. Stage 4 included all discs with more than 
moderate papilloedema, defined as ‘obvious, well established papilloedema with 
haemorrhages and exudates’ - additional features that are disregarded by the Frisen 
classification. The stage was therefore broader, encompassing a wider range of 
abnormalities than the original Frisen stages and should, in theory, have been easier for 
raters to reach agreement about. 
Not only has the Frisen scheme never been formally tested, the evaluation of optic disc 
appearances in IIH in general has not been subject to rigorous examination. Whilst the 
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importance of papilloedema in the clinical assessment of IIH is widely accepted, the 
determination of improvement or deterioration in papilloedema is usually the individual 
judgement of a sole clinician. Some measure of the variability of this subjective assessment 
would be of benefit, particularly in the interpretation of data from those studies in IIH with 
optic disc appearance as a key feature. 
 
4.2 Preliminary study of inter-rater variability in the 
assessment of papilloedema  
A pilot study was carried out in 2008, comparing the opinions of two consultant neuro-
ophthalmologists in the evaluation of papilloedema in IIH. The aim of the exercise was to 
investigate the feasibility of a larger study and to provide some indication of the inter-
observer variability that could be expected when photographs of a cohort of patients with 
IIH were assessed. 
4.2.1 Methods 
A selection of optic disc photographs from the patients enrolled in the IIH Trial Pilot was 
used for this study. Sets of two, three or four disc photographs were included, to give a total 
of 42 photographs from 12 patients. Within every set, each photograph showed the same 
eye (right or left) taken at a different time point in the trial. 
Photographs were labelled “Xn”, where X = patient identified by letter from A to R and n = 
number in sequence, i.e. 1, 2, 3 or 4. Although photographs were taken from patients at 
successive visits for the IIH Trial Pilot and were stored in chronological order, for the purpose 
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of this study they were presented to the raters in an order defined using a computer-
generated random list. 
Two senior neuro-ophthalmologists, with expertise in the assessment of optic discs as well 
as in the management of IIH, independently rated the photographs. Images were coded as 
above and presented as JPG files, viewed using Windows Photo Gallery© (Microsoft 
Corporation). The raters, who had no access to clinical information about the patients, were 
asked to consider two questions: 
1. Is there papilloedema - yes or no? 
2. For each set of photographs, in the order they are presented, is each disc better or 
worse than the preceding disc in terms of papilloedema severity?  
4.2.2 Results 
For question 1, a total of 42 discs were assessed by each rater for the presence of absence of 
papilloedema. The results of each assessment were then compared. Disagreement between 
the raters occurred in seven of the 42 comparisons. In two of these cases, the answer 
‘possible’ was given by one of the raters and ‘no’ (no papilloedema) by the other. The results 
are summarised in Table 4.4. 
For question 2, a total of 24 comparisons were made by the two raters. In eight out of 24 
cases there was disagreement between the raters as to whether the appearance of the disc 
was better or worse than the previous one. In two of these cases, one rater had assessed the 
disc as the same as the previous one. The results are shown in Table 4.5. 
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Table 4.4: Assessment of presence or absence of papilloedema 
Occurrences of disagreement between the two raters are highlighted in yellow 
 
 
 
Code  
 
1 2 3 4  
Papilloedema yes (Y)  or no (N) 
(Responses of rater 1 in blue, rater 2 
in green) 
No. of 
comparisons 
A 
Y Y Y Y  
Y Y Y Y 4 
B 
Y Y Y Y  
Y Y Y Y 4 
C 
Y Y Y Y  
Y Y Y Y 4 
D 
N Y Y   
Y Y Y  3 
E 
Y N Y Y  
Y N POSS Y 4 
G 
N Y N Y  
N Y N N 3 
J 
Y Y Y   
Y Y Y  3 
K 
Y Y Y Y  
Y Y Y Y 4 
L 
Y Y Y   
N Y Y N 3 
M 
Y N N Y  
Y Y POSS Y 4 
P 
Y N Y   
Y Y Y  3 
R 
Y Y    
Y Y   3 
    TOTAL 42 
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Table 4.5 Comparisons of papilloedema in successive disc photographs 
 
Code  
 
1 2 3 
No. of 
comparisons 
Appearance worse (W) or better (B)?  
(Responses of rater 1 in blue, rater 2 in green) 
B 
B W W  
B W W 3 
D 
W B   
W SAME  2 
E 
B W B  
B B B 3 
H 
W B   
W W  2 
J 
W B   
B B  2 
K 
W B B  
W W B 3 
L 
B W B  
W W SAME 3 
M 
B B W  
B B B 3 
P 
B W   
B W  2 
R 
B    
B   1 
TOTAL 24 
 
 
In the first part of the exercise, the presence or absence of papilloedema, there was a crude 
rate of 85.7% agreement between the two raters. In the second part, the rate of agreement 
over the assessment of papilloedema as worse or better was only 66.7%. Thus in one third of 
cases, there was discrepancy between the two raters. 
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4.2.3 Discussion 
This small scale pilot demonstrates the importance of considering inter-rater reliability in the 
assessment of papilloedema in IIH. In a simple exercise in which two senior neuro-
ophthalmologists, from the same UK specialist centre, were presented with sets of disc 
photographs from a cohort of patients with IIH under identical conditions, rates of 
disagreement reached 33%. Whilst interpretation of the results of this exercise is limited by 
the small sample size, low number of raters and lack of a repeat assessment to exclude intra-
rater variability, the findings raise questions regarding the methods of papilloedema grading 
used in larger studies. 
There was greater agreement over the presence or absence of papilloedema (85.7%) than 
the determination of papilloedema status as better or worse (66.7%). It would seem 
reasonable from this finding to predict even greater levels of inter-rater variability in the 
assignment of grades of papilloedema, such as those described in the Frisen scheme, for 
which there are six possible options. 
Since the Frisen scheme appears currently to be the favoured method for describing 
papilloedema in world IIH literature, further assessment of its performance as a measure in 
the condition is warranted. 
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4.3 Assessment of Papilloedema and the Frisen Scheme in IIH: 
The Blinded Disc Rating Study 
In an attempt to shed further light on the applicability of the Frisen scheme for grading 
papilloedema in patients with IIH, a study of ‘blinded rating’ of a collection of disc 
photographs was conducted. The aim of the study was to estimate the inter-rater reliability 
of the Frisen scheme and investigate its use when comparing the papilloedema of IIH at 
different points in the clinical course of the disease. The sensitivity of the Frisen grading in 
IIH was explored. The hypothesis that changes in disc appearance could be recognised 
between discs assigned the same Frisen grade was tested.  
4.3.1 Methods 
Disc photographs were collected from 25 patients with newly diagnosed (acute) IIH and 22 
patients with chronic IIH. Photographs were collected at two time points from each 
participant. In the case of the newly diagnosed IIH patients, photographs were collected on 
entry to and at the final 12-month visit of the IIH Trial Pilot. The chronic IIH patient cohort 
had photographs taken prior to and upon completion of a three month period of an 
intensive very low calorie total meal replacement diet, as part of a prospective evaluation of 
the effect of weight loss in IIH.(Sinclair et al., 2009) Thus, a participant had optic disc 
photography before and after a period of therapeutic intervention for IIH. Photographs were 
taken within the same ophthalmology department using the same equipment. All patients 
had pupils dilated. 
All photographs were assigned a computer-generated, random numerical code known only 
to the investigators. Photographs of each eye from each patient, before and after treatment, 
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were kept in pairs, in folders also assigned random numerical codes. The folders were then 
arranged in a random sequence. The ‘blinded rating’ was performed by clinicians with 
expertise in optic disc evaluation: three consultants and one fellow in neuro-ophthalmology 
and two consultant neurologists with special interest in neuro-ophthalmology. The six 
observers, blinded to the identity of the patient and all clinical information, examined the 
paired photographs using Windows Photo Gallery© (Microsoft Corporation), on separate 
occasions and without conferring. The status of the therapeutic intervention (before or after 
intervention) was also masked for each photograph. Each observer assigned a Frisen grade 
to each disc photograph, using guidance from standard descriptions and photographic 
examples. In addition, observers were asked to compare the severity of papilloedema 
between pairs of photographs. For each pair, observers were asked to state which one 
showed the least severe disc swelling, or whether they appeared the same. This produced a 
ranking of the appearance of the discs in each pair. 
To examine the agreement between observers, results of the Frisen grading were analysed 
for all possible pairings of the six observers, totalling 15 possible combinations of observers. 
This permitted calculation of probabilities of the assigned Frisen grades being the same, or 
differing by one, two, three, four or five grades.  
The results of ranking pairs of discs were analysed in a similar way. The rankings from two 
observers on any given pair of disc were compared and three codes assigned to the result as 
follows: Code “0” if both observers gave the same result, code “1” if one observer assessed 
the photographs as the same, but the other observer ranked one as showing less 
papilloedema than the other and code “2” if both observers ranked the photographs 
differently (one observer chose one photograph as showing the least papilloedema and one 
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chose the other photograph). This can be summarised as: 0 = both observers agree, 1 = 
‘minor’ disagreement, 2 = ‘maximum disagreement’. By analysing the results in this way for 
all possible combination of pairs of observers, probabilities for each code were calculated. 
The assigned Frisen grades were then compared to the ranking for each pair of photographs, 
to explore the agreement between the two methods. For this, all photographs were 
analysed in the same chronological order. Assigned Frisen grades were examined for each 
pair and coded as “F0” if the first photograph had the lower Frisen grade, “F1” if both 
photographs had the same Frisen grade or “F2” if the second photograph had the lower 
Frisen grade. A similar code was applied to the ranking data, (code “R0” if the first 
photograph of the pair was ranked as having less severe papilloedema, “R1” if photographs 
were judged to be the same and “R2” if the second photograph was ranked as having the 
less severe papilloedema.) The coding systems were compared and a final ‘agreement’ code 
applied to each pair of photographs, where the three options were complete agreement (F 
and R codes numerically the same, code A0), minor disagreement (F and R codes differed by 
1, code A1) or maximum disagreement (F and R codes differed by 2, code A2). 
An evaluation of the sensitivity of the two methods was obtained by examining whether the 
Frisen grading and the ranking method used by each of the six observers detected a 
difference between a given pair of photographs. The number of times that the Frisen grading 
showed a difference was compared to the number of times the rating showed a difference, 
for the 94 pairs of photographs. 
Results were analysed for the whole cohort, as well as separately for patients with acute and 
chronic IIH. For the acute cohort only, the original identifications of the photographs were 
used to match the assigned Frisen grade and ranking with the assessment of disc status 
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performed as part of the IIH Trial. This allowed comparison between the blinded rating and 
the assessment of optic disc status at the final visit of the trial. 
4.3.1.1 Statistical analysis 
Statistical analyses were performed using SPSS 17.0 (Statistical Package for Social Sciences, 
SPSS Inc., Chicago, IL.) Continuous variables were analysed using descriptive statistics. 
Dichotomous variables were compared using the Sign test. The degree of agreement 
between rankings was calculated using Kendall’s tau-b statistic. Significance was set at 0.05.  
4.3.2 Results 
Photographs from each eye of 47 patients, before and after therapeutic intervention, were 
included. Thus a total of 188 photographs were assessed by each of the six observers. 
Results were collated onto a single spreadsheet. A section of the spreadsheet showing 
results for the first ten pairs of photographs is shown in figure 4.1. Additional columns in the 
spreadsheet were created from the comparison of results between pairs of observers. To 
demonstrate how the various analyses were performed, figure 4.2 shows a worked example 
from the results of two observers on one pair of disc photographs. 
Ob1 Ob2 Ob3 Ob4 Ob5 Ob6 Ob1 Ob2 Ob3 Ob4 Ob5 Ob6 Ob1 Ob2 Ob3 Ob4 Ob5 Ob6
446 1 0 1 1 1 1 470 0 0 0 0 0 1 470 470 470 470 470 470
443 0 1 1 2 2 1 461 0 1 1 1 2 1 S 461 461 461 461 S
441 5 4 3 4 4 3 424 0 0 1 1 0 1 424 424 424 424 424 424
404 4 2 3 4 4 3 450 3 1 2 4 3 2 450 450 450 450 450 450
437 3 1 2 3 4 2 490 2 1 2 3 4 2 490 S 437 S 490 490
484 4 1 2 4 4 2 475 3 1 1 4 4 2 475 475 475 475 475 475
416 5 4 4 4 4 4 440 1 0 1 1 1 1 440 440 440 440 440 440
494 4 1 3 3 4 2 468 3 1 1 3 1 2 468 468 468 468 468 468
435 2 1 1 2 2 2 411 0 0 0 0 0 0 411 411 411 411 411 411
420 5 2 3 4 4 3 402 2 1 1 1 2 2 402 402 402 402 402 402
Photo 
Code
Photo 
Code
Rank: Photo with least papilloedema 
or S if same
Frisen Grade AssignedFrisen Grade Assigned
 
 
Figure 4.1: Section of results spreadsheet showing sets of results for ten pairs of photographs. 
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 Ob1 = results from observer 1, Ob2 = observer 2 etc. 
  
 
 
Results of Observer 1: Frisen Grades: 443=Grade 0, 461=Grade 0. Ranked discs as same. 
Results of Observer 2: Frisen Grades: 443=Grade 1, 461=Grade 1. Ranked photo 461 as the disc with 
the least papilloedema. 
 
Difference between assigned Frisen grade:  
Photo 443: grade 0 (observer 1) compared to grade 1 (observer 2) = difference of 1 grade 
Photo 461: grade 0 (observer 1) compared to grade 0 (observer 2) = difference of 1 grade  
 
Difference between assigned Rank: Observer 1 ranked discs as same, Observer 2 selected photo 461 
as showing the least papilloedema. Ranking code therefore = 1 (Minor disagreement). 
 
Agreement between Frisen and Ranking:  
Discs are considered in same chronological order, photo 443 then photo 461. 
Observer 1 gave the first disc, photo 443, the same Frisen grade as the second disc, photo 461. 
This result is assigned the code F1. 
Observer 1 ranked the photos as the same. This result is assigned the code R1. 
Observer 2 gave the first disc, photo 443, the same Frisen grade as the second disc, photo 461. 
This result is assigned the code F1. 
Observer 2 ranked the second disc, photo 461, as showing the least papilloedema. This is assigned 
the code R2. 
 
The agreement between the Frisen and Ranking methods are as follows. 
For Observer 1, F1 and R1 are numerically the same, so agreement code is A0 (Complete agreement) 
For Observer 2, F1 and R2 is a difference of 1, so agreement code is A1 (Minor disagreement) 
 
Sensitivity: 
Observer 1: Frisen grade same, ranking result same. Sensitivity of two methods appears equal. 
Observer 2: Frisen grade same, ranking result different. Ranking appears more sensitive. 
 
 
Figure 4.2: Example of analysis applied to results for one pair of photographs by two observers 
Photo 443 Photo 461 
461 
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4.3.2.1 Frisen Grading 
All six Frisen grades were identified, with different frequencies. The frequency of assignment 
of each grade is shown in figure 4.3. Grades 1 and 2 were observed most often, in both the 
acute and chronic cohort. Only 16 instances of Frisen grade 5 occurred (1.4%), 12 in the 
acute and four in the chronic patient group. 
  
Figure 4.3: Distribution of Frisen Grades assigned by six raters by IIH cohort 
 
There were only three instances of total agreement about the assigned Frisen grade 
amongst the six observers, out of a possible 188 (1.6%). In two cases, the agreed grade was 
1, in one case grade 0. There were a total of 16 out of 188 instances (8.5%) in which five of 
the six observers agreed about the Frisen grade. 
Agreement over the assigned Frisen grade between pairs of observers is shown in table 4.6. 
For the whole patient cohort, the number of instances where there was total agreement 
between pairs of raters was 1019 from a total of 2820 possible comparisons, thus the 
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probability of agreement was 36.1%. In contrast, there were only two instances of a 
difference of five Frisen grades between two raters (probability 0.1%). There was no 
difference between the results when acute and chronic cases were considered separately 
(Kendall’s tau-b statistic 0.016, p=0.360).) 
Table 4.6: Inter-observer variability in Frisen grading 
Difference between assigned 
Frisen grade 
Number of instances (%) 
All cases Acute cohort Chronic cohort 
0 1019 (36.1) 545 (36.3) 474 (35.9) 
1 1288 (45.7) 696 (46.4) 592 (44.8) 
2 429 (15.2) 225 (15) 204 (15.5) 
3 71 (2.5) 33 (2.2) 38 (2.9) 
4 11 (0.4) 1 (0.1) 10 (0.8) 
5 2 (0.1) 0(0) 2 (0.2) 
 
To examine where in the Frisen grading scale the differences were seen, the maximum 
assigned Frisen grades were compared with the minimum grades by cross tabulation as 
shown in table 4.7. For example, there were 27 occurrences of the difference being between 
grades 4 and 5, compared with 364 instances of the assigned grades being 0 and 1. 
Table 4.7: Instances of differences between Frisen grades 
  Maximum Frisen Grade 
M
in
im
u
m
 F
ri
se
n
 G
ra
d
e 
 0 1 2 3 4 5 
0 157 364 124 23 8 2 
1  373 449 104 39 3 
2   312 299 170 9 
3    107 149 31 
4     66 27 
5      4 
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4.3.2.2 Ranking 
There were 40 instances of total agreement between the six observers when ranking the 
pairs of photographs according to which one had the least papilloedema, from a total of 94 
comparisons (42.5%).  
Agreement between pairs of observers, when all possible combinations were analysed, is 
shown in table 4.8. Amongst the whole cohort, the probability of agreement between raters 
was 71.7%. The probability of one observer judging the degree of disc swelling to be the 
same and one ranking the photographs as different was 24.9%. 
Table 4.8: Agreement in ranking between pairs of observers  
 Number of instances (%) 
Ranking code All   Acute Chronic 
0 (both raters agree) 994 (71.7) 652 (87.4) 342 (52.4) 
1 (minor disagreement) 349 (24.9) 85 (11.4) 264 (40.4) 
2 (maximum disagreement) 56 (4.0) 9 (1.2) 47 (7.2) 
 
There was a significant difference between the acute and chronic cases when photographs 
were ranked in this way. Disagreement between observers was significantly more common 
amongst the chronic cohort than the acute (Kendall’s tau-b 0.380, p<0.001.) 
 
4.3.2.3 Agreement between Frisen grading and ranking 
Table 4.9 shows the results of the comparisons of Frisen grading and ranking. There were 
only two instances of ‘maximum disagreement’ (Code A2) between the two methods. One 
instance occurred amongst the acute cohort and one, the chronic IIH cohort. In both cases, 
one photograph had been assigned a higher (worse) Frisen grade, yet been ranked as the 
 216 
 
disc with the least papilloedema. The number of instances of complete agreement between 
the Frisen grading and the ranking was 437 from a total of 563 (77.6%).  
Table 4.9: Agreement between Frisen grade and rank 
Frisen v Rank 
Agreement Code 
Number of Instances (%) 
All Acute Chronic 
A0: Complete 
agreement 
437 (77.6) 248 (82.7) 189 (71.9) 
A1: Minor 
disagreement 
124 (22.0) 51 (17.0) 73 (27.8) 
A2: Complete 
disagreement 
2 (0.4) 1 (0.3) 1 (0.4) 
 
Amongst all comparisons, a difference in the ranking when there was no difference in the 
assigned Frisen grades occurred in 22%. When acute and chronic cases were analysed 
separately, the frequencies were 17% and 27.8% respectively. There was a significant 
difference in agreement of the Frisen grading and ranking between the acute and chronic 
cases. Disagreement was significantly more common amongst the chronic than the acute 
cohorts (Kendall’s tau = 0.129, p=0.002.) On each occasion of ‘minor disagreement’, the 
difference was in the rank and not in the assigned Frisen grade. 
4.3.2.4 Comparison of Sensitivities between Frisen and ranking 
The comparisons between Frisen grading and ranking in the detection of a difference 
between pairs of photographs are summarised in table 4.10. The assigned Frisen grade was 
the same in 46.8% of all patients, compared with ranking which was the same in only 24.8%. 
Ranking of the disc (as ‘same’ or ‘different’) was significantly more likely to detect a 
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difference than assigning a Frisen grade (p<0.001). This was the case when acute and chronic 
cases were analysed separately (both p<0.001).  
Table 4.10: Comparison between Frisen grading and ranking in the identification of difference 
between pairs of photographs by all observers 
  Number (%) 
  All Acute Chronic 
Frisen 
Same 264 (46.8) 82 (27.3) 182 (68.9) 
Different 300 (53.2) 218 (72.7) 82 (31.1) 
Rank 
Same 140 (24.8) 31 (10.3) 108 (40.9) 
Different 424 (75.2) 269 (89.7) 156(59.1) 
   
The assigned Frisen grades and the rank were more likely to be the same amongst the 
chronic than the acute cohort. The Frisen grade was different in 72.7% of acute, but only 
31.1% of chronic cases. This difference was significant (Kendall’s tau-b statistic =-0.565, 
p<0.001.) There was also a significant difference in the ranking between acute and chronic 
cases, where 89.7% of acute cases but only 59.1% of chronic cases were different (Kendall’s 
tau-b statistic =-0.525, p<0.001.) 
 
4.3.2.5 Comparison of blinded rating with IIH Trial Results 
In the case of 24 pairs of photographs, data was available from the IIH Trial for comparison.  
The presence or absence of papilloedema was documented at each trial visit. All of the 24 
patients were recorded as having papilloedema at the start of the trial. Analysis of assigned 
Frisen grades by all six observers to disc photographs from the start of the trial is 
summarised in figure 4.4. There were 15 instances (5.2%) of a Frisen grading of 0 (normal 
disc appearance) overall despite all patients reportedly having papilloedema. 
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Figure 4.4: Frisen grades assigned by six blinded observers to disc photographs from 24 patients in 
the IIH Trial Pilot taken at the baseline trial visit 
 
 
Amongst the photographs from the final visit of the trial, there were six from patients 
recorded as having no papilloedema and 18 from patients with papilloedema present at that 
visit. In the group recorded as having no papilloedema, no photographs were assigned Frisen 
grades of 3, 4 or 5. Equal numbers were assigned grades 0 and 1 (both 45.8%) and the 
remainder (8.3%) grade 2. In the group recorded as having papilloedema present, a Frisen 
grade of 0 was assigned in 19.9% of cases. The distribution of assigned Frisen grades is 
shown in figure 4.5. 
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Figure 4.5:  Frequencies of Frisen grades assigned by six observers to disc photographs by presence 
or absence of papilloedema as recorded at the IIH Trial final visit. 
 
The Frisen grades assigned by all six raters to the photographs taken at the final visit of the 
IIH Trial were then compared to the assigned ‘final optic disc status’ as recorded at the end 
of the trial. Table 4.11 shows the distribution of the Frisen grades in the three categories of 
disc status, ‘normal’, ‘abnormal, stable’ and ‘deteriorating’. No observer assigned a Frisen 
grade of 5 to any disc and no discs in the ‘deteriorating’ category had a Frisen grade of 0.  
Table 4.11:  Frequencies of assigned Frisen grades in blinded rater study grouped by assigned final 
disc status in IIH Trial Pilot 
  Assigned Frisen Grade  
  
0 1 2 3 4 5 
(Total 
number) 
Fi
n
al
 D
is
c 
St
at
u
s 
Normal 32 43 27 6 0 0 (108) 
Abnormal, stable 44 64 35 8 5 0 (156) 
Deteriorating 0 4 6 10 4 0 (24) 
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The mean Frisen grade assigned by the six observers was calculated for each category of 
final disc status, ‘normal’, ‘abnormal, stable’ and ‘deteriorating’. The mean Frisen grades in 
the ‘normal’, ‘abnormal, stable’ and ‘deteriorating’ categories were 1.1, 1.1 and 2.6, as 
shown in figure 4.6. When all results were analysed by category, there was no difference 
between the mean Frisen grades in the ‘normal’ and ‘abnormal, stable’ categories (p=0.78). 
The mean values in the ‘deteriorating’ category were significantly higher than those in 
categories ‘normal’ (p=0.002) and ‘abnormal, stable’ (p=0.005). Analysis of left and right eyes 
separately did not change the results significantly. 
  
Figure 4.6: Scatter plot showing mean Frisen grades from blinded rating in the three categories of 
assigned optic disc status from the IIH Trial Pilot. The mean value in each group is shown in red. 
 
The ranking of the photographs was compared to the assigned final disc status from the IIH 
trial. Only two of the 24 pairs of photographs were from patients whose discs were assessed 
in the trial as ‘deteriorating’ at the final visit. In one case, all six raters selected the 
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photograph from the baseline visit as showing the better appearance (least papilloedema), 
for both right and left eyes, in keeping with deterioration. All six raters also gave a higher 
(worse) Frisen grade to the photograph from the final visit, by at least one grade, with the 
exception of two instances for the right eye (16.7%).  For the second patient, the results 
were more surprising; all six raters chose the photograph from the final visit as showing the 
better appearance (both eyes) and most of the assigned Frisen grades showed improvement 
(in the right eye, five improved and one was unchanged, in the left eye also five improved 
and one was unchanged). Thus the blinded rating suggested improvement over the 12-
month period despite the assessment of the disc in the IIH Trial as ‘deteriorating’. The disc 
photographs with their assigned Frisen grading are shown in figure 4.7.  
To explore this finding, data from the IIH trial for the patient in question was examined. The 
Humphrey visual field MD values at baseline were -7.39 (left) and -4.12 (right). At the final 
visit the values had improved, to -4.39 (left) and -2.15 (right). Visual acuity was unchanged 
between visits. The headache score had worsened, from 6 at baseline to 9 at the final visit 
and tinnitus as well as headache status were described as ‘deteriorating’ at the final visit, 
when the overall IIH status was also recorded as ‘active IIH deteriorating’.  
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Baseline visit, left eye: 
Assigned Frisen grades 2,3,3,4,4 and 4 
 mean = 3.3 
Baseline visit, right eye: 
Assigned Frisen grades 1,2,3,3,4 and 4 
 mean = 2.8 
  
Final visit, left eye: 
Assigned Frisen grades 1,2,2,3,3 and 4, 
mean = 2.5 
Final visit, right eye: 
Assigned Frisen grades 1,1,1,2,3 and 3 
mean = 1.8 
Figure 4.7: Optic disc photographs from one patient in the IIH Trial Pilot as included in the blinded 
rater study, showing the assigned Frisen grades by the six observers 
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4.3.3 Discussion 
4.3.3.1 Inter-rater variability 
In this study, complete agreement between six observers over the assigned Frisen grades of 
188 photographs occurred in just 1.6%. The probability of two raters agreeing completely, a 
measure of the inter-rater reliability, was only 36.1%. Any two raters were more likely to 
disagree by one grade (probability 45.7%). There was thus high variability between the 
observers, with probability of disagreement by at least one Frisen grade of 63.9%.  
The greatest variability occurred amongst the lowest Frisen grades (0-2). Interestingly, the 
inter-observer reliability of Frisen grading was equivalent when cases were separated into 
acute and chronic cohorts (probabilities of same grade assigned 36.3% and 35.9% 
respectively, p=0.360). This is reflected in the spread of Frisen grades within the two cohorts 
(Figure 1). 
In the original paper by Frisen, (1982) three observers reached exact agreement about the 
Frisen grade in 49% of 78 photographic slides. In the study by Karam and Hedges, (2005) two 
observers reached agreement over the grade in 62% of 104 photographs. The patient groups 
in both studies were heterogeneous. No study has evaluated the Frisen staging scheme in 
IIH. 
The method of ranking the discs showed greater agreement between observers. Complete 
agreement was seen in 42.5% and inter-rater reliability was 71.7%. The effect of the number 
of options within each system (six possible Frisen grades but only three choices for ranking) 
is likely to contribute to this finding, although it is difficult to quantify. 
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4.3.3.2 Sensitivity 
Ranking disc photographs according to the severity of papilloedema appears to be more 
sensitive than relying on Frisen grades to detect a difference. The ranking method identified 
a difference in 75.2% of photographs compared to 53.2% detected by the Frisen grading, an 
increase of 22%. This difference was even more pronounced amongst the chronic IIH cohort 
(27.8% compared to 17.0% difference in acute cases.) When Frisen grading and ranking were 
compared, ‘minor disagreement’ (Code A1) always described a situation in which the Frisen 
grade remained the same, but a difference was observed in the ranking, (22.0% of cases). 
The situation of a pair of photographs being assigned different Frisen grades yet not ranked 
in severity did not occur. The two instances of ‘maximum disagreement’ (Code A2) between 
the Frisen grading and the ranking (one photograph assigned a higher Frisen grade, yet 
ranked as the disc with least papilloedema) are likely to represent observer error. 
The assessment of papilloedema in IIH appears to be affected by the duration of the disease. 
There was a significant difference in the sensitivity of both methods of assessing disc 
appearance between acute and chronic IIH cases, such that both Frisen grading and ranking 
had greater sensitivity amongst the acute cohort (both p<0.001). This contrasts with the 
inter-observer variability of the two methods, which was affected differently by the disease 
chronicity. Whilst there was no difference in the inter-observer variability of Frisen grading 
between the acute and chronic cases (p=0.360), there was a greater degree of variability 
amongst the chronic cases than the acute cohort when ranking the photographs. The 
probability of any two observers agreeing was 87.4% in the acute cases, but only 52.4% in 
the chronic IIH cases and the difference was significant (p<0.001). 
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4.3.3.3 IIH Trial Data Comparisons 
Comparison between the Frisen grading system and the assessment of papilloedema in the 
IIH Trial revealed marked inconsistencies. A Frisen grade of 0, describing normal optic discs, 
was assigned to discs recorded as having papilloedema in 5.2% of instances at the initial trial 
visit and 19.9% of instances at the final (12-month) visit. Similarly, amongst patients 
recorded as having no papilloedema at the final visit, grades other than 0 were assigned in 
over half of instances (54.1%). 
In addition, when the subjective assessments of optic discs in the IIH Trial Pilot  were 
compared with the results of the blinded rating, only 29.6% of discs assigned a final status of 
‘normal’ had a Frisen grade of 0. The assigned Frisen grade did not discriminate between 
discs in the categories of ‘normal’ and ‘abnormal, stable’. Discs assessed as ‘deteriorating’ in 
the trial did have a significantly higher mean Frisen grade, although numbers were too small 
to draw meaningful conclusions (n=4).  
Possible explanations exist for these findings. First, the IIH Trial considered disc status as 
applicable to both eyes, where the blinded rating assessed left and right eyes separately. In 
the IIH Trial, ‘papilloedema present’ could refer to a case of asymmetrical or unilateral 
papilloedema, such that Frisen grade for each eye could vary considerably and include grade 
0 for one eye. The assigned status of ‘normal’ optic disc status in the IIH trial could be 
applied to eyes which had no signs of active papilloedema, but whose photographs showed 
some degree of abnormality such that a Frisen grade of 0 was not appropriate. Longstanding 
papilloedema results in changes to the optic disc that are not fully reversible.(Acheson, 
2006) Markers of chronicity include disc pallor, choroido-retinal collateral blood vessels and 
axonal degradation products on the optic nerve head (corpora amylacea). (Sanders, 1997) 
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Such changes are not accommodated within the Frisen staging scheme, designed to describe 
disc swelling during its development. Clinical experience suggests that a majority of patients 
with longstanding IIH have optic disc appearances that never return to a truly ‘normal’ state 
as described by Frisen grade 0. 
Further comparison between the assessment of papilloedema in the IIH Trial and that of the 
blinded rating study data is limited by the marked differences in the methods. The IIH trial 
required a subjective assessment at the final trial visit, based on the three-dimensional 
appearance of the optic discs on slit lamp examination. The assessing clinician had access to 
clinical information to inform his or her judgment, including other tests of visual function 
that would bias the conclusion reached. In contrast, the blinded rating study involved 
assessment of a single, two-dimensional disc photograph with no clinical information 
provided.  
There are other limitations to this study. Stereoscopic retinal photography was not available 
and the images obtained were two-dimensional, although this was also the case in the 
original description and validation of the Frisen scheme. In normal practice, the assessing 
clinician uses a slit lamp to obtain a highly magnified, three-dimensional view of the retina, 
allowing additional features not captured by the Frisen scheme to be appreciated. The need 
for blinding or masking of clinical information precludes the use of slit lamp examination in 
most clinical trials so a comprehensive descriptor of the features and severity of 
papilloedema in IIH is required.  
The observers performed the assessment of the discs on a single occasion in this study, so no 
measure of intra-rater reliability could be made. This was for practical considerations due to 
the time-consuming nature of the assessments (188 photographs for each observer to 
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examine, grade and compare in pairs). Fatigue amongst observers could have led to an error 
rate which is difficult to quantify. It is also impossible to draw firm conclusions from this 
study about the optimum number of observers to recommend for future similar studies. 
4.3.3.4 Recommendations 
Given the limitations of the Frisen scheme, there is a need for a novel classification of 
papilloedema that would encompass most of the changes seen in IIH, including those that 
occur in chronic forms of the disease. In order for such a scheme to be included in pragmatic 
trials, it would need to have high reliability and sensitivity as well as reproducibility. Any 
alternative grading scheme proposed for the evaluation of papilloedema in IIH would require 
rigorous testing to address this. 
 Each grade would require a clear illustration of the key features. Categories of the 
classification would need to reflect the subtle changes seen in longstanding IIH and allow for 
additional features such as haemorrhages to be commented upon. Johnson et al(Johnson et 
al., 1998) used photographic ‘gold standards’ for their assessment of papilloedema in the 
study exploring weight loss and acetazolamide treatment in IIH. However, the disc 
photographs they used were not exclusively from patients with IIH and they adopted a four-
grade system based on the Frisen scheme, with no allowance for the changes of 
longstanding disc swelling or clinical improvement. It is feasible that future studies could 
explore the development of an agreed set of standard photographic examples of 
papilloedema in IIH, including examples of discs exhibiting the residual changes of treated 
disease.  
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More objective assessments of papilloedema such as optical coherence tomography (OCT) 
and confocal scanning laser ophthalmoscopy (SLO) should be further explored in IIH. Case 
reports and small studies have shown that OCT demonstrates measurable differences in the 
retinal nerve fibre layer that can relate to papilloedema severity as measured clinically. 
(Hudson et al., 1995; Karam and Hedges, 2005) Mulholland et al (1998) carried out a study in 
which confocal SLO was used to assess papilloedema in eight patients with IIH. Cases of 
acute, chronic and recurrent disease were included and the sensitivity of the method was 
clearly demonstrated. The volumes of optic disc swelling were significantly different 
between the left and right eyes despite the Frisen grading showing no difference, in all 
cases. SLO was also shown to correlate closely with changes in Humphrey visual field mean 
deviation in the early stages of acute disease and to demonstrate the effect of treatment by 
detecting stable, decreasing or increasing disc volume. However, the degree of disc swelling 
was not related to the visual function in established disease. Decreasing volume may 
indicate resolution of papilloedema, but is also seen in secondary optic atrophy, so other 
measures of visual function remain important. Despite the accuracy of measures of optic 
disc volume such as SLO and OCT, they cannot be relied upon to fully evaluate papilloedema 
in IIH. In addition, the availability of the techniques is currently restricted to specialist 
centres. Nevertheless, such techniques may have important roles in future clinical trials.  
This study provides evidence that the Frisen staging scheme is insufficiently sensitive, 
specific and reliable to justify its use as a major outcome measure in trials of IIH. Alternative 
grading schemes should be sought and evaluated. Until such alternatives are defined, 
comparison or ranking of discs according to the degree and severity of papilloedema appears 
to be a better tool in the evaluation of IIH. Whilst such an approach is simplistic and 
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subjective, its demonstrated greater sensitivity to change and inter-rater reliability has much 
to recommend it as an alternative to the Frisen scheme.  
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CHAPTER 5  CONCLUSIONS 
 
Since its original description over 100 years ago, uncertainty has surrounded the condition of 
idiopathic intracranial hypertension. Even the diagnostic criteria are contentious: whilst 
many clinicians and researchers adhere to the modern ‘strict’ criteria of raised intracranial 
pressure for which no cause can be identified, in keeping with the term idiopathic, there are 
supporters of a broader terminology, in which the diagnosis of pseudotumour syndrome 
allows for the inclusion of conditions where some identified factor, such as venous sinus 
thrombosis or medication, is the cause of the raised pressure. There is convincing evidence 
that truly idiopathic IIH is a discrete clinical entity, affecting overweight, young to middle age 
females in the great majority of cases. Why IIH occurs at all amongst less typical groups, such 
as males and young children, remains unclear, but these patients in particular warrant 
exhaustive investigation to exclude an alternative cause of their elevated pressure. The 
exclusion of occult cerebral venous sinus thrombosis by the most sensitive imaging modality 
available is mandatory in all cases. Screening for anaemia is recommended due to its 
common occurrence and the clinical improvement that results from its correction. (Mollan et 
al., 2009) 
5.1 Obesity and IIH Pathogenesis 
The high prevalence of obesity in IIH has greatly influenced the direction of attempts to 
discover its cause as well as to determine successful management strategies. The association 
of IIH with female gender and obesity is robust and widely accepted. Using this association 
as the basis for aetiological studies has yielded promising results, despite failing to explain 
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the occurrence of the condition in other patient groups. The finding of elevated leptin in the 
CSF of a cohort of female patients, described in chapter 2, provides a promising link between 
the inflammatory state of obesity and IIH. The fact that the actions of leptin are influenced 
by gender adds strength to the theory that this adipokine has a role in IIH pathogenesis. The 
case for dysregulation of leptin at the level of the hypothalamic receptors playing a key role 
is supported. An alternative hypothesis, that leptin dysregulation in IIH actually causes or 
potentiates the obesity in IIH is worthy of consideration.  
The finding of significantly elevated CSF leptin as well as its non-linear relationship with BMI 
and CSF pressure amongst patients with IIH should firstly be confirmed in larger cohorts of 
human subjects, although such studies are restricted by the ethics of obtaining CSF samples 
from healthy overweight controls. Exploration of leptin action at the cellular level, in 
structures likely to be related to IIH pathogenesis, would be of value. Reduced absorption of 
the CSF appears to be the most plausible of the mechanisms to explain the elevated 
pressure, but most data so far has been from animal studies. The actions of peptide 
molecules and their receptors at the arachnoid granulations are largely unknown. Studies 
using human tissue from post mortem examinations are needed to determine whether 
impairment of arachnoid function or metabolic failure of transport across the arachnoid-
endothelial barrier underlies the disease process in IIH. Arachnoid granulations would seem 
an appropriate initial target for histochemical studies, which should include investigation of 
the actions of leptin. 
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5.2 Management of IIH 
The optimum management of IIH is almost as widely debated as its underlying cause. 
Consensus has been reached over the need for careful monitoring of visual function in light 
of the established occurrence of blindness in the condition, albeit infrequently. The use of 
perimetry in identifying visual dysfunction has also been widely adopted in routine clinical 
practice. How to identify patients at greatest risk of visual loss and how best to treat them 
remains undetermined and the need for evidence from well designed clinical trials is 
universally acknowledged.  
The IIH Trial Pilot, reported in chapter 3, highlights the practical difficulties of conducting 
randomised, controlled trials in the condition. IIH is not uncommon and the rising prevalence 
of obesity suggests the incidence will increase. Nevertheless, recruitment of 50 patients 
from five centres in this trial took almost two years. A sample size of around 300 patients 
would be required for a substantive trial using similar outcome measures, so extended 
recruitment periods or expansion to multiple centres would need to be undertaken. No 
patient in the pilot became blind and only two of the 50 patients required surgical 
intervention. To detect treatment effects upon meaningful outcomes, such as blindness, 
significant visual loss or need for surgery, would require even greater numbers of subjects. 
The patients recruited in this pilot under-represent those with the greatest threat of 
blindness and instead tended to include patients with a mild, self- limiting course 
irrespective of intervention. One concern with the findings of this trial would be the 
implication that IIH is always a benign condition, thus relaxing the approach of clinicians in 
monitoring vision. In fact, the lack of clear markers of impending visual damage in IIH 
demands even greater vigilance amongst neuro-ophthalmologists, since patients lose vision 
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unpredictably and often when exhibiting very few symptoms or signs. Future IIH trials must 
strive to focus on the management of more aggressive disease. The concept of randomised 
controlled trials comparing optic nerve sheath fenestration with CSF diversion procedures, 
or comparing ventriculoperitoneal with lumboperitoneal shunts are enticing, but practical 
difficulties of low patient numbers and local preferences for certain procedures limit the 
likelihood of such trials going ahead. Patients would be unlikely to consent to join trials in 
which the choice between two such different procedures was left to chance. Pragmatic 
solutions must be found to ensure that trials are large enough for robust conclusions to be 
drawn, yet capture patients with more severe disease, whose course is most likely to be 
influenced by treatment. 
The prescription of acetazolamide in IIH should be questioned. There have been no 
prospective, randomised controlled trials to justify its widespread use. Whilst not powered 
to show a treatment effect, the IIH Trial Pilot showed that the drug was poorly tolerated or 
that patients were disinclined to take it. Again, the bias towards milder disease limits the 
wider applicability of this observation and the lack of use of placebo in the trial can be 
criticised. There was a trend towards greater weight reduction amongst the patients 
allocated to receive acetazolamide and it is known to affect taste. It is feasible that some of 
its apparent effect in IIH is exerted via appetite suppression or dietary modification resulting 
in weight loss.  
Although the final outcome was not observed to be influenced by weight loss in this pilot 
study, there is growing evidence in the literature to suggest that weight reduction is a key 
component of IIH management. (Johnson et al., 1997; Sinclair et al., 2009) Future trials 
amongst patients with milder or chronic forms of IIH would seem to be more appropriately 
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focussed on careful assessment of the effect of weight reduction than that of acetazolamide 
or other diuretics. It would be unethical to design trials in which patients were encouraged 
not to lose weight, but patients could be randomly allocated to receive either a supervised, 
intensive low calorie diet such as that used by Sinclair et al (2009) or the standard dietary 
advice provided in current NHS practice. Comparison could then be made between 
‘intensive’ weight management strategies and routine dietary advice, as well as 
acetazolamide treatment with and without weight reduction, using a 2x2 factorial design. 
5.3 Outcome Measurement 
Whilst a single outcome measure for IIH has not been identified, this and other studies have 
demonstrated that often a combination of symptoms and examination findings in IIH 
determine the action taken by treating clinicians. A simple scoring system has been tested, 
based on the most common clinical symptoms and signs (headache, tinnitus, visual 
obscurations, acuity, visual field and papilloedema) and its use demonstrated in the 50 
patients. Visual field assessment and optic disc appearance have been shown to exert the 
greatest influence on clinical decision-making, but other features of the assessment are also 
taken into account. This was reflected in the relative concordance of the various 
components of the score upon the final outcome and further corroboration of the findings is 
warranted. There is great potential for the creation of a composite outcome measure for 
patients with IIH using these key clinical features that can be easily reproduced and modified 
for lager studies. The use of blinding would improve the tool and compensate for its 
subjective nature, but would involve additional personnel. The desire to reduce bias through 
blinding must always be carefully balanced against the strength of the pragmatic trial design 
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in evaluating normal clinical practice. A composite score should be tested at all time points 
in subsequent trials, and not restricted to the final visit as in this study. In addition, 
weighting could be added to reflect the importance of visual field and optic disc assessments 
in the overall evaluation and is worthy of further study, along with rigorous evaluation of the 
reliability and validity of the tool.  
Visual fields remain the ‘gold standard’ for measurement of visual function in IIH, despite the 
recognised limitations of functional variations and learning effect. (Keltner, 2000) Even when 
modern techniques such as optical coherence tomography and scanning laser 
ophthalmoscopy are used to accurately measure the papilloedema they fail to show 
differences that significantly correlate with visual dysfunction (Mulholland et al., 1998). The 
place of perimetry in the clinical evaluation of IIH is assured until newer technologies of 
equivalent sensitivity and improved reliability emerge. 
5.4 Assessment of Papilloedema in IIH 
Optic disc appearance also remains a critical indicator of the clinical status in IIH. Various 
factors influence the appearance of the optic disc, such as intracranial pressure fluctuations, 
duration of elevated pressure and morphology, perfusion and susceptibility of the disc itself, 
as discussed in chapter 1. Attempts to classify the optic disc in IIH must take account of 
these factors as well as the effect of duration on the appearance of papilloedema. The 
commonly used Frisen staging scheme fails to reflect resolving papilloedema and optic 
atrophy, as well as failing to describe the subtle changes noted on clinical examination of the 
patient with IIH. In the assessment of papilloedema in patients with IIH of recent onset as 
well as more longstanding disease, the Frisen scheme has been shown to have poor 
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sensitivity and reliability, as reported in chapter 4. Ranking papilloedema severity has been 
shown by the study to exhibit superior inter-observer reliability and sensitivity to change, 
especially in cases of chronic disease. 
Use of the Frisen grading scheme in IIH needs to be replaced with a novel, validated and 
more clinically applicable system. This would need to identify and describe features of 
evolving, stable and improving papilloedema, rather than give a rigid classification. Until 
such a scheme exists, it would appear there is a role for simple ranking of discs by masked 
observers as a pragmatic solution for the much-needed large trials in IIH.  
 
5.5 Conclusions and Recommendations 
In conclusion, this thesis has addressed key areas in the study of IIH. (Table 5.1) A role for 
leptin in the relationship between IIH and both obesity and female gender is strongly 
suggested by the novel finding of elevated CSF leptin. Future goals for pragmatic trials have 
been identified, to evaluate the effect of treatment, especially weight reduction. The 
innovative use of a composite outcome measure has been tested and a scoring system 
proposed as a useful tool in IIH assessment. Finally, the need to replace the use of the Frisen 
scheme in the assessment of papilloedema in IIH has been clearly demonstrated.  
Recommendations for future work leading on from the findings of this thesis are also 
summarised in table 5.1. Assays of leptin should be repeated amongst larger IIH cohorts and 
matched controls, under stricter metabolic conditions as well as repeated at various time 
points throughout the course of the disease. Examination of the actions of leptin at a cellular 
level should target the arachnoid granulations to explore its effect, if any, on CSF outflow. 
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Table 5.1: Summary of Key Findings and Recommendations 
Theme Findings Recommendations 
 
IIH Pathophysiology 
 
Significant elevation of 
CSF leptin levels in 
patients with IIH 
compared to matched 
controls 
 
Cytokines identified in IIH 
but not in a classically 
inflammatory profile 
 
 
Corroborate findings with larger, 
controlled studies of leptin in IIH 
 
Cellular and histochemical studies 
focussing on arachnoid granulations and 
CSF absorption pathways 
 
Trial Design 
 
50 patients prospectively 
recruited to randomised 
controlled trial pilot 
 
 
 
Substantive trial to recruit minimum of 
300 subjects 
 
Retain pragmatic design for future trials 
 
Trial subjects 
 
Low incidence of visual 
dysfunction and need for 
surgery in population 
studied 
 
Poor compliance with 
acetazolamide 
 
 
Early recruitment and other measures to 
include patients at greater risk of visual 
loss in future trials 
 
Include intensive weight loss arm in 
future randomised trials 
 
Outcome measures  
 
Visual fields and optic disc 
appearance best 
indicators of disease 
status 
 
Main clinical features of 
IIH create an effective 
composite scoring system 
 
 
Weighting of composite scoring systems 
to reflect importance of perimetry and 
optic disc appearance 
 
Formal study of the validity and reliability 
of composite scoring systems in IIH 
 
Assessment of 
papilloedema in IIH 
 
Frisen staging scheme has 
low inter-rater reliability 
and sensitivity in IIH 
 
Ranking discs has greater 
reliability and sensitivity 
 
Novel papilloedema classification for IIH 
to replace Frisen scheme 
 
Blinded disc ranking as alternative to 
Frisen in pragmatic trials 
 
Evaluation of objective techniques of  
papilloedema measurement in IIH 
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 A multi-centre clinical trial should be undertaken, to prospectively assess a minimum of 300 
patients with newly diagnosed IIH, with treatment arms including intensive dietary 
intervention, intensive dietary intervention plus acetazolamide, acetazolamide alone and no 
intervention, except for the standard advice to lose weight, which should be given to all 
overweight subjects. A pragmatic trial design should be adopted to ensure adequate 
recruitment. Outcome measurement should include the use throughout of a scoring system 
comprising the key clinical features, weighted to attach greatest importance to optic disc 
swelling and visual field abnormalities. The validity and reliability of such a scale could be 
confirmed by studies in clinical settings prior to its use in a substantive trial. The creation of a 
bespoke grading scheme for the accurate assessment of papilloedema in IIH, to replace the 
Frisen scheme, should also be a priority and its validation could include comparisons with 
objective measurement by optical coherence tomography. 
Whilst IIH is not a common disorder, it is likely to become more so as the population gains 
weight. For many sufferers, it is a long term condition with high levels of morbidity and 
disability. For some, it is a sight threatening condition. For these reasons, IIH must remain a 
focus for careful further study. The findings in this thesis provide valuable insight into the 
directions that such research should follow.  
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IIH Trial Data Collection Forms 
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    Main randomisation 
BASELINE DATA  
Part 1: PATIENT  DETAILS  
 
Patient’s initials:      
 
Hospital Number:      
 
Date of Birth (dd/mmm/yyyy):    
 
Ethnic Group 
 
White Black/ Black British 
(tick one only) British Caribbean 
 Irish African 
 Other White Other Black 
 
Asian/ Asian British Mixed 
 
Chinese or Other Ethnic Group 
Indian Mixed White/ Black Caribbean Chinese 
Pakistani Mixed White/ Black African Any Other 
Bangladeshi Mixed White/ Asian  
Other Asian Other Mixed Background  
 
Part 2: PATIENT’S MEDICAL DETAILS: 
1. Pre-existing ocular conditions?  YES [  ]  NO [  ]  
Details: 
 
 
2. Known neurological conditions?    YES [  ]  NO [  ]  
Details: 
 
 
3. Relevant current medication?    YES [  ]  NO [  ] 
Details: 
 
 
4. PREVIOUS MEDICATION: 
 
 
a. Antibiotic use in previous six months? 
 
YES 
 
[  ] 
 
NO 
 
[  ] 
 
Unknown 
 
[  ] 
 
Details: 
 
 
 
b. Hormonal medication? 
    (Contraceptives / HRT / corticosteroids/ 
      Growth Hormone or other) 
 
[  ] 
 
[  ] 
 
[  ] 
 
 
 
 
c. Vitamin A or derivatives? 
 
[  ] 
 
[  ] 
 
[  ] 
 
 
 
d. Lithium? [  ] [  ] [  ] 
 
 
 
5. Other relevant medical / surgical history: 
 
 
 
 
 Yes No Comment 
6. Imaging studies:                 MRI / CT brain scan normal? 
Venogram / angiography normal? 
 
[  ] [  ]  
[  ] [  ] 
  
7. Baseline blood tests normal? 
 
[  ] [  ]  
8. Elevated CSF opening pressure? 
(if lumbar puncture performed in lateral decubitus position) 
[  ] [  ]  
Recorded CSF pressure(cm H20): 
 
 
 
HEIGHT: 
(centimetres)   
WEIGHT: 
(kilogram) 
DATE: 
 
  
  
 
Part 3: PATIENT’S SYMPTOMS         Page 2 of 2 
 
Headache 
YES 
[  ] 
NO 
[  ] 
Detail: 
 
 
Enter patient-assessed pain score 
(1= no pain, 10 = pain as bad as it can be): 
 
Tinnitus / intracranial noises 
(state right or left if applicable) 
 
[  ] 
 
[  ] 
 
 
 
Disturbance of sense of smell 
 
[  ] 
 
[  ] 
 
 
 
Visual loss 
 
[  ] 
 
[  ] 
 
 
 
Diplopia 
 
[  ] 
 
[  ] 
 
 
 
Visual obscurations 
 
[  ] 
 
[  ] 
 
 
 
Other 
 
[  ] 
 
[  ] 
 
 
 
*ATTACH ALL COMPLETED QUESTIONNAIRES* 
Part 4: VISUAL ASSESSMENT 
 
Contrast sensitivity (please circle the number, on each grid, nearest to the faintest triplet for which 2 of the 3 letters are named correctly. 
   Note that actual letter sequences may vary) 
 
LEFT  EYE 
 
RIGHT EYE 
 
BINOCULAR 
0.00 H S N D S N 0.15     0.00 H S N D S N 0.15  0.00 H S N D S N 0.15 
0.30 C K R Z V R 0.45  0.30 C K R Z V R 0.45  0.30 C K R Z V R 0.45 
0.60 N D C O S K 0.75  0.60 N D C O S K 0.75  0.60 N D C O S K 0.75 
0.90 O Z K V H Z 1.05  0.90 O Z K V H Z 1.05  0.90 O Z K V H Z 1.05 
1.20 N H O N R D 1.35  1.20 N H O N R D 1.35  1.20 N H O N R D 1.35 
1.50 V R C O V H 1.65  1.50 V R C O V H 1.65  1.50 V R C O V H 1.65 
1.80 C D S N D C 1.95  1.80 C D S N D C 1.95  1.80 C D S N D C 1.95 
2.10 K V C O H R 2.25  2.10 K V Z O H R 2.25  2.10 K V Z O H R 2.25 
 
 LEFT eye RIGHT eye Comments 
 
LogMAR 
 
   
Humphrey Perimetry: 
Mean Deviation   MD 
 
Pattern Standard Deviation   PSD 
   
  
Papilloedema 
 
 
Retinal photographs taken? 
* Attach photographs where available * 
 
Present [  ] 
Absent [  ]  
Present [  ] 
Absent [  ] 
 
 
Yes [  ]   No  [  ] 
 
Yes [  ]   No [  ] 
 
 ATTACH COPIES OF HUMPHREY PERIMETRY* 
 
 
 Part 5: CONTACT DETAILS 
Name / Position of clinician completing form Telephone number Fax number 
 
 
 
 
  
Please place the completed form and attachments in the envelope provided and leave for collection as arranged,  
or post to Dr Alex Ball, Department of Neurology, DGM Building, City Hospital, Dudley Road, Birmingham B18 7QH. 
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 Main randomisation VISIT 2  
(3 MONTHS Post-Randomisation) 
 
 
Part 1: PATIENT DETAILS:  
 
Patient’s Initials:      
 
Hospital Number:      
 
 
Date of Birth (dd/mmm/yyyy):    
 
TRIAL NUMBER   WEIGHT (kilogram)    DATE   
      
           
 
 
Part 2: TREATMENT:    
Initial treatment randomisation 
 
Acetazolamide      No Acetazolamide    
 
 
Initial treatment = acetazolamide: Initial treatment = NO acetazolamide: 
i. Still taking 
acetazolamide? 
(please tick) 
Yes [  ] 
(complete sections ii to iv below) 
i. Has acetazolamide 
been added? 
(please tick) 
Yes [  ] 
(complete sections ii to iv below) 
No [  ] 
(complete section v below) 
No [  ] 
(Go to part 3) 
ii.Current Dose: ii. Date commenced acetazolamide  
 
(if applicable): ____/____/_______        
iii. Has dose been changed? 
(please tick) 
yes [  ]  
iii. Current dose (if applicable): no  [  ] 
iv. Reason for dose change (if known) 
 
 
 
v. Reason(s) for stopping acetazolamide 
Please tick all that apply from the list below: 
iv. Reasons for adding acetazolamide: 
Please tick all that apply from the list below 
 
Adverse effects of medication   
Details: 
 
 
[  ] 
 
 
 
Worsening visual field 
 
[  ] 
 
Worsened disc appearance 
 
[  ] 
 
Reduced acuity 
 
[  ] 
Patient preference 
Details: 
 
[  ] 
 
 
 
 
 
 
Development of afferent pupillary defect 
 
[  ] 
 
Headaches failing to resolve 
 
[  ] 
 
New visual obscurations 
 
[  ] 
Pregnancy or planned pregnancy 
Details: 
 
 
Other reason 
 
Details: 
 
 
 
 
[  ] 
 
 
 
[  ] 
 
Worsening tinnitus 
 
[  ] 
 
Worsening impairment of colour vision 
 
[  ] 
 
Other (please give details below) 
 
 
 
 
 
[  ] 
(Please tick one and 
complete appropriate 
sections) 
 
 
 
  
 
 
Part 3: PATIENT’S SYMPTOMS          page 2 of 2 
 
Headache 
YES 
[  ] 
NO 
[  ] 
Detail: 
 
 
Enter patient-assessed pain score (1= no pain, 10 = pain as bad as it can be): 
Tinnitus / intracranial noises [  ] [  ] 
 
 
Visual loss [  ] [  ] 
 
 
Diplopia [  ] [  ] 
 
 
Visual obscurations [  ] [  ] 
 
 
Other [  ] [  ] 
 
 
*ATTACH ALL COMPLETED QUESTIONNAIRES* 
Part 4: VISUAL ASSESSMENT 
Contrast sensitivity (please circle the number, on each grid, nearest to the faintest triplet for which 2 of the 3 letters are named correctly. 
   Note that actual letter sequences may vary) 
 
LEFT  EYE RIGHT EYE BINOCULAR 
0.00 H S N D S N 0.15     0.00 H S N D S N 0.15  0.00 H S N D S N 0.15 
0.30 C K R Z V R 0.45  0.30 C K R Z V R 0.45  0.30 C K R Z V R 0.45 
0.60 N D C O S K 0.75  0.60 N D C O S K 0.75  0.60 N D C O S K 0.75 
0.90 O Z K V H Z 1.05  0.90 O Z K V H Z 1.05  0.90 O Z K V H Z 1.05 
1.20 N H O N R D 1.35  1.20 N H O N R D 1.35  1.20 N H O N R D 1.35 
1.50 V R C O V H 1.65  1.50 V R C O V H 1.65  1.50 V R C O V H 1.65 
1.80 C D S N D C 1.95  1.80 C D S N D C 1.95  1.80 C D S N D C 1.95 
2.10 K V C O H R 2.25  2.10 K V Z O H R 2.25  2.10 K V Z O H R 2.25 
 
 LEFT eye RIGHT eye Comments 
LogMAR    
Humphrey Perimetry: 
Mean Deviation   MD 
 
Pattern Standard Deviation   PSD 
   
  
Papilloedema 
 
Frisen Grade:  
(see photographic guide) 
 
Retinal photographs taken? 
* Attach photographs where available * 
Present [  ] 
Absent [  ]  
Present [  ] 
Absent [  ] 
 
 
…………….. 
 
Yes [  ]  No [  ] 
 
……………. 
 
Yes [  ]   No [  ] 
*ATTACH COPIES OF HUMPHREY PERIMETRY* 
 
 Is surgical intervention required for this patient? YES [  ] (complete questions below) NO [  ]  (go to part 5) 
 
 
Part 5: ADVERSE EVENTS YES N0 Details 
 
Blood test abnormalities? 
 
[  ] [  ] 
 
 
 
SUSARs? 
(Serious unexpected suspected adverse reactions) 
 
[  ] [  ]  
 
 
 
Part 6: Contact details 
Name / Position of clinician completing form Telephone number Fax number 
 
  
  
 
Reason surgical intervention is required: 
 
 
 
  
   
   
  
 
 Main randomisation VISIT 5 
(12 MONTHS Post-Randomisation) 
 
Final Additional Data 
 
Patient Trial Number: ………………  Patient Initials: ……… 
Date of visit:  ……../….…../……… 
 
For each of the six outcomes below, please select the most appropriate description 
for the patient at this visit: 
 
Item Description Select 
one ( ) 
1. Headache 
Absent [  ] 
Present, stable [  ] 
Deteriorating [  ] 
   
2. Tinnitus 
Absent [  ] 
Present, stable [  ] 
Deteriorating [  ] 
   
3. Visual obscurations  
Absent [  ] 
Abnormal, stable [  ] 
Deteriorating [  ] 
   
4. Visual Acuity  
Normal [  ] 
Abnormal, stable [  ] 
Deteriorating [  ] 
   
5. Optic Disc 
Normal [  ] 
Abnormal, stable [  ] 
Deteriorating [  ] 
   
6. Visual Field 
Normal [  ] 
Abnormal, stable [  ] 
Deteriorating [  ] 
 
 
In your clinical opinion, which of the following best describes the patient’s IIH at this 
visit? (Please tick one) 
 
a. IIH in remission   [  ] 
b. Active IIH improving  [  ] 
c. Active IIH but stable  [  ] 
d. Active IIH deteriorating  [  ] 
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For each statement, please tick one response. 
 
1. I feel tense and ‘wound up’ 
 
()  2. I feel as if I am slowed down: () 
Most of the time  [  ]  Nearly all the time [  ] 
A lot of the time [  ]  Very often [  ] 
Time to time, occasionally [  ]  Sometimes [  ] 
Not at all [  ]  Not at all [  ] 
     
3. I still enjoy the things I used 
to enjoy: 
()  4. I get a sort of frightened feeling 
like ‘butterflies’ in the stomach: 
() 
Definitely as much [  ]  Not at all [  ] 
Not quite so much [  ]  Occasionally [  ] 
Only a little [  ]  Quite often [  ] 
Hardly at all [  ]  Very often [  ] 
     
5. I get a frightened sort of feeling 
as if something awful is about to 
happen: 
() 
 6. I have lost interest in my 
appearance: () 
Very definitely and quite badly [  ]  Definitely [  ] 
Yes but not too badly [  ]  I don’t take so much care as I should [  ] 
A little but it doesn’t worry me [  ]  I may not take quite as much care 
 
[  ] 
Not at all [  ]  I take just as much care as ever [  ] 
     
 
 
  
 
7. I can laugh and see the 
funny side of things: 
()  8. I feel restless as if I have to 
be on the move: 
() 
As much as I always could [  ]  Very much indeed [  ] 
Not quite so much now [  ]  Quite a lot [  ] 
Definitely not so much now [  ]  Not very much [  ] 
Not at all [  ]  Not at all [  ] 
     
9. Worrying thoughts go 
through my mind: 
()  10. I look forward with 
enjoyment to things: 
() 
A great deal of the time [  ]  As much as I ever did [  ] 
A lot of the time [  ]  Rather less than I used to [  ] 
From time to time but not too 
often 
[  ]  Definitely less than I used to [  ] 
Only occasionally [  ]  Hardly at all [  ] 
     
11. I feel cheerful: ()  12. I get sudden feelings of 
panic: 
() 
Not at all [  ]  Very often indeed [  ] 
Not often [  ]  Quite often [  ] 
Sometimes [  ]  Not very often [  ] 
Most of the time [  ]  Not at all [  ] 
     
13. I can sit at ease and feel 
relaxed: 
 
()  14. I can enjoy a good book or 
radio or TV programme: 
() 
Definitely [  ]  Often [  ] 
Usually [  ]  Sometimes [  ] 
Not often [  ]  Not often [  ] 
Not at all [  ]  Very seldom [  ] 
 
  
 
 QUESTIONNAIRE 2: 
OVERALL HEALTH 
 
 
The following questions ask for your views about your health and how 
you feel about life in general. If you are unsure about how to answer 
any question, try and think about your overall health and give the best 
answer you can. Do not spend too much time answering, as your 
immediate response is likely to be the most accurate. 
 
1. In general, would you say your health is:   
                      Excellent  
             (Please tick one box) Very good  
 Good  
 Fair  
 
 
 
Poor  
2. Compared to 3 months ago, how would you rate your health in 
general now? 
 (Please tick one box) Much better than 3 months ago  
 Somewhat better than 3 months ago  
 
About the same  
 Somewhat worse now than 3 months ago  
 Much worse now than 3 months ago  
 
  
 
3. The following questions are about activities you might do during a 
typical day.  
 
 Does your health limit you in these activities? If so, how  much? 
 
 
                                                                         
 
  
    (Please tick one box on each line) 
Yes, 
limited 
a lot 
Yes, 
Limited 
a little 
No, not 
limited 
at all 
a) Vigorous activities, such as running, lifting heavy 
objects, participating in strenuous sports 
   
b) Moderate activities, such as moving a table, 
pushing a vacuum, bowling or playing  golf 
   
c) 
 
Lifting or carrying groceries    
d) 
 
Climbing several flights of stairs    
e) 
 
Climbing one flight of stairs    
f) 
 
Bending, kneeling or stooping    
g) 
 
Walking more than a mile    
h) 
 
Walking half a mile    
i) 
 
Walking 100 yards    
j) 
 
Bathing and dressing yourself    
 
 
  
 
4. During the past 2 weeks, how much time have you had any of the 
following problems with your work or other regular daily activities as a 
result of your physical health? 
 
 (Please tick one box on each line) All of 
the 
time 
Most 
of the 
time 
Some 
of the 
time 
A little 
of the 
time 
None 
of the 
time 
 
a) 
 
Cut down on the amount of time you 
spent on work or other activities 
     
 
b) 
 
Accomplished less than you would like      
 
c) 
 
Were limited in the kind of work or other 
activities 
     
 
d) 
 
Had difficulty performing the work or 
other activities (eg it took more effort) 
     
 
 
 
5. During the past 2 weeks, how much time have you had any of the 
following problems with your work or other regular daily activities as a 
result of any emotional problems (such as feeling depressed or anxious)? 
 
 (Please tick one box on each line) 
 
All of 
the 
time 
Most 
of the 
time 
Some 
of the 
time 
A little 
of the 
time 
None 
of the 
time 
 
a) 
 
Cut down on the amount of time you 
spent on work or other activities 
 
     
 
b) 
 
Accomplished less than you would like 
 
     
 
c) 
 
Didn’t do work or other activities as 
carefully as usual 
     
 
  
 
6. During the past 2 weeks, to what extent have your physical health or 
emotional problems interfered with your normal social activities with 
family, friends, neighbours or groups? 
  Not at all  
  
Slightly  
 (Please tick one box) Moderately  
  Quite a bit  
  Extremely  
 
7. How much bodily pain have you had during the past 2 weeks? 
  None  
  
(Please tick one box) 
Very mild  
  Mild  
  Moderate  
  Severe  
  Very Severe  
 
 
8. During the past 2 weeks how much did pain interfere with your normal 
work (including work both outside the home and housework)? 
  Not at all 
Slightly 
 
 (Please tick one box) Moderately  
  Quite a bit  
  Extremely  
 
  
 
9. These questions are about how you feel and how things have been with 
you during the past 2 weeks. For each question please give the one answer 
that comes closest to the way you have been feeling. 
               (Please tick one box on each line) 
 How much time during 
the last 2 weeks: 
All 
of the 
time 
Most  
of the  
time 
A good 
bit of the 
time 
Some  
of the  
time 
A little  
of the 
time 
None  
of the 
time 
 
a) 
 
Did you feel full of life?       
 
b) 
 
Have you been a very 
nervous person? 
      
 
c) 
 
Have you felt so down in the 
dumps that nothing could 
cheer you up? 
      
 
d) 
 
Have you felt calm and 
peaceful? 
      
 
e) 
 
Did you have a lot of 
energy? 
      
 
f) 
 
Have you felt downhearted 
and low? 
      
 
g) 
 
Did you feel worn out? 
      
 
h) 
 
Have you been a happy 
person? 
      
 
i) 
 
Did you feel tired?       
 
 
  
 
 Questionnaire 2 Page 1 of 1 
10.  During the past 2 weeks, how much of the time has your physical 
health or  emotional problems interfered with your social activities (like 
visiting friends, relatives etc.)? 
 
      (Please tick one box)                                      All of the time                                                                                    
 
                                                                      Most of the time 
 
 
                                                                     Some of the time 
 
 
                                                                    A little of the time 
 
 
                                                                      None of the time 
 
 
 
11. How TRUE or FALSE is each of the following statements for you? 
                                                                     (Please tick one box on each line) 
 
  
 Definitely 
true 
Mostly 
true 
Not 
sure 
Mostly 
false 
Definitely 
false 
a) I seem to get ill more easily than 
other people 
     
b) I am as healthy as anybody I 
know 
     
c) I expect my health to get worse      
d) My health is excellent      
 
  
  
 
 Questionnaire 3  
 
Please answer the questions by ticking one box in each group.  
Please indicate which statement best describes your own health today. 
Mobility 
 
I have no problems walking about 
 
I have some problems in walking about 
 
I am confined to bed 
 
Self care 
 
I have no problems with self-care 
 
I have some problems washing or dressing myself 
 
I am unable to wash or dress myself 
 
Usual activities e.g. work, study, housework, family or leisure activities 
 
I have no problems with performing 
my usual activities 
 
I have some problems with 
performing my usual activities 
 
I am unable to perform my usual activities 
 
Pain/ Discomfort 
 
I have no pain or discomfort 
 
I have moderate pain or discomfort 
 
I have extreme pain or discomfort 
 
Anxiety/ Depression 
 
I am not anxious or depressed 
 
I am moderately anxious or depressed 
 
I am extremely anxious or depressed  
 
 
 
 
  
 
 
Worst 
imaginable 
Best imaginable 
health state 
9 0 
8 0 
7 0 
6 0 
5 0 
4 0 
3 0 
2 0 
1 0 
0 
100 
Your own 
health state 
today 
To help people say how good or bad 
their health state is, we have drawn a 
scale (rather like a thermometer) on 
which the best state you can imagine is 
marked by 100 and the worst state you 
could imagine is marked by 0. 
We would like you to indicate on the 
scale how good or bad your own health 
is today, in your opinion. Please do this 
by drawing a line from the box to 
whichever point on the scale indicates 
how good or bad your current health 
state is. 
 
© EuroQoL Group 
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